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This thesis considers some of the cognitive, social and psychological factors which impact 
upon the wellbeing of people with Parkinson’s. Section One reports a systematic literature 
review of the relationship between anxiety and cognition for people with Parkinson’s. The 
electronic databases CINAHL, Medline, PsycINFO and Web of Science were searched and 
39 eligible studies were identified. The findings suggested that higher anxiety is associated 
with worse global cognition and worse performance in specific cognitive domains (attention, 
working memory, executive functioning, memory, language, semantic verbal fluency and 
visuospatial skills) among people with Parkinson’s. However, several studies did not identify 
significant relationships. Studies varied in design and quality, several having small samples. 
Relationships between anxiety and cognition among people with Parkinson’s appear to be 
complex and may be influenced by other factors. Implications for clinical practice are 
discussed. Section Two describes a quantitative, cross-sectional, observational study into the 
relationships between self-compassion, stigma and psychological distress among people with 
Parkinson’s. Participants were 138 people with Parkinson’s, who completed questionnaires 
measuring self-compassion, enacted and felt stigma, and depression, anxiety and stress. All 
variables were found to correlate significantly in the expected directions. The stigma 
variables were significant mediators in the relationships between self-compassion and the 
three outcome variables - depression, anxiety and stress. Part of the relationship between self-
compassion and psychological distress appears to occur via the internalisation of stigma. 
These findings may be relevant to individualised and societal interventions with the aim of 
improving the psychological wellbeing of people with Parkinson’s. Section Three provides a 
critical appraisal of the thesis. This includes a summary of the main findings, consideration of 
language and concepts, a discussion of some of the issues relating to each paper and 
suggestions for further research.  
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Purpose. Cognitive decline is common among people with Parkinson’s and is negatively 
associated with quality of life. Previous systematic reviews have found greater cognitive 
difficulties among people with Parkinson’s to be associated with increased symptoms of 
depression and apathy, but have identified relatively few studies examining relationships 
between cognitive factors and anxiety. The current review aimed to address this gap by 
expanding upon the search strategies used in the previous reviews. 
Methods. A quantitative systematic literature review was conducted. The electronic 
databases CINAHL, Medline, PsycINFO and Web of Science were searched for studies 
which analysed relationships between cognitive factors and anxiety among people with 
Parkinson’s. A total of 3883 studies were identified, of which 39 were eligible for inclusion 
in the review. 
Results. There was evidence to suggest that higher anxiety is associated with worse global 
cognition and worse performance in specific cognitive domains (attention, working memory, 
executive functioning, memory, language, semantic verbal fluency and visuospatial skills). 
There was also evidence to suggest predictive relationships between the variables, in both 
directions. However, there were inconsistencies between the papers, with several studies also 
finding null results. Studies varied in terms of design and quality, a common weakness being 
small sample sizes. 
Conclusions. Relationships between anxiety and cognition among people with Parkinson’s 
appear to be complex and may be influenced by other factors. Clinicians working with people 
with Parkinson’s should ensure that assessments, formulations and interventions consider the 
impact of, and relationships between, cognitive difficulties and experiences of anxiety.   
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Anxiety and Cognitive Functioning among People with Parkinson’s: A 
Systematic Review 
Parkinson’s disease (referred to throughout this review as “Parkinson’s”: the preferred 
terminology by the charity Parkinson’s UK) is a common neuro-degenerative condition with 
a worldwide prevalence rate of around 0.3% (Pringsheim, Jette, Frolkis & Steeves, 2014). 
Parkinson’s is classified as a movement disorder (Fahn, 2011), characterised by difficulties 
with initiating movement (akinesia), slowed movement (bradykinesia), tremor, rigidity, gait 
disturbance and speech difficulties (Moustafa et al., 2016). Other difficulties experienced by 
people with Parkinson’s can include symptoms of anxiety and depression, cognitive 
impairments, sensory disturbances, sexual dysfunction and continence problems (Rana, 
Ahmed, Chaudry & Vasan, 2015; Stacy, 2011).  
The cognitive sequelae of Parkinson’s are heterogeneous (Kehagia, Barker & 
Robbins, 2010), but often include impairment or decline in the domains of memory, attention, 
executive function and visuospatial abilities (Aarsland et al., 2010; Elgh et al, 2009). Changes 
in cognitive functioning can occur early in the progression of Parkinson’s, with around 30% 
of people newly diagnosed with Parkinson’s exhibiting impairments in at least one of the 
domains of semantic verbal fluency, episodic memory and executive function, while 
phonemic verbal fluency, naming, working memory and visuospatial skills remain relatively 
unaffected (Elgh et al., 2009). Cognition gradually declines over time as Parkinson’s 
progresses, with a broader range of domains affected, including a deterioration in visuospatial 
skills (Muslimović, Schmand, Speelman & De Haan, 2007; Roheger, Kalbe & Liepelt-
Scarfone, 2018). Approximately half of all people with Parkinson’s develop Parkinson’s 
Disease Dementia (PDD) within ten years of diagnosis (Williams-Gray et al., 2013), and 
approximately 80% develop PDD within 20 years (Hely, Reid, Adena, Halliday & Morris, 
2008). Parkinson’s Disease-Mild Cognitive Impairment (PD-MCI) is defined as the stage of 
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cognitive decline which is greater than expected given an individual’s age and level of 
education, but which, unlike PDD, does not negatively impact upon functional independence 
(Litvan et al., 2012; Weil, Costantini & Schrag, 2018). People with PD-MCI are at an 
increased risk of developing PDD (Janvin, Larsen, Aarsland & Hugdahl, 2006; Litvan et al., 
2012). 
Cognitive difficulties have been found to be associated with poorer quality of life 
(Lawson et al., 2014; Schrag, Jahanshani & Quinn, 2000), lower life-satisfaction (Rosqvist et 
al., 2017), higher levels of depression (Fernandez et al., 2009; Santangelo et al., 2009) and 
increased apathy (Butterfield, Cimino, Oelke, Hauser & Sanchez-Ramos, 2010) for people 
with Parkinson’s. Two previous reviews have sought to synthesise the literature concerning 
the relationships between cognitive and affective factors among people with Parkinson’s 
(Alzahrani & Venneri, 2015; Poletti, De Rosa & Bonuccelli, 2012). Both identified 
symptoms of depression and apathy to be associated with impairments in cognition, 
particularly in the executive functioning domain. However, both reviews highlighted a dearth 
of research into the relationship between anxiety and cognition: Alzahrani and Venneri 
(2015) finding only two studies addressing this relationship (Bogdanova & Cronin-Golomb, 
2012; Foster et al., 2010), and Poletti et al. (2012) finding just one (Foster et al., 2010). A 
scoping review by Lutz, Holmes, Ready, Jenkins and Johnson (2016) focused on correlates of 
anxiety for people with Parkinson’s, and found only three papers relating to cognition (Lee, 
Tsai, Gauthier, Wang & Fuh, 2012; Ryder et al., 2002; Zahodne, Marsiske & Bowers, 2013). 
All three reviews found evidence suggesting that greater cognitive impairment is associated 
with higher levels of anxiety, but recommended that further research should be carried out to 
clarify and expand upon existing findings. 
This apparent lack of research is surprising, particularly given that clinically 
significant levels of anxiety affect around one third of people with Parkinson’s (Broen, 
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Narayen, Kuijf, Dissanayaka & Leentjens, 2016), and relationships between anxiety and 
cognition in other populations are well-evidenced. For example, in older adults, anxiety has 
been found to be associated with impairments in memory, learning and executive functioning 
(Mantella et al., 2007; Yochim, Mueller & Segal, 2013). Similar relationships between 
anxiety and cognitive factors have been identified in people with other neurological 
conditions including multiple sclerosis (Julian & Arnett, 2009; Simioni, Ruffieux, 
Bruggimann, Annoni, & Schluep, 2007), traumatic brain injury (Gould, Ponsford & Spitz, 
2014) and stroke (Barker-Collo, 2007). These relationships may be bi-directional: anxiety 
may limit the resources available to engage in cognitive tasks (Vytal, Cornwell, Arkin & 
Grillon, 2012), while cognitive problems (particularly with executive functioning) might 
make it more difficult to implement cognitive strategies to reduce anxiety (Yochim et al., 
2013).  
It appears important for clinical psychologists, clinical neuropsychologists and other 
professionals to understand the relationship between anxiety and cognition when seeking to 
assess and formulate problems reported in either domain by people with Parkinson’s, in order 
to guide effective interventions. This is in line with the British Psychological Society’s (BPS) 
briefing document regarding psychological services for people with Parkinson’s (Macniven 
& Gaskill, 2009), which recommends a holistic approach to understanding the cognitive, 
psychological and social factors affecting each individual. Although previous reviews have 
considered the relationship between anxiety and cognition (Alzahrani & Venneri, 2015; Lutz 
et al., 2016; Poletti et al., 2012), they did so within broad research questions, therefore the 
search strategies may have lacked the specificity and sensitivity to identify all relevant 
papers. Additionally, an initial scoping search of the literature identified several relevant 
papers published since the previous reviews, suggesting that they may have drawn attention 
to the need for further research.  
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Therefore, this review sought to search, comprehensively and systematically, the 
literature regarding the relationship between anxiety and cognition among people with 
Parkinson’s, to enhance understanding of the current state of knowledge in the area. It was 
hypothesised that, as with other populations and the findings of the previous reviews, higher 
anxiety would be associated with greater cognitive impairments.  
Methodology 
 Given the nature of the review question, it was anticipated that the relevant studies for 
inclusion in the review would be largely observational in design. Mueller et al. (2018) 
highlight that much of the guidance for conducting systematic literature reviews is aimed at 
reviews of randomised controlled trials (RCTs), despite a large proportion of systematic 
reviews including observational data (Page et al., 2016). Mueller et al. (2018) have 
synthesised the existing guidance for systematically reviewing observational studies; this was 
referred to throughout the process of this review. The Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA; Moher, Liberati, Tetzlaff, Altman, & The 
PRISMA Group, 2009) statement was also followed as closely as possible in the reporting of 
this review; this being a recommendation for systematic review submissions to the target 
journal. Any deviations from the PRISMA statement are due to it being aimed at reviews of 
RCTs (Moher et al., 2009). No such reporting guidelines appear to exist for reviews of 
observational studies (Mueller et al., 2018). 
The purpose of a quantitative systematic literature review is to search the existing 
literature thoroughly and methodically, using explicit criteria to identify the relevant research 
papers, which are then critically reviewed. The intended outcome is a critical synthesis of the 
extant literature pertaining to a particular research question (Petticrew & Roberts, 2006). 
Given a systematic and explicit approach to searching, selecting and critiquing the literature, 
systematic reviews should be reproducible and relatively unbiased (Biondi-Zoccai, Lotrionte, 
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Landoni, & Modena, 2011; Gopalakrishnan & Ganeshkumar, 2013). Nonetheless, there 
remains a degree of subjectivity in the defining of the research question and selection criteria 
(Biondi-Zoccai et al., 2013). Therefore, throughout the current review, I have attempted to 
give an explicit account of, and rationale for, the procedures followed. 
Method 
Defining the Research Question  
A well-defined research question which is both meaningful and useful is vital for 
conducting a systematic review (Moher et al., 2009; Petticrew & Roberts, 2006). However, 
there are conflicting guidelines regarding how broad or specific the research question should 
be, and at what stage the research question should be defined, for systematic reviews of 
observational studies (Mueller et al., 2018). While some researchers argue that a precise 
research question is more scientific and economical (Rosenthal & DiMatteo, 2001; Thomas, 
Ciliska, Dobbins & Micucci, 2004), others suggest that the breadth of a review question 
should be determined by what the most meaningful outcomes may be (Price, Jefferson & 
Demicheli, 2004). Due to how little is known about the topic of this review, as confirmed by 
three previous reviews (Alzahrani & Venneri, 2015; Lutz et al., 2016; Poletti et al., 2012), a 
fairly broad question was decided to be appropriate. It was decided to be more useful to look 
at the relationship between anxiety and all aspects of cognitive functioning among people 
with Parkinson’s rather than focusing on a specific domain of cognitive functioning, given 
that there is not yet an empirical basis to support such a focus. Nonetheless, the current 
review question is more specific than the three prior reviews. The increased specificity was 
economical, allowing more resources to be used on defining the search terms relating to 
cognition, with the aim of identifying papers which may not have been retrieved by the 
search strategies used in the previous reviews.  
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A tool frequently used to formulate systematic review questions is PICO: an acronym 
for population, intervention, comparison and outcome (Richardson, Wilson, Nishikawa & 
Hayward, 1995). Given the breadth of the research topic and the aforementioned aim of 
looking at relationships between two types of outcome (anxiety and cognitive functioning) 
for people with Parkinson’s, it was decided that only the “population” and “outcome” 
variables were relevant to this review. Both anxiety and cognitive functioning were 
considered outcomes, rather than “exposure” and “outcome” (Moola et al., 2015), given that 
there was insufficient evidence to hypothesise about causality between these two variables. 
Thus, the question was defined with the “population” being people with Parkinson’s, and the 
“outcomes” being anxiety and cognitive functioning. 
Search Strategy 
A systematic search of the literature was completed in March 2019, using the 
electronic databases CINAHL, Medline, PsycINFO and Web of Science. The search strategy 
was reviewed and approved by an Academic Librarian.  
Cognitive function is an extremely broad outcome variable. As such, myriad search 
terms might have been used to identify papers measuring aspects of cognition. To address 
this, multiple sources were consulted from which the relevant terms were identified and 
extracted. The sources included: three recent systematic reviews concerning cognition and 
people with Parkinson’s (D’iorio, Maggi, Vitale, Trojano & Santangelo, 2018; Fengler et al., 
2017; Pushpanathan, Loftus, Thomas, Gasson & Bucks, 2016), two Cochrane systematic 
reviews concerning cognition and other neurological conditions (Hoffmann, Bennett, Koh & 
McKenna, 2010; Rosti-Otajärvi & Hämäläinen, 2014) and consultation with two clinical 
neuropsychologists working in services for people with Parkinson’s. Once several terms had 
been identified, they were used to search subject heading libraries within the databases to 
generate further terms. The final list of terms searched in each database is summarised in 
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Table 1.1. The results of single-term subject heading searches and multiple-term free-text 
searches (in the Title and Abstract fields for CINAHL, Medline and PsycINFO, and in the 
Topic field for Web of Science) were combined using Boolean logic. The full electronic 
search strategy used in CINAHL is presented in Appendix 1B. 
 
<INSERT TABLE 1.1> 
 
The search results were collated in the reference management software Endnote. 
Duplicates were removed. Using the selection criteria, the records were screened by title and 
abstract, and the remaining papers were read in full to determine eligibility.  The reference 
lists of the selected papers, and the three previous reviews in the area of the topic (Alzahrani 
& Venneri, 2015; Lutz et al., 206; Poletti et al., 2012) were hand-searched for any additional 
relevant papers.  
Selection Criteria 
 The included papers were required to report on empirical studies which were 
quantitative in design, available in English, and published in a peer-reviewed journal. Grey 
literature was excluded since this is likely to be of lower quality so can introduce bias (Egger, 
Juni, Bartlett, Holenstein & Sterne, 2003). Although previous reviews have addressed similar 
research questions to the current review in recent years (Alzahrani & Venneri, 2015; Lutz et 
al., 206; Poletti et al., 2012), for comprehensiveness no date limits were set on the search. 
Therefore, all studies published up until the date of the search (March 2019) were considered.  
 Studies were required to have human participants, with a diagnosis of Parkinson’s, 
whose data were separable from any data from participants without Parkinson’s. Participants 
were required to be aged 18 and over. Studies had to include either a validated self-report 
measure of anxiety, or examination by a suitably qualified professional against widely-
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accepted criteria for the diagnosis of “anxiety disorders”. Data regarding anxiety had to be 
separable from other psychological or psychiatric data. Cognitive function had to be assessed 
using validated tools. Diagnoses of PDD or PD-MCI, in the absence of cognitive assessment 
data, were not sufficient measures of cognitive function, nor were self-report measures of 
cognitive function. Studies were required to have statistically analysed the relationships 
between anxiety and cognition. 
Search Results  
The search returned a total of 3883 records: 113 from CINAHL; 1266 from Medline; 
740 from PsycINFO and 1764 from Web of Science. After removing duplicates, 1604 records 
remained. Screening by titles and abstracts left 158 papers, which were read in full and 
assessed against the inclusion and exclusion criteria. This left 39 papers which were eligible 
for inclusion in the review. Manual searches did not identify any further papers for inclusion. 
Figure 1.1 shows the study selection process.  
 
< INSERT FIGURE 1.1> 
 
Assessment of Risk of Bias  
The PRISMA statement (Moher et al., 2009) and its associated Explanation and 
Elaboration paper (Liberati et al., 2009) state that the methodological quality of the studies 
included in a systematic review should be assessed to gain an understanding of the risk of 
bias in each study, which may influence the findings of the review. Numerous tools exist for 
assessing risk of bias, with Sanderson, Tatt and Higgins (2007) identifying 86 different tools 
for assessing the methodological quality of observational studies. In this review, an adapted 
version of a tool developed for assessing the risk of bias in observational studies by the 
Agency for Healthcare Research and Quality (Williams, Plassman, Burke, Holsinger & 
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Benjamin, 2010) was utilised. This tool was originally designed for research into cognitive 
decline among people with Alzheimer’s disease. The tool was selected due to its applicability 
to observational studies and the overlap in the research questions concerning 
neurodegenerative conditions and cognitive decline. Furthermore, the tool uses a qualitative 
rating system based upon the presence or absence of bias-related issues, rather than numerical 
summary scores. This allows the quality issues consistently affecting the research in the topic 
area to be identified, which is more meaningful to the findings of the review (Jüni, Witschi, 
Bloch, and Egger, 1999; Liberati et al., 2009). 
Some small adaptations to Williams et al.’s (2010) tool were required to ensure its 
relevance to the current research question. For example, items relating to “intervention” or 
“exposure” were removed since these were not applicable to the research question, as 
described above. The original 11-item tool, with descriptions of what should be considered 
when rating each item, is attached in Appendix 1C. A table explaining the adaptations made 
to the tool for this review is attached in Appendix 1D, and the final adapted eight-item tool is 
displayed in Table 1.2.  
 
<INSERT TABLE 1.2> 
 
Each study was given a rating of “yes” (y), “no” (n), “partially” (p), “can’t tell” (c) or 
“not applicable” (n/a) for each item. The risk of bias assessment was completed by the 
author, and a subset of the papers were also assessed by a trainee clinical psychologist 
colleague, who acted as a second reviewer to check the author’s fidelity to the tool. The 
second reviewer’s appraisals are attached in Appendix 1E. No differences in ratings were 
noted between reviewers. No studies were excluded from the review based on their risk of 
bias, since awareness of the methodological quality of the papers was valuable for developing 
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an understanding of the overall picture of research pertaining to the research question (Jüni et 
al., 1999). However, quality was considered when synthesising the results. 
Data Extraction 
 Data were extracted from the papers by the author. The information collected for each 
paper included: study design and methods of data analysis; a description of the sample 
including country of recruitment, sample size, sex distribution, age of participants and time 
since diagnosis; tools used to measure anxiety and cognition; and a summary of the relevant 
results (findings from all reported analyses of relationships between anxiety and cognition 
variables). 
Results 
Characteristics of Studies  
The characteristics of the studies included in this review are reported in Table 1.3. 
The characteristics reported are those relevant to the analyses pertaining to the research 
question of this review where these are different to the study as a whole (for example, 
sometimes the relevant analyses only used a subset of the participants). 
The studies were published between 1993 and 2019. Ten of the 39 studies were 
conducted in the USA, six in the UK, three in Italy and three in China. Other studies were 
conducted in Australia, Brazil, Canada, Croatia, Egypt, France, Israel, Malaysia, the 
Netherlands, Portugal and Taiwan. Two studies recruited internationally (Petkus, Filoteo, 
Schiehser, Gomez & Petzinger, 2019; Starkstein et al., 2014). Most of the studies were cross-
sectional, either in their overall design or in the design of the analyses pertaining to the 
question of this review. Only two of the papers (Petkus et al., 2019; Rutten et al., 2017) 
reported relevant longitudinal analyses. Many of the studies measured the relationships 
between the variables of interest using correlation or regression analyses, while others 
compared the means of groups of participants split by cognitive abilities or anxiety levels.  
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Sample sizes ranged from 22 to 468 participants. Apart from two studies, females 
made up 24-53% of the samples, suggesting that the sex distribution of the population of 
people with Parkinson’s (Wooten, Currie, Bovbjerg, Lee & Patrie, 2004; Moisan et al., 2016) 
was generally reflected in the samples. In one study (Starkstein, Robinson, Leiguarda & 
Preziosi, 1993), it was not possible to ascertain the sex distribution of participants due to 
inconsistencies in the participant information table. Ryder et al. (2002) recruited male 
participants only. The average age of participants ranged from 59 to 77 years. Where 
reported, the average number of years since diagnosis ranged from zero to 13 across the 
studies, with four of the 39 studies specifically investigating newly-diagnosed or early-stage 
Parkinson’s (Dissanayaka et al., 2017; Hu et al., 20014; LaBelle, Walsh & Banks, 2017; 
Rutten et al., 2017). Ten of the papers did not report participants’ time since diagnosis. 
Self-report tools used for measuring anxiety included the Beck Anxiety Inventory 
(BAI; Beck, Epstein, Brown & Steer, 1988), Hospital Anxiety and Depression Scale (HADS; 
Zigmond & Snaith, 1983), Hamilton Anxiety Rating Scale (HAM-A; Hamilton, 1959), Leeds 
Anxiety and Depression Scale (LADS; Snaith, Bridge & Hamilton, 1976), Movement 
Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-
UPDRS; Goetz et al., 2007), Neuropsychiatric Inventory (NPI; Cummings et al., 1994), 
State-Trait Anxiety Inventory (STAI; Spielberger, Gorsuch, Lushene, Vagg & Jacobs, 1983), 
Symptom Checklist-90-Revised (SCL-90-R; Derogatis, 1994), and the anxiety subscale of 
the Geriatric Depression Scale (GDS; Adams, Matto & Sanders, S, 2004; Yesavage et al., 
1982). Structured clinical interviews used to identify the presence or absence of clinical 
levels of anxiety included variations of the Mini-International Neuropsychiatric Interview 
(MINI, MINI-plus; Sheehan et al., 1998) and the Chinese-Bilingual Structured Clinical 
Interview for the Diagnostic and Statistical Manual of Mental Disorders–4th Edition (CB-
SCID-DSM-IV; So et al., 2003). 
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A multitude of tools were used to measure cognition. Thirteen of the studies used only 
a summary score from a measure of global cognition – the Mini-Mental State Exam (MMSE; 
Folstein, Folstein & McHugh, 1975) or the Montreal Cognitive Assessment (MoCA; 
Nasreddine et al., 2005) - in the relevant analyses (although other studies included global 
measures as part of their battery of tests). Five studies used batteries of tests to assess 
participants for PD-MCI, then analysed relationships between PD-MCI status and anxiety. 
The remaining studies analysed relationships between anxiety and single subtest and/or 
cognitive domain scores.   
The relationship between anxiety and cognition was a main research question in 21 of 
the studies. In the remaining 18 studies, the relationship was analysed as a supplement to the 
main research question, for example to check whether anxiety was a confounding variable in 
some other relationship.  
 
< INSERT TABLE 1.3 > 
 
Quality Assessment 
Table 1.4 shows the quality assessment ratings given for each of the reviewed studies, 
using the adapted version of the quality appraisal tool by Williams et al. (2010). 
 
< INSERT TABLE 1.4 > 
 
To be rated “yes” for sample representativeness and validity, studies were required to 
specify appropriate inclusion and exclusion criteria, recruit from more than one source, 
explain how participants were confirmed to have a diagnosis of Parkinson’s, and describe the 
characteristics of the sample including age, gender and time since diagnosis. Thirteen studies 
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met these criteria. The study by Ryder et al. (2002) had a small, all-male sample, recruited 
from one source, therefore was not considered to be representative of the population of 
people with Parkinson’s, and the study by Foster et al. (2010) did not report how participants 
were recruited, nor how their Parkinson’s diagnosis was confirmed. The remaining studies 
were missing only one of the criteria for this item, therefore were rated “partial”.  
Almost all studies adequately described their samples in terms of age and gender, 
however ten of the studies lacked information about time since diagnosis. This was 
considered an important oversight, since both cognition and anxiety have been found to be 
related to disease duration (Stefanova, Ziropadja, Petrovic, Stojkovic & Kostic, 2013; 
Verbaan et al., 2007). The study by Starkstein et al. (1993) was unclear in the reporting of 
demographic information, with some inconsistencies in the participant information table. The 
study by Manor, Balas, Giladi, Mootanah and Cohen (2009) adequately described the sample 
for their main research question, but not the subset of the sample upon which the analyses 
relevant to this review were based. 
Eighteen of the samples were limited in their representativeness through recruiting 
from only one clinic or site. Pauletti et al. (2017) did not describe from where they recruited 
their sample. The remaining studies recruited from multiple sites or large databases. 
The “comparable groups” item was only relevant to the sixteen studies which split 
participants into groups. A “partial” rating was given to the eight studies which demonstrated 
a degree of demographic similarity between groups, and a “yes” rating was given to the five 
studies where groups were demonstrated to be comparable in all measured variables apart 
from the experimental variables, or where differences in groups were controlled for within 
the analyses. In three studies, there was insufficient evidence to assess the comparability of 
groups. 
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Only one study (Klepac, Hajnšek & Trkulja, 2010) reported a power analysis – 
though not for the part of the analysis relevant to this review. However, for studies which 
used simple analyses and clearly reported the parameters of the data, it could be established 
whether sample sizes were large enough to detect medium effects at 80% power for p< .05. 
For other studies this could not be achieved with the information available. Eight studies 
were found to be adequately powered, ten studies were found not to be adequately powered, 
and 21 were rated “can’t tell”. Six of the ten underpowered studies (according to my power 
calculations), found significant effects, therefore power was not an issue in these cases.  
 To be rated “yes” on the “measures” item of the quality assessment, it was required 
that authors reported the conditions in which cognitive assessments took place, that these 
were consistent across participants, and that the individual(s) administering and scoring the 
assessments were adequately qualified to do so. Eleven studies met these criteria. The 
remaining studies were rated “can’t tell” due to a lack of clarity in reporting.  
Given that all studies were observational, uncontrolled trials, it was expected to be 
difficult to identify and control for all possible confounding variables. However, all studies 
reported some consideration of potential confounding variables, thus were rated “partial”. 
The method of data analysis was judged to be appropriate in all the included studies.   
Synthesis of Findings 
 Anxiety and global cognition. Of 33 analyses which compared scores on a measure 
of global cognition to scores on a measure of anxiety (from 26 studies, as some studies used 
multiple measures), 22 did not identify significant relationships between anxiety and 
cognition. However, only six of the 22 analyses with non-significant results could be 
confirmed to be adequately powered, suggesting that several studies may have failed to find 
an effect due to their samples being too small. However, some analyses had sufficient 
participants to detect an effect, but did not, indicating that some other factors were involved 
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in whether a relationship was detected (or existed for that particular group). Upon 
comparison of the studies which did and did not find effects, it was not obvious what these 
factors might be. 
The 11 analyses (from ten studies) which found significant relationships, all found 
higher levels of anxiety to be associated with higher levels of global impairment. Most of 
these were correlation analyses. A regression analysis controlling for age, sex, and education 
found higher LADS anxiety scores to significantly predict lower scores (indicating greater 
impairment) on the MoCA (Hu et al., 2014). Trait anxiety was also found to account for a 
significant proportion of variance in total scores on the Repeatable Battery for the 
Assessment of Neuropsychological Status (RBANS; Randolph, Tierney, Mohr & Chase, 
1998) when controlling for depression (Ryder et al., 2002). When participants were split by 
MoCA scores, participants with low MoCA scores (indicating more cognitive impairment) 
had significantly higher HAM anxiety ratings (indicating a higher level of anxiety) than 
participants with high MoCA scores (Zhang et al., 2016). When participants were split by 
levels of trait anxiety on the STAI, the high trait anxiety group showed significantly more 
impairment on the MMSE than the low trait anxiety group (Manor et al., 2009). Additionally, 
lower MoCA scores at baseline were associated with an increase in state anxiety, as measured 
by the STAI, over a two-year period (Rutten et al., 2017). In summary, although there were 
inconsistencies as to whether relationships were found (sometimes within studies, depending 
on the measures used), the relationships identified were consistent in nature and appeared to 
be bi-directional. 
 Anxiety and PD-MCI. Three of the five studies which assessed participants for PD-
MCI found no significant relationships between PD-MCI status and anxiety (Leroi, Pantula, 
McDonald & Harbishettar, 2012; Mamikonyan et al., 2009; Monastero, Di Fiore, 
Ventimiglia, Camarda & Camarda, 2013). Participants were grouped differently in each of 
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these studies. Leroi et al. (2012) studied differences between no cognitive impairment, PD-
MCI and PDD groups, Mamikonyan et al. (2009) looked for predictors of PD-MCI 
(compared to no PD-MCI) and Monastero et al. (2013) compared non-cognitively-impaired, 
amnesic PD-MCI and non-amnesic PD-MCI groups.  
 Baschi et al. (2018) found a significant effect of group membership on anxiety, in a 
study examining the correlates of subjective memory complaints (SMC) for participants with 
and without PD-MCI. Participants were divided into four groups: PD-MCI with SMC; PD-
MCI without SMC; no PD-MCI but SMC; and neither PD-MCI nor SMC. Participants in the 
PD-MCI with SMC group were significantly more likely to report clinical levels of anxiety 
than participants with neither PD-MCI nor SMC. However, there was no significant 
difference in anxiety prevalence between participants with PD-MCI without SMC and 
participants with neither PD-MCI nor SMC. These findings suggest that the relationship 
between anxiety and PD-MCI may be influenced by an awareness or perception of cognitive 
decline. A further study by Dissanayaka et al. (2017) grouped participants by the presence or 
absence of anxiety using the MDS-UPDRS, and tested a range of cut-offs for classifying PD-
MCI. The Movement Disorder Society Task Force criteria (Litvan et al., 2012) specify that 
impairment should be between one and two standard deviations (SD) below normative values 
for individuals to be classed as having PD-MCI. Dissanayaka et al. (2017) found that 
participants with anxiety were three times more likely than those without anxiety to show 
PD-MCI using the 1SD cut-off, controlling for age, education and motor severity. However, 
anxiety did not significantly predict PD-MCI when cut-offs of 1.5SD and 2SD were used (the 
authors suggested this to be attributable to the small sample size). 
 Anxiety and cognitive domains. The findings concerning relationships between 
anxiety and cognitive domains are collated in Table 1.5. Because the studies were not directly 
comparable in terms of measures used, sample demographics or overall quality, the columns 
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stating the numbers of studies with and without significant results are intended to summarise 
the findings, rather than to indicate the strength of the evidence.  
 
< INSERT TABLE 1.5 > 
 
Attention. Of the 11 studies that reported using measures of attention, only three 
found significant relationships with anxiety. Hepp et al. (2013) found anxiety to be 
significantly but weakly correlated with part A of the Trail Making Test (TMT-A; Reitan & 
Wolfson, 1985), which was used to assess visual attention. Higher anxiety was associated 
with a longer time taken to complete the task, suggesting greater attentional impairment, 
though this may also have been related to other factors such as reduced psychomotor speed 
(Muslimović, Post, Speelman & Schmand, 2005). Similarly, Klepac et al. (2010) found 
higher anxiety to be an independent predictor of worse performance on TMT-A. However, 
other studies that used TMT-A found no association with anxiety (Ehgoetz Martens et al., 
2016; Reynolds, Hanna, Neargarder & Cronin-Golomb, 2017), though it should be noted that 
these studies had particularly small sample sizes, reducing the power of their analyses to 
detect effects. Ehgoetz Martens, Silveira, Intzandt and Almeida (2018) found a significant 
relationship between state anxiety and an attention/working memory domain, however the 
tests used did not primarily measure attention, therefore these results are reported in the next 
section. 
Working memory. Five studies used measures of working memory, of which three 
found significant relationships with anxiety. Ehgoetz Martens et al. (2018) calculated 
attention/working memory domain scores using the Corsi Block Test, which is primarily a 
visuospatial short-term memory task (Corsi, 1973), and the Digit Span backwards test from 
the Wechsler Adult Intelligence Scale-4th Edition, designed to test working memory (WAIS-
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IV, Wechsler, 2008). Higher state anxiety significantly predicted worse performance in this 
domain. Also using the Digit Span task, Ehgoetz Martens (2016) found significantly worse 
working memory in participants “with anxiety” (indicated by HADS anxiety scores above 8) 
scores compared to those “without anxiety”. Foster et al. (2010) found a significant 
interaction of side of onset (right or left) and anxiety (high or low) on Digit Span score, with 
participants with left-hemibody onset and high anxiety scoring significantly lower on Digit 
Span than those with left-hemibody onset with low anxiety (with disease duration entered as 
a covariate). Meanwhile, participants with left-hemibody onset and high anxiety scored 
significantly lower than participants with right-hemibody onset and high anxiety, suggesting 
that side of onset is a factor in the relationship between anxiety and working memory for 
people with Parkinson’s.  
Klepac et al. (2010) and Reynolds et al. (2017) also used the Digit Span task to 
measure working memory, but did not find significant relationships with anxiety. Reynolds et 
al.’s (2017) study was underpowered for its correlation analysis, therefore the lack of effect 
may have been due to the small sample size. It could not be established whether Klepac et 
al.’s (2010) study was adequately powered for its multiple regression analysis. 
Executive functioning. Of the ten studies that used measures of executive 
functioning, five found significant relationships with anxiety. There was inconsistency 
among the findings, with two of three studies using versions of the Stroop task (e.g. Golden, 
1978) and three of four studies using Part B of the Trail Making Task (TMT-B; Reitan & 
Wolfson, 1985) finding significant effects. These tasks measure elements of cognitive 
flexibility: response inhibition on the Stroop, and set-shifting on the TMT-B. Reynolds et al. 
(2017) found that higher anxiety correlated significantly with poorer set-shifting (TMT-B), 
even after removing the psychomotor component. Klepac et al. (2010) and Ehgoetz Martens 
et al. (2018) both found higher anxiety to significantly predict worse performance on 
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executive tasks, with Eghoetz Martens et al. (2018) controlling for age, depression and 
symptom severity within their analysis. Comparing groups with and without anxiety, as 
described above, Ehgoetz Martens et al. (2016) found the group without anxiety to perform 
significantly better on TMT-B. There were also significant but weak correlations found 
between anxiety and performance on the executive functioning domain of the Brazilian 
version on the Scales for Outcomes in Parkinson’s Disease – Cognition (SCOPA-COG; 
Carod-Artal, Martínez-Martin, Kummer & da Silveira Ribeiro, 2008), with lower levels of 
anxiety correlating with better performance.  
Five studies (Athey et al., 2005; Bugalho, da Silva, Cargaleiro, Serra & Neto, 2012; 
Dissanayaka et al., 2017; Fonoff et al., 2015; Schiehser et al., 2009) did not find significant 
relationships between anxiety and tests of executive function. Only one of these (Athey et al., 
2005) could be confirmed to be adequately powered. 
Memory. Eleven studies investigated the relationship between anxiety and memory, 
of which five found significant effects. Carod-Artal et al. (2008) found a weak but significant 
correlation between higher anxiety and lower scores on the SCOPA-COG memory domain 
(indicating worse memory). Three further significant findings (Ehgoetz Martens et al., 2018; 
Klepac et al., 2010; Ryder et al., 2002) came from regression analyses, with higher anxiety 
predicting worse memory performance in each case across tests of both verbal and visual 
memory, when controlling for appropriate variables. In the study by Dissanayaka et al. 
(2017), where memory impairment was a dichotomous dependent variable in a logistic 
regression analysis, the relationship between anxiety and memory was significant when the 
cut-off for impairment was set at one SD below the normative mean, but not when the cut-off 
was set at 1.5 or 2SD. The authors suggested that this may have been due to the small sample. 
Ehgoetz Martens et al. (2016) found that the relationship between anxiety and 
performance on an immediate story recall task was approaching significance at the 5% level, 
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but that the relationship between anxiety and delayed story recall was not significant. Five 
further studies found no significant relationships between anxiety and memory (Athey et al., 
2005; Brown & Fernie, 2015; Gao et al., 2015; Hurt et al., 2012; Sarno et al., 2019). Sample 
size did not appear to be a problem in these studies, and there were no obvious differences in 
the design or quality between these studies and those which did find significant effects. 
Therefore, the relationship between anxiety and memory for people with Parkinson’s may be 
complex and influenced by other variables. 
Language. Seven studies used tasks aimed at assessing language skills, including 
naming, fluency and verbal comprehension. Two of these found significant effects. Ehgoetz 
Martens et al. (2018) found that state anxiety, but not trait anxiety, predicted performance on 
language tasks after controlling for age, depression, and motor symptom severity. 
Conversely, Ryder et al. (2002) found that trait anxiety accounted for a significant proportion 
of the variance in language scores after controlling for depression (they did not measure state 
anxiety). Five studies (Athey et al., 2005; Brown & Fernie, 2015; Dissanayaka et al., 2017; 
Hurt et al., 2012; Sarno et al., 2019) did not find significant relationships between anxiety 
and performance on language tasks, and this did not seem to be attributable to any particular 
design or quality issues. 
Bogdanova and Cronin-Golomb (2012) examined the interaction between side of 
Parkinson’s onset and performance on verbally-mediated and non-verbally-mediated tasks. It 
was found that anxiety strongly correlated with performance on verbally mediated tasks in 
right-side onset Parkinson’s, with better cognitive performance associated with lower levels 
of anxiety.  
Verbal fluency. In some studies, semantic and phonemic verbal fluency tasks were 
used alongside other tasks to obtain domain scores for executive functioning and language 
abilities, and so are reported in the sections above. In seven studies the analyses relating 
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specifically to the relationship between verbal fluency and anxiety were extractable, but only 
one of these found a significant effect: Klepac et al. (2010) found higher anxiety to 
significantly predict worse semantic (but not phonemic) fluency. There were no obvious 
factors differentiating this study different from those which found no significant effects 
(Brown & Fernie, 2015; Ehgoetz Martens et al., 2016; Hepp et al., 2013; Hurt et al., 2012; 
Reynolds et al., 2017; Sarno et al., 2019).  
Visuospatial abilities. Visuospatial abilities, assessed by tasks where participants 
were asked to copy simple line drawings and judge the orientation of lines, were found to be 
significantly related to anxiety in two of the nine relevant studies. Higher anxiety was weakly 
associated with better performance in this domain (Carod-Artal et al., 2008) and accounted 
for a significant proportion of variance after controlling for depression (Ryder et al., 2002). 
Again, there were no obvious factors making these studies different to those which found no 
significant effects (Athey et al., 2005; Brown & Fernie, 2015; Dissanayaka et al., 2017; 
Ehgoetz Martens et al., 2018; Hurt et al., 2012; Klepac et al., 2010; Sarno et al., 2019).  
Bi-directional findings. The only study examining bi-directional relationships was 
by Petkus et al. (2019). This was a particularly robust study in terms of quality, with a large, 
international sample; it was also one of only two longitudinal studies. Using bivariate latent 
change modelling, Petkus et al. (2019) found worse cognitive performance (in the domains of 
attention, working memory, episodic memory and semantic fluency) to be significantly 
associated with subsequently higher state and trait anxiety. The strongest association was in 
the domain of working memory. Conversely, they found that higher state and trait anxiety 
scores were not significantly associated with subsequent declines in cognitive performance 





 This review considers the evidence regarding relationships between anxiety and 
cognition for people with Parkinson’s. Previous reviews (Alzahrani & Venneri, 2015; Lutz et 
al., 2016; Poletti, De Rosa & Bonuccelli, 2012) have addressed this question but have found 
minimal research in this area (between one and three studies), whereas the current review 
found 39. This review has unearthed many relevant papers not included in the previous 
reviews by increasing the specificity of the question, using broad inclusion criteria and an 
expansive list of search terms to identify cognitive data. This review also identified several 
relevant studies published since the publication of the previous reviews.  
The nature of relationships between anxiety and cognition was similar in all studies 
with significant results: higher levels of anxiety (or the presence of anxiety) was consistently 
associated with more cognitive impairment (or the presence of cognitive impairment), while 
lower levels of anxiety (or the absence of anxiety) was consistently associated with better 
cognitive performance (or the absence of cognitive impairment). However, there were 
inconsistencies as to whether significant results were identified, even in studies using 
apparently similar methodologies. It is likely that these inconsistencies were influenced by 
the wide range of tools used to measure both anxiety and cognition, differences in the 
demographics of the samples, and differences in the quality of the studies (of particular note, 
many of the studies had small samples, reducing their power to detect effects).  
Significant correlations were identified between anxiety and cognition (global 
cognition, PD-MCI status and the cognitive domains of attention, working memory, 
executive functioning, memory, language, semantic verbal fluency and visuospatial abilities). 
This suggests that, at least in some circumstances, there is some relationship between these 
variables for people with Parkinson’s. Moreover, significant predictive relationships and 
group differences in means between anxiety and cognition were found (given that all studies 
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were observational, no causal relationships could be inferred). Most studies of these designs 
took cognitive findings as their dependent variables, though some took anxiety. There were 
significant findings in both directions. This is in keeping with findings in other (and 
potentially overlapping) populations such as older adults (Mantella et al., 2007; Yochim et 
al., 2013), and people with other neurological conditions (Barker-Collo, 2007; Gould et al., 
2014; Julian & Arnett, 2009; Simioni et al., 2007). 
There are various potential explanations for the relationships identified between 
anxiety and cognition. Several authors have suggested that neuroanatomical factors play a 
role, highlighting that the striatum and prefrontal circuits projecting to ventral areas of the 
brain, which are affected by Parkinson’s, are important for both cognition and anxiety 
regulation (Lago, Davis, Grillon, & Ernst, 2017; Sylvester et al., 2012). A cognitive 
perspective may suggest that anxiety limits the resources available for cognitive activity 
(Vytal et al., 2012), and that cognitive impairments (particularly with executive functioning) 
lead to difficulties with identifying and managing stressors (Petkus et al., 2019) and 
implementing strategies to reduce anxiety (Yochim et al., 2013). From a psychological 
perspective, the findings of Baschi et al. (2018) and Petkus et al. (2019) suggest that an 
awareness or perception of cognitive decline can be a source of anxiety for people with 
Parkinson’s.  
Limitations of the Included Studies 
In addition to the limitations described above, there were some limitations concerning 
the validity of the variables. Although all studies used validated measures, not all could be 
confirmed to have been sufficiently validated for use with people with Parkinson’s. 
Skorvanek et al. (2017) reviewed global cognitive measures commonly used with people with 
Parkinson’s. Of significance to this review, the RBANS, CAMCOG and MMSE were not 
recommended due to problems with, or lack of evidence for, validity, reliability and 
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sensitivity to change. Cognitive assessments have also been shown to lack ecological 
validity, scores not always predicting how people perform in complex real-life situations 
(Burgess, Alderman, Evans, Emslie & Wilson, 1998). Therefore, studies may not have 
provided an accurate representation of participants’ cognitive abilities. 
Additionally, despite evidence that symptoms of anxiety and depression commonly 
co-occur among people with Parkinson’s (Sagna, Gallo & Pontone, 2014), and the well-
evidenced relationship between depression and cognition (Alzahrani & Venneri, 2015; Poletti 
et al., 2012), relatively few of the identified studies attempted to control for symptoms of 
depression in their analyses. Indeed, although some studies did control for potentially 
confounding variables, it cannot be concluded that any of the studies were able to isolate 
anxiety as a variable, as discussed in the Quality Assessment section.  
Limitations of this Review  
 A common criticism of systematic literature reviews is the likelihood of 
heterogeneity, making it difficult to synthesise the data in a truly meaningful way and reach a 
clear conclusion (Biondi-Zoccai, Lotrionte, Landoni, & Modena, 2011; Gopalakrishnan & 
Ganeshkumar, 2013). There was certainly evidence of heterogeneity in the samples, 
methodologies and findings in the current review. This is reflected in the variation among 
studies as to whether significant results were found. Further clarification might have been 
gained by considering effect sizes and conducting meta-analyses on some of the findings.  
It should also be highlighted that there was a great deal of variation in the cognitive 
assessment measures used across the studies, from very crude global measures such as the 
MoCA and MMSE, to highly sensitive measures of specific cognitive functions. There was 
also some variation between studies in the cut-off scores or normative data adopted for each 
measure. These differences in the measurement of cognition are likely to have contributed to 
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some of the variation in the findings of the studies, and therefore to the validity of the overall 
findings of this review.  
The method of synthesising findings by cognitive domain in this review is also likely 
to have had an impact on the findings. The domains were selected based on which function 
the authors of the papers intended to measure with each cognitive test. However, cognitive 
assessments tend to load onto more than one cognitive domain. For example, verbal fluency 
was considered by some studies a cognitive domain in its own right; in others, a component 
of executive functioning or language abilities. The findings of this review are therefore likely 
to have been affected by how the cognitive domains were conceptualised. A more rigorous 
conceptualisation may have been achieved by grouping the tests in a consistent way. For 
example, by using the compendium of cognitive tests by domain according to Lezak, 
Howieson, Bigler and Tranel (2012).  
Clinical Implications  
 The findings of this review have implications for clinical psychologists and 
neuropsychologists working with people with Parkinson’s, in keeping with BPS 
recommendations for a holistic approach to considering the cognitive, psychological and 
social factors affecting people with Parkinson’s (Macniven & Gaskill, 2009). Given the 
seemingly bidirectional relationship between anxiety and cognition, psychological 
assessment of either factor should include due consideration of the other. Exploration of 
relationships between anxiety and cognitive factors at the individual level might point 
towards the utility of certain psychological interventions. For example, if an awareness of 
cognitive decline is a source of anxiety, psychoeducation and psychological models focussing 
on acceptance, such as acceptance and commitment therapy (ACT) and mindfulness, may 
have a role. A systematic review found ACT to be a promising intervention for long term and 
chronic conditions (Graham, Gouick, Krahe & Gillanders, 2016), whilst qualitative research 
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has suggested that a mindfulness-based cognitive therapy group was an acceptable 
intervention for people with people with Parkinson’s (Fitzpatrick, Simpson & Smith, 2010). 
Furthermore, interventions focussing on anxiety should be adapted according to each 
individual’s cognitive abilities (Knight, Dissanayaka & Pachana, 2016).  
Research Implications 
 Given that the findings of the studies included in this review were somewhat 
inconsistent as to whether relationships between anxiety and cognition were found, it is likely 
that other variables affect or are involved in their interaction. As such, more complex models 
may be useful in future research for developing understanding of how anxiety and cognition 
interact among people with Parkinson’s. Variables for inclusion in these models might 
include depression, side of onset, time since diagnosis and subjective cognitive performance. 
Qualitative research into the psychological impact of cognitive decline for people with 
Parkinson’s might identify further areas for exploration. 
Conclusions 
 A systematic review of the literature found inconsistent evidence for a relationship 
between anxiety and cognition among people with Parkinson’s. The quality of studies was 
variable, with many studies having small samples, possibly contributing to the lack of 
consistency as to whether significant relationships were found. The significant relationships 
identified were consistent in nature, and suggested a bidirectional relationship between 
anxiety and cognition, with higher anxiety associated with more cognitive impairment. 
Clinicians working with people with Parkinson’s should consider the potential interaction 
between these factors in assessments and interventions. Future research should focus on 
better understanding the relationship between anxiety and cognition among people with 
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searching reference lists: 
n=0 
Total records: n=3883 Duplicates removed: n=2279 
Records screened by title 
and abstract: n=1604 Records excluded: n=1446 
Full text articles assessed 
against selection criteria: 
n=158 
Full text articles excluded: n=119 
 
Reasons 
Paper not available in English: n=2 
Participants did not have 
Parkinson’s: n=1 
Data for participants with 
Parkinson’s not extractable 
from sample: n=2 
Did not measure anxiety: n=8 
Anxiety data not separable from 
other psychological/psychiatric 
data: n=5 
Did not measure cognition: n=3 
Measured cognition using self-
report: n=3 
Took relevant measures but did not 
compare them: n=95 
Papers eligible for review: 
n=39 (based on 39 studies) 
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Table 1.1  
Search Terms Used 
Database Subject Heading Terms Free-Text Terms 
CINAHL Parkinson Disease; 
 




Neuropsychological Tests; Mental 
Processes; Impulsive Behavior; 








“executive”; “metacognit*”; “frontal”; 
“process*”; “problem solv*”; 
“reason*”; “concept formation”; 




“perception*”; “orient*”; “spatial”; 
“visuospatial”; “visuoconstruct*”; 
“language”; “verbal”; “comprehen*”; 
“learn*”; “dement*”; “MCI”. 
 
Medline Parkinson Disease; 
 







Cognition; Cognitive Dysfunction; 
Cognitive Neuroscience; Mental 
Processes; Neuropsychology; 
Neuropsychological Tests; 
Executive Function; Metacognition; 
Problem Solving; Concept 
Formation; Set (Psychology); 
Impulsive Behavior; Attention; 






“executive”; “metacognit*”; “frontal”; 
“process*”; “problem solv*”; 
“reason*”; “concept formation”; 




“perception*”; “orient*”; “spatial”; 
“visuospatial”; “visuoconstruct*”; 
“language”; “verbal”; “comprehen*”; 
“learn*”; “dement*”; “MCI”. 
 
PsycINFO Parkinson’s Disease;  
 
Anxiety; Anxiety Disorders; 
 
Cognition; Cognitive Ability; 
Cognitive Processes; Cognitive 
Assessment; Neurocognition; 
Neuropsychology; Executive 
Function; Dysexecutive Syndrome; 
Metacognition; Cognitive 
Processing Speed; Problem 






“executive”; “metacognit*”; “frontal”; 
“process*”; “problem solv*”; 
“reason*”; “concept formation”; 





Formation; Set Shifting; 
Impulsiveness; Distractibility; 
Perseveration; Attention; 
Concentration; Memory; Memory 
Disorders; Perception; 
Communication Disorders; 
Learning; Dementia.  
 
“perception*”; “orient*”; “spatial”; 
“visuospatial”; “visuoconstruct*”; 
“language”; “verbal”; “comprehen*”; 









“executive”; “metacognit*”; “frontal”; 
“process*”; “problem solv*”; 
“reason*”; “concept formation”; 




“perception*”; “orient*”; “spatial”; 
“visuospatial”; “visuoconstruct*”; 
“language”; “verbal”; “comprehen*”; 




Quality Assessment Tool (Adapted from Williams et al., 2009) 
Short Title   Criterion 
Sample 
 
Sample is valid and representative 
Comparable groups Selection minimizes baseline differences in prognostic factors 
(only relevant to studies using between-groups comparisons) 
 
Power Sample size is large enough to detect a significant 
effect/relationship in at least one primary outcome measure at 
the 5% level 
 
Measures Measures implemented consistently across participants and 
cognitive assessments are carried out by a suitably qualified 
individual  
 
Follow-up consistency The length of follow-up is the same across all groups (only 




Completeness of follow-up (only relevant to longitudinal 
studies) 
 
Confounding variables Analysis controls for confounding variables 
 





Summary of Study Characteristics and Relevant Findings 






































HADS-A CAMCOG-R  No significant correlations found 
between anxiety scores and any of the 
CAMCOG-R domain scores 
(orientation, comprehension, 
expression, memory, attention and 
calculation, praxis, abstract thinking, 




























Participants with PD-MCI and 
subjective memory complaints 
reported significantly more anxiety 
than participants with neither PD-
MCI nor subjective memory 
complaints; there was no significant 
difference in anxiety ratings between 
participants with PD-MCI (and no 
subjective memory complaints) and 
participants with neither PD-MCI nor 






























In left-side onset Parkinson’s, anxiety 
was not associated with performance 
on non-verbally mediated tasks (TMT 
B, Spatial Span, Visual Symbol 
Search); in right-side onset 














strongly correlated with performance 
on verbally mediated tasks (BNT, 
CVLT, Clock Reading, and 
Controlled Oral Word Association), 
with better cognitive performance 













Not stated HADS-A ACE-R No significant correlations were 
found between anxiety and any of the 
ACE-R domains (attention and 
orientation, memory, fluency, 


















MMSE; FAB No significant correlations were 
found between anxiety and the 
MMSE or FAB total scores 
	 55	




















HADS-A SCOPA-COG Significant but weak correlations 
were found between anxiety and total 
SCOPA-COG scores, and anxiety and 
SCOPA-COG domains memory, 
executive functions and visuospatial 
functions; better SCOPA-COG 
performance was associated with 
lower levels of anxiety; there was 
also a weak negative correlation 
between anxiety and SCOPA-COG 
attention, but this was not significant.  
 














CC-MMSE No significant difference in CC-








between participants with and 
without an anxiety disorder diagnosis 
 
Dissanayaka 



































No significant difference in total 
MMSE or MoCA scores was found 
between the anxious and non-anxious 
groups; participants with anxiety 
were significantly more likely than 
participants without anxiety to have 
PD-MCI (with cut-off set at 1 SD 
below the mean) and to show 
impairment (1 SD below the mean) 
on memory tasks; there were no 
significant relationships found 
between anxiety and the other 
cognitive domains (attention, 
executive function, visuospatial 











‘impairment’ cut-off was set at 1.5 
and 2 SDs below the mean, no 
significant relationships were found 















Not stated MINI-plus; 
HAM-A 
 
MMSE; PDCRS No significant associations were 
found between anxiety and total 














STAI MoCA; Digit 
Span; Corsi 
Block Test; 
Neither trait or state anxiety predicted 
overall cognitive function (MoCA) 














depression, and motor symptom 
severity, state anxiety predicted 
performance in the attention/working 
memory, executive function, memory 
and language domains but not 
visuospatial function; after 
controlling for age, depression and 
symptom severity, trait anxiety 
predicted performance in the 







































There were no differences between 
the scores of the PDA+ and PDA- 
groups on the MMSE, TMT-A, 
Logical Memory II test performance 
or % retention, or COWAT semantic 
fluency or phonemic fluency; the 




 significantly worse performance than 
the PDA- group on the TMT-B and 
Digit Span forward and backward; on 
the Logical Memory I immediate 
recall test there was a trend 
approaching significance that the 
PDA+ group had worse new verbal 
learning and immediate recall 
abilities than the PDA−  group 
 
Fan, Chang 

















BAI MMSE There was no significant correlation 
found between BAI and MMSE 
scores; there was no significant 
difference in MMSE scores between 
groups split by BAI classification 
(normal, mild, moderate and severe) 
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HAM-A CPT-II; WCST There was a significant moderate 
correlation between anxiety and CPT-
II reaction time, with higher anxiety 
associated with a slower reaction 
time; no significant correlations were 
found between anxiety and any other 
subscales  
 













STAI MMSE; DRS-II, 
Digit Span from 
WMS-III 
An ANOVA found no significant 
direct effect of anxiety group (high or 
low) on MMSE or DRS-II scores; an 
ANCOVA with disease duration as a 
covariate found a significant  
interaction effect of side of onset 
(right or left) and anxiety (high or 
low) on Digit Span score; participants 
with left hemibody onset and high 
anxiety scored significantly lower on 
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Digit Span than those with left 
hemibody onset with low anxiety. 
 


















There was a weak but significant 
correlation between anxiety and 
WAIS-RC total scores, with higher 
anxiety associated with lower WAIS-
RC scores; there were no significant 
correlations found between anxiety 
and the other cognitive test scores 
 

















No significant correlations were 
found between RAVLT and BAI 
scores; scores on TMT-A correlated 
significantly with BAI – higher 
anxiety was associated with a longer 
time taken to complete the task 
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MoCA Higher anxiety significantly predicted 
lower scores on the MoCA 
(indicating more impairment) 
 












HADS-A ACE-R No significant correlations were 
found between anxiety and any of the 
ACE-R domains (attention and 
orientation, memory, fluency, 



















HAM-A MMSE There was a weak but significant 
correlation between anxiety and total 
MMSE scores, with higher anxiety 




























Higher anxiety independently 
predicted worse performance in 
Stroop 1, Stroop 3, COWAT Plant, 
SDMT, RAVLT, ROCF recall, and 
TMT-A tests; anxiety did not predict 
performance in Stroop 2, Digits 
forward or backward, COWAT FAS, 
and ROCF copy; none of the 



























Six classes were identified with 
different cognitive profiles; there 
were no significant differences in 
state anxiety or total anxiety between 
the classes; the “weak-overall” class 
(scoring below the 25th percentile in 





higher trait anxiety than the “typical-
overall” class (scoring between the 























MMSE There was a very weak but significant 
correlation between anxiety and 
MMSE scores, with higher anxiety 





























There were no significant differences 
found in NPI Anxiety scores between 
groups with no cognitive impairment, 
PD-MCI and PDD; there was no 
significant difference found in 
HADS-A scores between groups with 
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WCST; 5-





no cognitive impairment and PD-
MCI (the PDD group did not 
complete the HADS-A) 
Mamikonyan 
























State anxiety was not a significant 





















MMSE Significantly lower MMSE scores 
were found in the high anxiety group 
(the 25% of participants with the 






part of the 
analysis 
part of the 
analysis 
the low anxiety group (the 25% of 










































There were no significant differences 
in NPI Anxiety scores between the 
three groups: normal cognition, 
amnesic PD-MCI and non-amnesic 
PD-MCI 
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Not stated HADS-A MMSE There was no significant difference in 
mean MMSE scores between 
participants with HADS-A ≤7 and 
participants with HADS-A>7 























STAI ANT No significant correlations were 
found between anxiety (state or trait) 






























Across all cognitive domains, worse 
performance was significantly 
associated with higher state and trait 
anxiety over time; working memory 
had the largest effect size in terms of 
subsequent increases in anxiety; 
however higher state and trait anxiety 
scores were not significantly 
associated with declines in cognitive 

























Higher anxiety correlated with poorer 
set-shifting (TMT-B), even after 
removing the psychomotor 
component (TMT B-A). Anxiety did 
not correlate with performance on 




phonemic fluency, or categorical 
fluency. 
 













Not stated STAI MoCA Lower MoCA scores at baseline were 
associated with an increase in STAI 
State Anxiety scores over time 
 
 












Stepwise multiple regression 
analyses, including all significant 
correlates except MMSE, showed that 
Trait Anxiety accounted for a 
significant proportion of the variance 
in the RBANS indexes Immediate 
Memory, Delayed Memory, 
Visuospatial/Construction and 
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Language, and RBANS total score, 
but not the Attention index 
 











BAI MMSE; SDMT; 
BNT; COWAT; 




No significant differences were 
identified between participants with 
(BAI ≥ 10) and without (BAI< 10) 





















No significant correlations were 














Not stated MINI; 
HAM-A; 
BAI 
MMSE There were no significant differences 
in MMSE scores found between the 



























HAM-A MMSE No significant correlation was found 
between MMSE and HAM-A scores 
Wan 
Mohamed, 
















HADS-A PDCRS The PDCRS subtest scores for 
confrontation naming, sustained 
attention, working memory, 
unprompted clock drawing and copy 
clock drawing were significantly 
correlated with anxiety, with lower 
scores associated with higher anxiety; 
there were no significant associations 
found between anxiety and verbal 
	 72	
Note.  AAB = Aachener Aphasie Battery; ACE-R = Addenbrookes Cognitive Examination - Revised; ANT = Attention Network Test; BAI = Beck Anxiety Inventory; 
BNT = Boston Naming Test; CAMCOG-R = Cambridge Cognitive Assessment –Revised; CANTAB = Cambridge Neuropsychological Test Automated Battery; CB-
SCID-DSM IV = Chinese-Bilingual Structured Clinical Interview for DSM-IV; CC-MMSE = Chinese-Cantonese Mini-Mental State Examination; CDR = Cognitive 
Drug Research Battery; COWAT = Controlled Oral Word Association Test; CPT-II = Continuous Performance Test – Second Edition; CVLT-II = California Verbal 
Learning Test – Second Edition; DKEFS = Delis-Kaplan Executive Function System; DRS-II = Dementia Rating Scale-2; FAB = Frontal Assessment Battery; GDS 
memory, delayed free recall, 
















STAI MMSE There were weak but significant 
correlations found between MMSE 
scores and both state and trait anxiety 
scores, with higher anxiety associated 
with lower MMSE scores 
  















HAM-A MoCA HAM-A scores were significantly 
higher in participants with cognitive 
dysfunction (MoCA≤	24) than 




= Geriatric Depression Scale; HADS-A = Hospital Anxiety and Depression Scale – Anxiety subscale; HAM-A = Hamilton Anxiety Scale; HVLT-R = Hopkins Verbal 
Learning Test - Revised; JoLO = Benton’s Judgement of Line Orientation; LADS = Leeds Anxiety and Depression Scale; MDRS = Mattis Dementia Rating Scale; 
MDS-UPDRS = Movement Disorder Society Unified Parkinson’s Disease Rating Scale; MMSE = Mini-Mental State Examination; MoCA = Montreal Cognitive 
Assessment; NPI = Neuropsychiatric Inventory; PDCRS = Parkinson’s Disease Cognitive Rating Scale; PDD = Parkinson’s Disease Dementia; PD-MCI = 
Parkinson’s Disease Mild Cognitive Impairment; PoA = Power of Attention; RAVLT = Rey Auditory Verbal Learning Test; RBANS = Repeatable Battery for the 
Assessment of Neuropsychological Status; RCPM = Raven’s Coloured Progressive Matrices; ROCF = Rey=Osterrieth Complex Figure; SCL-90-R = Symptom 
Checklist – Revised; SCOPA-COG = Scales for Outcomes in Parkinson’s Disease – Cognition; SDMT = Symbol Digit Modality Test; STAI = State Trait Anxiety 
Inventory; TMT = Trail Making Test; TMT-A = Trail Making Test – Part A; TOL-DX = Tower of London Test; VOSP = Visual Object and Space Perception 
Battery; WAIS-IV = Wechsler Adult Intelligence Scale – Fourth Edition; WAIS-RC = Wechsler Adult Intelligence Scale – Revised by China; WCST = Wisconsin 






































































Athey et al. (2005) p n/a y c n/a n/a p y 




y n/a n c n/a n/a p y 
Brown & Fernie 
(2015) 
p n/a y c n/a n/a p y 
Bugalho et al. 
(2012) 
p n/a n c n/a n/a p y 
Carod-Artal et al. 
(2008) 
p n/a y y n/a n/a p y 
Chen et al. (2010) y y c y n/a n/a p y 
Dissanayaka et al. 
(2017) 
y y c c n/a n/a p y 
Dissanayaka et al. 
(2015) 
p p c y n/a n/a p y 
Ehgoetz Martens et 
al. (2018) 
p n/a c c n/a n/a p y 
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Ehgoetz Martens et 
al. (2016) 
y y c c n/a n/a p y 
Fan et al. (2016) p p c c n/a n/a p y 
Fonoff et al. (2015) y n/a n c n/a n/a p y 
Foster et al (2010) n y c c n/a n/a p y 
Gao et al. (2015) p n/a y c n/a n/a p y 
Hepp et al. (2013) p n/a n c n/a n/a p y 
Hu et al. (2014) y n/a c y n/a n/a p y 
Hurt et al. (2012) y n/a y c n/a n/a p y 
Khedr et al. (2012) p n/a y c n/a n/a p y 
Klepac et al. 
(2010) 
p y c y n/a n/a p y 
LaBelle et al. 
(2017) 
y p c c n/a n/a p y 
Lee et al. (2012) p n/a y c n/a n/a p y 
Leroi et al. (2012) y y c c n/a n/a p y 
Mamikonyan et al. 
(2009) 
y p c y n/a n/a p y 
Manor et al. (2009) p c c c n/a n/a p y 
Monastero et al. 
(2013) 
p p c c n/a n/a p y 
Nègre-Pagès et al. 
(2010) 
p c c c n/a n/a p y 
Pauletti et al. 
(2017) 
p n/a n y n/a n/a p y 
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Petkus et al. (2019) p n/a c c y c p y 
Reynolds et al. 
(2017) 
y n/a n c n/a n/a p y 
Rutten et al. (2017) p n/a c c y y p y 
Ryder et al. (2002) n n/a n y n/a n/a p y 
Sarno et al. (2019) p c c y n/a n/a p y 
Schiehser et al. 
(2009) 
p n/a n c n/a n/a p y 
Starkstein et al. 
(2014) 
y p c c n/a n/a p y 
Starkstein et al. 
(1993) 
p p n y n/a n/a p y 
Wan Mohamed et 
al. (2015) 
p n/a n c n/a n/a p y 
Zahodne et al. 
(2013) 
p n/a y c n/a n/a p y 
Zhang et al. (2016) p p c y n/a n/a p y 




Summary of Relationships Found between Cognition and Anxiety, by Cognitive Domain 
Domain Number of 
studies which 














3 0 - ACE-R; CAMCOG 
Attention 7 3 Higher anxiety was 
associated with and 
predictive of worse 





Block Test*; Digit 
Span backwards from 
WAIS-IV*; Digit 
Vigilance Accuracy 





2 3 Higher anxiety was 
associated with and 
predictive of worse 
performance on working 
memory tasks. 
  
Corsi Block Test*; 
Digit Span from 
WAIS-IVº; Digit 
Span from WMS-III 
Executive 
function 
3 5 Higher anxiety was 
associated with and 







performance on executive 
tasks 
 
Memory 5  6 Higher anxiety was 
associated with and 
predictive of worse 










Language 5 2 Higher anxiety was 
associated with and 
predictive of worse 






Verbal fluency 6 1 Higher anxiety was 
predictive of worse 
performance on a 







7 2 Higher anxiety was 
associated with and 









Note. *= effect found in all analyses using this test; º= effect found in some analyses using this test but not 
in others; ACE-R = Addenbrookes Cognitive Examination - Revised; ANT = Attention Network Test; BNT 
= Boston Naming Test; CAMCOG = Cambridge Cognitive Assessment; CANTAB = Cambridge 
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Neuropsychological Test Automated Battery; CDR = Cognitive Drug Research Battery; COWAT = 
Controlled Oral Word Association Test; CVLT-II = California Verbal Learning Test – Second Edition; 
FAB = Frontal Assessment Battery; JoLO = Benton’s Judgement of Line Orientation; MMSE = Mini-
Mental State Examination; MoCA = Montreal Cognitive Assessment; PoA = Power of Attention; RAVLT = 
Rey Auditory Verbal Learning Test; RBANS = Repeatable Battery for the Assessment of 
Neuropsychological Status; ROCF = Rey=Osterrieth Complex Figure; SCOPA-COG = Scales for 
Outcomes in Parkinson’s Disease – Cognition; SDMT = Symbol Digit Modality Test; TMT = Trail Making 
Test; TMT-A = Trail Making Test – Part A; WAIS-IV = Wechsler Adult Intelligence Scale – Fourth 
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Search Strategy used in the Electronic Database CINAHL 
 
1. MH “Parkinson Disease” 
2. Ti: Parkinson* 
3. Ab: Parkinson* 
4. 1 OR 2 OR 3 
5. MH “Anxiety”  
6. MH “Anxiety Disorders” 
7. Ti: anxiet* 
8. Ab: anxiet* 
9. 5 OR 6 OR 7 OR 8 
10. MH “Cognition Disorders” 
11. MH “Neuropsychology” 
12. MH “Neuropsychological Tests” 
13. MH “Mental Processes” 
14. MH “Impulsive Behavior” 
15. MH “Attention” 
16. MH “Memory” 
17. MH “Perception” 
18. MH “Dementia” 
19. Ti: cognit* OR neuropsycho* OR executive OR metacognit* OR frontal OR process* 
OR problem solv* OR reason* OR concept formation OR sequenc* OR *shift* OR 
impulsiv* OR distract* OR initiat* OR perseverat* OR attention OR concentration 
OR memory OR perception* OR orient* OR spatial OR visuospatial OR 
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visuoconstruct* OR language OR verbal OR comprehen* OR learn* OR dement* OR 
MCI 
20. Ab: cognit* OR neuropsycho* OR executive OR metacognit* OR frontal OR 
process* OR problem solv* OR reason* OR concept formation OR sequenc* OR 
*shift* OR impulsiv* OR distract* OR initiat* OR perseverat* OR attention OR 
concentration OR memory OR perception* OR orient* OR spatial OR visuospatial 
OR visuoconstruct* OR language OR verbal OR comprehen* OR learn* OR dement* 
OR MCI 
21. 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 





Quality Assessment Tool for Observational Studies (Williams et al., 2010; unmodified) 
 
1) Unbiased selection of the cohort?  
Factors that help reduce selection bias:  
• Prospective study design and recruitment of subjects  
• Inclusion/exclusion criteria  
o Clearly described (especially re: age and cognitive status)  
o Assessed using valid and reliable measures  
• Recruitment strategy  
o Clearly described  
o Relatively free from bias (selection bias might be introduced, e.g., by 
recruitment via advertisement)  
2) Selection minimizes baseline differences in prognostic factors?  
Factors to consider: 
• Was selection of the comparison group appropriate? Note: This may not be an issue 
in the cohort studies we review. In general, the exposed and unexposed groups should 
be from the same source. However, it is possible that for some medical condition 
exposures the exposed group will be patients from a specialty medical clinic and the 
unexposed comparison group will be from another source. Consider whether these 
two sources are likely to differ on factors related to the outcome (besides the exposure 
factor). 
• In addition to selecting the cohort in an unbiased way, did study investigators do 
other things to ensure that exposed/unexposed groups were comparable, e.g., by using 
stratification, matching, or propensity scores?  
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3) Sample size calculated/5% difference?  
Factors to consider:  
• Did the authors report conducting a power analysis or describe some other basis for 
determining the adequacy of study group sizes for the primary outcome(s) of interest 
to us?  
• Was the sample size sufficiently large to detect a clinically significant difference of 
5% in event rates or an OR/RR increase of ≥ 1.5 or decrease of ≥ 0.67 between groups 
in at least one primary outcome measure of interest to us?  
4) Adequate description of the cohort?  
Consider whether the cohort is well-characterized in terms of baseline:  
• Age  
• Sex  
• Race  
• Educational level  
• Cognitive status  
• For genetic association studies, were the diseased and non-diseased populations 
drawn from groups with the same ethnic/racial mix?  
5) Validated method for ascertaining exposure?  
Factors to consider:  
• Was the method used to ascertain exposure clearly described? (Details should be 
sufficient to permit replication in new studies.)  
• Was a valid and reliable measure used to ascertain exposure? (Subjective measures 
based on self-report tend to have lower reliability and validity than objective measures 
such as clinical reports and lab findings.)  
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• For gene association studies, is the “call rate” of genotyping (the proportion of 
samples in which the genotyping provides an unambiguous reading) reported? Were 
quality checks implemented or rules established to determine when genotyping results 
would be considered valid? To clarify your score, please make a note of the 
method/measure used to ascertain exposure.  
6) Validated method for ascertaining clinical outcomes?  
Factors to consider:  
• Were primary outcomes (AD and/or cognitive decline) assessed using valid and 
reliable measures? (See details below.)  
• Were these measures implemented consistently across all study participants?  
7) Outcome assessment blind to exposure?  
• Were the study investigators who assessed outcomes blind to the intervention or 
exposure status of participants?  
8) Adequate follow-up period?  
Factors to consider:  
• Minimum adequate follow-up period is 2 years for AD and 1 year for cognitive 
decline  
• Follow-up period should be the same for all groups  
o In cohort studies, length of follow-up should be the same across all groups.  
o In nested case-control studies, period between the intervention/exposure and 
outcome should be the same for cases and controls.  
o OK if differences in follow-up time were adjusted for using statistical 
techniques, e.g., survival analysis.  
9) Completeness of follow-up?  
Factors to consider:  
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• Did attrition from any group exceed 30%? (Attrition is measured in relation to the 
time between baseline/allocation and outcome measurement. Where different 
numbers of patients are followed up for different outcomes, use the number followed 
up for the primary outcome for this calculation.)  
• Did attrition differ between groups by more than 10% percent?  
10) Analysis controls for confounding?  
Factors to consider:  
• Did the analysis control for any baseline differences between groups?  
• Does the study identify and control for important confounding variables and effect 
modifiers? (Confounding variables are risk factors that are correlated with the 
intervention/exposure and outcome and may therefore bias the estimation of the effect 
of intervention/exposure on outcome if unmeasured. Effect modifiers are not 
correlated with the intervention/exposure, but change the effect of the 
intervention/exposure on the outcome. Age, race/ethnicity, education, and measures 
of SES are examples of effect modifiers and confounding variables for the exposures 
and outcomes of interest in this study.)  
11) Analytic methods appropriate?  
Factors to consider:  
• Was the kind of analysis done appropriate for the kind of outcome data?  
o Dichotomous – logistic regression, survival  
o Categorical – mixed model for categorical outcomes  
o Continuous – ANCOVA, mixed model  
• Was the analysis done on an intention-to-treat basis? (That is, was the impact of loss 
to follow-up [or differential loss to followup] assessed, e.g., through sensitivity 
analysis or another intent-to-treat adjustment method?  
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• Was the number of variables used in the analysis appropriate for the sample size? 
(The statistical techniques used must be appropriate to the data and take into account 
issues such as controlling for small sample size, clustering, rare outcomes, multiple 
comparison, and number of covariates for a given sample size. The multiple 
comparisons issue may be a problem particularly when performance results on 
numerous cognitive measures are being compared. When assessing change on 
cognitive measure over time, consider whether change score should be adjusted for 
baseline score, and consider distribution of baseline scores and change scores.)  
• For gene association studies:  
o Did the investigators conduct statistical tests to check whether the observed 
genotype frequencies are consistent with the Hardy-Weinberg Equilibrium?  





Adaptations to Williams et al.’s (2009) Quality Assessment Tool 
 
Item Original criterion   Adaptations made Reasons for adaptations 
1 Unbiased selection 
of the cohort 
Combined with Item 4 to 
become “sample is valid and 
representative” 
It was difficult to establish bias 
in sampling methods or the 
representativeness of the 
sample without the sample 












3 Sample size 
calculated / 5% 
difference 
Sample size required to be 
large enough to detect a 
significant 
effect/relationship in at least 
one primary outcome 
measure at the 5% level 






description of the 
cohort 
Combined with Item 1 to 
become “sample is valid and 
representative” 
It was difficult to establish bias 
in sampling methods or the 
representativeness of the 
sample without the sample 
being adequately described 
 




Item removed Not relevant to research 
question 
6 Validated method 
for ascertaining 
clinical outcomes 
Changed to: measures 
implemented consistently 
across participants and 
cognitive assessments are 
carried out by a suitably 
qualified individual  
 
Part of this criterion was 
covered by study selection 
criteria (since it was required 
that validated measures were 
used), therefore only part of 





assessment blind to 
exposure 
 





Changed to: in longitudinal, 
between-groups studies, the 
Selected the part of the 
criterion which was relevant to 
the research question 
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length of follow-up is the 























- All Addition of “not applicable” 
(n/a) rating 
Some items were not 








































































Athey et al, 2005 p na y ct na na p y 
Dissanayaka et al, 2017 y y ct ct na na p y 
Hepp et al, 2013 p na n ct na na p y 
Mamikonyon et al, 2009 y p ct y na na p y 
Ryder et al, 2002 n na n y na na p y 
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Objectives: People with Parkinson’s can experience stigma, both through the attitudes and 
actions of others (enacted stigma) and through anticipation of enacted stigma and 
internalisation of negative stereotypes (felt stigma). Previous research has suggested that self-
compassion protects against the impact of enacted stigma upon felt stigma and negative 
outcomes. This study aimed to investigate the relationships between self-compassion, stigma 
and psychological distress among people with Parkinson’s. 
Design: In a quantitative, questionnaire-based design, correlation and mediation models were 
used to investigate the relationships between the variables.  
Methods: 138 people with Parkinson’s completed questionnaires measuring self-compassion, 
enacted and felt stigma, and depression, anxiety and stress.  
Results: All variables correlated significantly in the expected directions. The stigma 
variables were found to be significant mediators in the relationships between self-compassion 
and the three outcome variables - depression, anxiety and stress. Higher self-compassion was 
associated with less reported stigma, which was in turn associated with lower levels of 
psychological distress. 
Conclusions: Part of the relationship between self-compassion and psychological distress 
appears to occur via the internalisation of stigma. Self-compassion may also predict how 
likely a person is to notice or report enacted stigma. Therefore, people with Parkinson’s who 
are higher in self-compassion may experience less enacted stigma (even when they are 
exposed to it), and therefore experience lower levels of distress. These findings may be 
relevant to the development of individualised and societal interventions with the aim of 




Stigma, Self-Compassion and Psychological Distress among People with 
Parkinson’s 
Parkinson’s disease (referred to throughout this paper as “Parkinson’s”: the preferred 
terminology by the charity Parkinson’s UK) is a neuro-degenerative condition affecting 
around 0.3% of people worldwide (Pringsheim, Jette, Frolkis & Steeves, 2014), with 
increasing prevalence after the age of 60 (Tysnes & Storstein, 2017). Parkinson’s is classified 
as a movement disorder (Fahn, 2011). Accordingly, people with Parkinson’s can experience 
problems with initiating movement (akinesia), slowed movement (bradykinesia), tremor, 
rigidity, gait disturbance and speech difficulties (Moustafa et al., 2016). Other difficulties 
experienced by people with Parkinson’s can include anxiety, depression, cognitive 
impairments, sensory disturbances, sexual dysfunction and continence problems (Rana, 
Ahmed, Chaudry & Vasan, 2015; Stacy, 2011).  
 Experiences of psychological distress are common among people with Parkinson’s. A 
systematic review of the literature found that 35% of people with Parkinson’s experience 
clinically significant symptoms of depression (Reijnders, Ehrt, Weber, Aarsland & Leentjens, 
2008), while the prevalence of anxiety is estimated at 25% (Dissanayaka et al., 2010). 
Conceptualisations of these experiences have traditionally assumed a neuro-biological stance, 
suggesting that psychological distress occurs as a direct consequence of pathological 
processes, such as changes in dopaminergic, serotonergic, and noradrenergic systems and 
fronto-striatal circuitry (Aarsland, Marsh & Schrag, 2009; Kano et al., 2011; Remy, Doder, 
Lees, Turjanski & Brooks, 2005). However, in addition to the recognised role of neuro-
biological changes, growing evidence suggests that social and psychological factors are 
important in the development of psychological distress (Garlovsky, Overton & Simpson, 
2016). It is important to develop a better understanding of these factors so that holistic 
assessment and support can be provided, as recommended in the British Psychological 
2-4	
	
Society’s (BPS) briefing document regarding psychological services for people with 
Parkinson’s (Macniven & Gaskill, 2009). The current paper therefore focusses on two 
psycho-social factors in relation to psychological distress among people with Parkinson’s: 
stigma and self-compassion.  
Goffman’s (1963) early conceptualisation of stigma described it as an individual 
attribute which is discredited by society, leading to loss of social status. Later, stigma was 
more comprehensively defined as a phenomenon whereby individuals are labelled, 
stereotyped, discredited and discriminated against, based on certain attributes which are 
devalued by society, in a context where they have reduced power (Link & Phelan, 2001; 
2006). “Enacted stigma” is a term used to describe the negative reaction that the stigmatised 
individual receives from others, through their attitudes and actions (Scambler, 1989). When 
an individual expects or fears enacted stigma, this is known as “felt stigma”, or “internalised 
stigma” (Corrigan, Watson & Barr, 2006). Felt stigma may also involve identification with 
negative stereotypes, and the application of discrediting attitudes to the self (Watson, 
Corrigan, Larson & Sells, 2007). Experiences of felt stigma have been found to be associated 
with feelings of shame and low self-esteem (Link & Phelan, 2001; Rao et al., 2009). 
In the context of illness and impairment, where difference may be highly visible, 
individuals may be at a higher risk of stigmatisation (Campbell & Deacon, 2006; Joachim & 
Acorn, 2000). People with Parkinson’s may present with visible differences, through the 
more overt motor and facial symptoms and communication difficulties, increased dependence 
on others, and lifestyle changes necessitated by symptoms (Hermanns, 2013). Research has 
demonstrated stigmatising views towards people with Parkinson’s held by both professionals 
(Tickle-Degnen, Zebrowitz & Ma, 2011) and members of the public (Hemmesch, 2014; 
Moore & Knowles, 2006). Several qualitative studies have described the enacted and felt 
stigma that people with Parkinson’s can experience in relation to the more visible symptoms 
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of the condition (Bramley & Eatough, 2005; Caap-Ahlgren & Lannerheim, 2002; Hermanns, 
2013; Nijhof, 1995). Experiences of stigma have been found to be associated with heightened 
levels of anxiety, depression and stress among people with Parkinson’s (Ma et al., 2016; 
Simpson, Lekwuwa, & Crawford, 2014; Schrag, Jahanshahi & Quinn, 2001). Felt stigma has 
been found to be prevalent among people with Parkinson’s even in the absence of direct 
experience of enacted stigma, demonstrating the importance of implicit public attitudes (Ma 
et al., 2016). Simpson, McMillan and Reeve (2013) describe the structural disablism faced by 
people with Parkinson’s (active barriers to inclusion at the public level, such as workplace 
discrimination, costs of care and inaccessibility of information), and how this may lead to 
psycho-emotional disablism (the internalisation of oppressive attitudes and subsequent 
restrictions placed upon the self). Therefore, enacted stigma can contribute to the 
internalisation of stigma and experiences of psychological distress (Simpson et al., 2013). Ma 
et al. (2016) found a stronger relationship between felt stigma and depression than enacted 
stigma and depression, suggesting that the internalisation of stigma is an important factor 
relating to the development of psychological distress.  
Self-compassion is defined as a non-judgemental acknowledgement of one’s own 
suffering, and a self-directed response based upon “kindness, concern and support” (Neff & 
Dahm, 2015, pp.121). Self-compassion is considered an important element of emotional 
regulation, access to which is affected by early relational experiences (Gilbert, 2009; 2010). 
Gilbert (2009; 2010; 2014) describes how, if a child receives attuned care when they are 
distressed, where they are soothed and helped to feel safe, then they will internalise the 
ability to recognise their distress and self-soothe (i.e. to show compassion towards 
themselves). Conversely, difficult early relational experiences (such as miss-attuned 
caregiving, abuse and neglect) present few opportunities to learn self-compassion or access 
affiliative emotion regulation systems; instead a child may learn to be hypervigilant to 
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potential threats and experience heightened shame and self-criticism (Gilbert, 2009; 2010). 
Thus, the development of self-compassion affects how we cope with difficult life events and 
experiences – how we appraise threats, experience affiliative emotions, view and relate to 
ourselves and self-soothe. Across a range of populations, self-compassion has been shown to 
be positively associated with psychological wellbeing (Zessin, Dickhäuser & Garbade, 2015) 
and negatively associated with symptoms of depression and anxiety (MacBeth & Gumley, 
2012). Further, it has been demonstrated that interventions aimed at increasing self-
compassion can alleviate psychological distress in people with neurological problems – for 
example, traumatic brain injury (Ashworth, Gracey & Gilbert, 2011), dementia (Collins, 
Gilligan & Poz, 2018) and multiple sclerosis (Nery-Hurwit, Yun & Ebbeck, 2018). However, 
self-compassion does not appear to have yet been studied among people with Parkinson’s. 
Individuals whose early experiences have supported the development of self-
compassion may have different interpretations of, and responses to, experiences of stigma 
than those who have had limited opportunities to develop self-compassion.  Wong, Knee, 
Neighbors and Zvolensky (2019) offer a theoretical framework for how self-compassion may 
protect against the effects of enacted stigma upon felt stigma and negative outcomes (such as 
psychological distress). Drawing upon the literature, Wong et al. (2019) suggest that there are 
cognitive, emotional, and social mechanisms through which self-compassion affects the 
processing of stigma, which are summarised here. Cognitively, an individual with higher self-
compassion may be more able to accurately appraise the threats of stigmatisation and 
positively reframe experiences of enacted stigma, allowing them to feel safer and more 
content, and thus internalise stigma less. In line with the aforementioned conceptualisation by 
Gilbert (2009; 2010), Wong et al. (2019) also describe how self-compassion can facilitate the 
processing and regulation of emotions, allowing an individual to better cope with both 
enacted and felt stigma and therefore experience less distress. Finally, it is suggested that 
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more self-compassionate individuals are both more able to seek social support, and are more 
forgiving of stigma enactments, due to a sense of shared humanity and connection (given 
their increased capacity for affiliative emotions); this may in turn reduce anxieties about 
social rejection due to the stigmatised attribute (Wong et al., 2019). It is currently unclear 
whether this framework is applicable to people with Parkinson’s, since this has not previously 
been investigated.  
Consequently, the overall aim of this study was to investigate the relationships 
between the constructs of stigma, self-compassion, and psychological distress (as measured 
by depression, anxiety and stress scores) among people with Parkinson’s. A survey was used 
to measure these constructs quantitatively. Correlation analyses were employed to assess the 
strength and direction of the relationships between these constructs, and mediation models 
were utilised to establish whether any relationships between self-compassion and 
psychological distress occurred via (i.e. were mediated by) experiences of stigma. 
It was hoped that the findings of this study would be useful to professionals working 
with people with Parkinson’s in clinical or community psychology contexts, by further 
developing theoretical understandings in this area. It was anticipated that the findings may 
have implications for clinical and therapeutic interventions, as well as providing evidence to 
support activism addressing stigmatised attitudes towards people with Parkinson’s.   
 It was expected that individuals who experienced more stigma would have higher 
levels of depression, anxiety and stress, and that more self-compassionate individuals would 
experience lower levels of depression, anxiety and stress. Given Wong et al.’s framework, it 
was hypothesised that more self-compassionate individuals would be less threatened or 
concerned by enacted stigma (therefore might report less of it), and would not experience as 
much felt stigma as those who were lower in self-compassion. Finally, it was anticipated that 
both felt and enacted stigma would mediate the relationships between self-compassion and 
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depression, anxiety and stress.  
Method 
Design  
This was a cross-sectional, observational study. Quantitative data were collected by 
means of a series of self-report questionnaires. The main statistical model used to analyse the 
data was simple mediation, using Hayes’ Process Tool (Hayes, 2018). The simple mediation 
model is used to investigate whether a relationship between a predictor variable and an 
outcome variable operates via a third (mediator) variable (Field, 2018; Hayes, 2018), as 
depicted in Figure 2.1. Mediation analysis tests four relationships, using linear regression: (i) 
does the predictor variable significantly predict the outcome variable (the direct effect, 
denoted by c’ in the Figure)? (ii) does the predictor variable significantly predict the mediator 
variable (denoted by a)? (iii) when the predictor and mediator variables are both entered into 
the regression model, does the mediator variable significantly predict the outcome variable 
(denoted by b)? (iv) is there an indirect effect (denoted by ab) of the predictor upon the 
outcome variable via the mediator variable? Mediation is said to have occurred when the 
confidence interval of the indirect effect does not contain zero (Field, 2018; Hayes, 2018). 
 
< INSERT FIGURE 2.1 > 
 
The predictor variable in each case was self-compassion. The mediator variables were 
felt and enacted stigma, and the outcome variables were scores on measures of depression, 
anxiety and stress. The six models tested are displayed in Figure 2.2. 
 






A total of 153 individuals completed the survey, however 15 were removed due to 
large amounts of missing data. The participants were therefore 138 individuals with a self-
reported diagnosis of Parkinson’s.  
A priori power calculations were conducted to determine the sample size required. 
Fritz and MacKinnon (2007) provide empirical estimates of the sample sizes required in 
mediation analyses to achieve statistical power at 80%. They suggest that a bias-corrected 
bootstrapped mediation analysis with medium effect sizes between the independent and 
mediator variables (!) and the mediator and dependent variables (") (!, " = 0.39) requires 
71 participants to be adequately powered. It was also calculated that, to detect a moderate 
correlation (# = 0.3) and for p=0.05 at 80% power, a two-tailed Spearman’s rho correlation 
requires 85 participants. Therefore, the sample of 138 participants was adequate. 
Participants were recruited via advertisements on the Parkinson’s UK website, in the 
Parkinson’s UK online newsletter, and on the social media platform Twitter. Participants 
were asked to confirm that they met the inclusion criteria for the study, namely that they: had 
a diagnosis of Parkinson’s; had had their diagnosis for a minimum of 6 months; and were 
aged 18 years or older. Four individuals contacted the researcher for paper copies of the 
questionnaires, which were posted along with stamped addressed envelopes for their return, 
however only one was returned. The remainder of the sample completed the questionnaires in 
online format. 
Procedure  
Early in the development of the study, consultation was sought with Patient and 
Public Involvement Volunteers from Parkinson’s UK. Four volunteers provided feedback, via 
email, on the layout, content, accessibility and wording of the proposed materials (apart from 
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standardised measures). Adaptations were made accordingly, including changing the wording 
of the survey title and providing a greater level of detail about the background to the study. 
Once the materials had been developed and ethical approval had been granted (as below), the 
study was advertised on the Parkinson’s UK website, in the Parkinson’s UK online 
newsletter, and on the social media platform Twitter. The study was active between 
November 2018 and March 2019. Potential participants were presented with a link to an 
“Information for Participants” page (attached in Section 4: Ethics and Appendices) and 
invited to either complete an online survey (via the web-based survey tool Qualtrics), or to 
contact the lead researcher via phone, text or email to request a hard copy be posted to them, 
along with a stamped addressed envelope in which to return it. 
Materials 
The materials for this study consisted of an online or paper-based survey comprising: 
an “Information for Participants” sheet; four questions to confirm eligibility to participate and 
informed consent; a demographic and clinical information questionnaire; a series of validated 
questionnaire measures; and a “Debrief” sheet (attached in Section 4: Ethics and 
Appendices). The demographic and clinical information questionnaire asked about age, 
gender, ethnic group or background, current place of living (country), current living 
arrangements, partnership status, employment status, time since diagnosis, and current 
treatment for Parkinson’s. In addition to these questions, the Functional Status Questionnaire 
(FSQ; Jette et al., 1986) was used to situate the sample in terms of severity of physical 
symptoms. 
Validated measures. 
Functional Status Questionnaire – physical function subscales. The FSQ - physical 
function subscales were included in the survey following the demographic and clinical 
information questions. The first subscale contains three items designed to assess functioning 
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in basic activities of daily living (ADLs), such as washing and dressing and moving around 
the home. The second subscale has six items and measures functioning in intermediate ADLs, 
such as completing housework and physical activities outside of the home. Items are scored 
from four (usually did with no difficulty) to one (usually did not do because of health), with 
the additional option, “usually did not do for other reasons”, which scores zero. Scaled scores 
(between zero and 100) are derived from the total scores for each subscale, with higher scaled 
scores representing higher levels of functional ability. Each subscale has a “warning zone” 
cut-off score, above which their functional ability is deemed “good”. In a systematic review 
of disability rating scales for people with Parkinson’s (Shulman et al., 2016), this measure 
was recommended for both clinical and research use. Jette et al. (1986) report that it has good 
internal consistency (Cronbach's alpha = 0.92). 
Self-Compassion Scale. The Self-Compassion Scale (SCS; Neff, 2003) is a 26-item 
validated measure of self-compassion, consisting of six subscales: self-kindness, self-
judgment, common humanity, isolation, mindfulness and over-identification.  Each item 
describes a self-compassion-related experience and is rated from one (almost never) to five 
(almost always). The self-judgement, isolation and over-identification subscales are reverse-
coded. The total self-compassion score is the mean of the six subscale means, therefore is 
also a number between one and five. Neff (2003) reports that the scale’s internal consistency 
is high (Cronbach’s alpha = 0.92), as is the its test-retest reliability (r=93). Though initially 
validated using a student sample (Neff, 2003), this scale has been widely used in research 
with people with chronic illness (Pinto-Gouveia, Duarte, Matos & Fráguas, 2014; Sirois, 
Molnar & Hirsch, 2015), people with neurological conditions (Baker, Caswell & Eccles, 
2019; Nery-Hurwit et al., 2018) and older adults (Allen, Goldwasser & Leary, 2012). 
Stigma Scale for Chronic Illness. The Stigma Scale for Chronic Illness (SSCI; Rao et 
al., 2009) is a 24-item multiple-choice questionnaire, designed and validated for use with 
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people with Parkinson’s (as well as other chronic illnesses). The first 13 items measure felt 
stigma, and the remaining 11 items measure enacted stigma. The total score measures overall 
stigma. Each item asks about a stigma-related experience, which is rated on a scale of one 
(never) to five (always). A higher total score indicates more stigma. Both the bifactor (felt 
and enacted stigma) and unifactor (overall stigma) models have been found to be valid (Rao 
et al., 2009). Cronbach’s alpha was reported by the authors of the scale at 0.97, although this 
analysis was conducted on a draft version of the questionnaire with 26 items, rather than the 
final 24-item version. Cronbach’s alphas were not available for the subscales. 
Depression, Anxiety and Stress Scale. The Depression, Anxiety and Stress Scale – 
21-item version (DASS-21; Lovibond & Lovibond, 1995) is a validated questionnaire 
designed for use with both clinical and non-clinical populations as a dimensional, rather than 
diagnostic, tool. The scale is comprised of 21 items, falling into three subscales: depression, 
anxiety and stress. Each item is rated for how much it applied over the last week, from zero 
(did not apply to me at all) to three (applied to me very much, or most of the time). A total 
score is generated for each subscale, with a higher score indicating a higher level of 
depression, anxiety or stress. Cronbach’s alphas have been found to be 0.94 for depression, 
0.87 for anxiety, and 0.91 for stress (Antony, Bieling, Cox, Enns, & Swinson, 1998). The 
DASS-21 is frequently used in studies with people with Parkinson’s (e.g. Birtwell, Dubrow-
Marshall, Dubrow-Marshall, Duerden, & Dunn, 2017; Troeung, Egan & Gasson, 2014). 
Ethical Considerations 
Ethical approval was granted by the Lancaster University Faculty of Health and 
Medicine Research Ethics Committee (reference: FHMREC18052). An amendment was 
sought (and granted) in January 2019, such that the recruitment strategy could be expanded to 
include advertisement on Twitter. A letter confirming ethical approval is attached in Section 
4: Ethics and Appendices. The research team at Parkinson’s UK agreed that this was 
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sufficient for them to promote the research. 
Efforts were made to ensure, as far as possible, that informed consent was given by 
every participant. Participants were asked to confirm that they had read and understood the 
“Information for Participants” and gave their consent for their data to be used in the research. 
This was deemed sufficient by the Research Ethics Committee. The potential for participants 
to experience distress as a result of completing the questionnaires was also considered. The 
details of organisations participants could contact for support in the event of distress were 
provided as part of the Information for Participants and Debrief sections of the survey. To 
protect participants’ right to privacy, data were submitted anonymously and stored securely 
on password protected software.  
Data Analysis  
The data were tabulated in the software IBM SPSS Statistics (Version 25.0). 
Participants with large amounts of missing data were removed from the dataset (four had 
missed at least one full measure, nine had missed more than one full measure and two had 
completed only the eligibility and consent questions). There were no participants with 
missing items within measures. Total and mean scores were calculated for the questionnaire 
measures as necessary. The data were visually and statistically inspected for outliers using a 
series of box plots and z-score calculations, with data points more than 3.29 standard 
deviations from the mean considered outliers (Field, 2018). One extreme data point in the 
“enacted stigma” variable was winsorized (replaced with the next highest score), to reduce 
the likelihood of biasing the results (Field, 2018). 
Next, the data distributions were visually inspected for normality using histograms. 
The “enacted stigma”, “depression” and “stress” data were all skewed towards lower scores. 
The assumptions of linearity and homoscedasticity of residuals were tested by visual 
inspection of a series of linear and multiple regression scatterplots, with standardised 
2-14	
	
residuals plotted against standardised predicted values, as outlined by Field (2018) and Kane 
and Ashbaugh (2017). The assumption of normality of error distributions was assessed using 
Q-Q plots (Field, 2018). All relationships appeared to respect the assumptions of linearity, 
homoscedasticity of residuals and normality of error distributions.  
Cronbach’s alphas for each of the questionnaire measures were calculated to assess 
their internal validity for the sample. Then, to assess the strength and direction of 
relationships between demographic, predictor, mediator and outcome variables, Spearman’s 
rho correlation coefficients were calculated. This test was selected due to the non-normal 
distributions of questionnaire scores, meaning that the data did not fit the assumptions for a 
parametric test.  
Finally, a series of mediation analyses were run using Hayes’ Process Tool (Hayes, 
2018), which employs a bias-corrected bootstrap model, enabling it to cope with non-normal 
data distributions. In each analysis, 5000 bootstrap samples were used to estimate the 
confidence intervals. In the first model, self-compassion was entered as the predictor 
variable, felt stigma as the mediator variable and depression as the outcome variable. This 
was repeated with anxiety and stress as outcomes. The same models were then repeated with 
enacted stigma entered as the mediator variable.  
Results 
Demographic and Clinical Characteristics 
Of the 138 participants whose data were included in the study, 79 (57%) identified as 
female. The remaining 59 participants (43%) identified as male. The ages of participants 
ranged from 36 to 89 years, with a mean of 64 years. Most participants (92%) identified their 
ethnic group or background as “white British” and 83% reported living in England. The 
majority of participants (68%) reported being retired from work. 
Participants had held their diagnosis of Parkinson’s for between six months and 30 
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years, with a mean of five years (the distribution was skewed, with most participants having 
been diagnosed relatively recently). The majority of participants (93%) were taking 
prescribed oral medication to treat their Parkinson’s symptoms.  
There was a wide range of functional ability among the sample, as measured by FSQ 
scores. On the “basic activities of daily living” scale, 62% of participants scored above the 
“warning zone” cut-off score of 88, indicating a “good” level of basic functional ability. On 
the “intermediate activities of daily living” scale, 46% of participants scored above the 
“warning zone” cut–off score of 78.  
The demographic and clinical characteristics of the sample which were measured on a 
continuous scale are summarised Table 2.1, and the categorical variables are presented in 
Table 2.2. 
 
< INSERT TABLES 2.1 AND 2.2 > 
 
Descriptive Statistics and Internal Consistency for Standardised Measures 
Table 2.3 shows the means, standard deviations, ranges and Cronbach’s alphas for the 
sample on each of the standardised measures. Of note, the mean total stigma score on the 
SCS among the sample was 49: somewhat higher than the normative sample mean (23% of 
whom had Parkinson’s) of 42.7 (Rao et al., 2009). Mean scores on the DASS-21 variables 
fell in the “mild” range for depression and stress, and the “moderate” range for anxiety.  
 
< INSERT TABLE 2.3 > 
 
The FSQ Basic ADLs subscale demonstrated adequate internal consistency 
(Cronbach’s alpha = .74) and the Intermediate ADLs subscale showed good internal 
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consistency (Cronbach’s alpha = .86). The SCS demonstrated excellent internal consistency 
(Cronbach’s alpha = .92). The SSCI also demonstrated excellent internal consistency for each 
of the felt stigma, enacted stigma and total stigma scales (Cronbach’s alpha = .93, .94 and .95 
respectively). The depression and stress scales of the DASS-21 both showed excellent 
internal consistency, with Cronbach’s alphas .96 and .92 respectively. However, the anxiety 
scale had a much lower Cronbach’s alpha of .73. Further inspection revealed that the item “I 
experienced trembling (e.g., in the hands)” was reducing the internal consistency of the scale. 
When this item was removed, Cronbach’s alpha increased to .80, indicating good internal 
consistency. Therefore, this item was removed for the subsequent analyses, meaning that the 
new possible range of scores was from zero to 19. 
Correlational Analyses 
A correlation matrix (using Spearman’s rho correlation coefficients) is displayed in 
Table 2.4. All tests were two-tailed. 
 
< INSERT TABLE 2.4 > 
 
 Demographic and clinical variables and self-compassion. There was a weak 
relationship between age and self-compassion (# =.212, p <.05) such that self-compassion 
increased with age.  
Demographic and clinical variables and stigma. Age correlated weakly and 
negatively with felt, enacted and total stigma (# =-.305, -.383, -.354 respectively, all p <.01) 
such that higher age was associated with lower levels of reported stigma. Time since 
diagnosis was weakly and positively associated with experiences of enacted stigma (# =.174, 
p <.05) but was not not significantly associated with felt stigma. 
 Demographic variables and psychological distress. There were weak, negative 
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relationships between age and anxiety (# =-.172, p <0.05) and age and stress (# =.232, p 
<.01).  
 FSQ scores. The FSQ Basic ADLs scaled scores showed moderate, negative 
correlations with felt and total stigma scores (# =-.409, -.455 respectively, all p <.01), with 
lower functional abilities associated with more reported stigma. The FSQ Intermediate ADLs 
scaled scores showed a moderate, negative correlation with total stigma scores (# =-.403, p 
<.01). The FSQ scores correlated significantly but weakly with all other questionnaire scores, 
in the expected directions.  
 Self-compassion, stigma and psychological distress.  
 Moderate to strong relationships were observed between self-compassion and 
depression, anxiety and stress (# =-.722, -.477, -.634 respectively, all p <.01). As expected, 
higher self-compassion was associated with lower levels of depression, anxiety and stress. A 
weak correlation was observed between self-compassion and enacted stigma (ρ =-.392, p 
<.01), while a moderate correlation was observed between self-compassion and felt stigma (ρ 
=-.555, p <.01). Again, these relationships were in the expected directions, with higher self-
compassion associated with lower levels of stigma. As anticipated, there were moderate to 
strong correlations between felt stigma and depression, anxiety and stress (# =.648, .591, .610 
respectively, all p <.01), with higher levels of felt stigma associated with higher levels of 
depression, anxiety and stress. Moderate relationships in the same direction were also 
observed between enacted stigma and the DASS-21 variables (# =.414, .489, .486 
respectively, all p <.01).    
Mediation Analyses 
 Since the demographic and clinical variables (excluding the FSQ) correlated only 
weakly with the questionnaire measures (# <.40), they were not included as covariates in the 
models. Given the moderate associations between FSQ scores and the stigma scales, both 
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FSQ variables were initially entered as covariates. Upon further inspection, these variables 
did not make significant contributions in several of the regression models, nor did they have 
any great impact upon the findings. Therefore, they were not included in the final models 
tested. In each analysis, the predictor variable was self-compassion, the mediator variable 
was felt or enacted stigma and the outcome variable was depression, anxiety or stress (as 
shown in Figure 2.2). Five-thousand bias-corrected bootstrap samples were used to estimate 
the confidence intervals. The main findings of the mediation analyses are displayed in 
Figures 2.3 and 2.4 and the SPSS outputs are attached in Appendix 2B. 
 The mediating effects of felt stigma. Higher self-compassion was predictive of 
lower felt stigma (a =-8.414, p <.01), and lower felt stigma was subsequently predictive of 
lower depression scores (b =.181, p <.01). A 95% bias-corrected confidence interval based on 
5000 bootstrap samples found the indirect effect (ab =-1.524) to be entirely below zero, CI= 
[-2.323, -.847], indicating a significant effect of self-compassion on depression through felt 
stigma. The size of the indirect effect was reported at -.201. There was also a direct effect of 
self-compassion on depression, with higher self-compassion predicting lower depression 
scores (c’ =-4.024, p <.01).  
In the next analysis, higher self-compassion was predictive of lower felt stigma (a = -
8.414, p <.01), and lower felt stigma was subsequently predictive of lower anxiety scores (b 
=.165, p <.01). A 95% bias-corrected confidence interval based on 5000 bootstrap samples 
found the indirect effect (ab =-1.388) to be entirely below zero, CI= [-2.030, -.834], 
indicating a significant effect of self-compassion on anxiety through felt stigma, with an 
effect size of -.278. A direct effect of self-compassion on anxiety was also identified, with 
higher self-compassion predicting lower anxiety scores (c’ =-1.002, p <.05). 
Also, higher self-compassion predicted lower felt stigma (a= -8.414, p<.01), and 
lower felt stigma subsequently predicted lower stress scores (b= .158, p<.01). A 95% bias-
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corrected confidence interval based on 5000 bootstrap samples found the indirect effect (ab = 
-1.325) to be entirely below zero, CI= [-2.177, -.607], indicating a significant effect of self-
compassion on stress through felt stigma. The size of this effect was reported at -.180. A 
direct effect of self-compassion on stress was found, with higher self-compassion predicting 
lower stress scores (c’ =-3.377, p <.01). 
 The mediating effects of enacted stigma. Higher self-compassion was predictive of 
less reported enacted stigma (a =-3.333, p <.01), and less reported enacted stigma was 
subsequently predictive of lower depression scores (b =.101, p <.05). A 95% bias-corrected 
confidence interval based on 5000 bootstrap samples found the indirect effect (ab =-.335) to 
be entirely below zero, CI= [-.767, -.003], indicating a significant effect of self-compassion 
on depression through enacted stigma, with an effect size of -.044. There was also a direct 
effect of self-compassion on depression, with higher self-compassion predicting lower 
depression scores (c’ =-5.213, p <.01). 
Higher self-compassion was predictive of lower reported enacted stigma (a =-3.333, p 
<.01), and lower reported enacted stigma was subsequently predictive of lower anxiety scores 
(b =.190, p <.01). A 95% bias-corrected confidence interval based on 5000 bootstrap samples 
found the indirect effect (ab =-.633) to be entirely below zero, CI= [-1.0854, -.2609], 
indicating a significant effect of self-compassion on anxiety through enacted stigma. The size 
of this effect was reported at -.167. There was also found to be a direct effect of self-
compassion on anxiety, with higher self-compassion predicting lower anxiety scores (c’ =-
1.756, p <.01). 
In the final analysis, higher self-compassion was predictive of less reported enacted 
stigma (a =-3.333, p <.01), and less reported enacted stigma was subsequently predictive of 
lower stress scores (b =.182, p <.01). A 95% bias-corrected confidence interval based on 
5000 bootstrap samples found the indirect effect (ab =-.608) to be entirely below zero, CI= [-
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1.121, -.183], indicating a significant effect of self-compassion on stress through enacted 
stigma, with an effect size of -.083. A direct effect of self-compassion on stress was also 
found, with higher self-compassion predicting lower stress scores (c’ =-4.094, p <.01). 
 
< INSERT FIGURES 2.3 AND 2.4 > 
 
Discussion 
 This study investigated the relationships between the variables of self-compassion, 
stigma (both felt and enacted) and psychological distress (depression, anxiety and stress) 
among people with Parkinson’s. This was considered important in order to develop 
understandings of psychological and social conceptualisations of distress for people with 
Parkinson’s, where neuro-biological understandings currently dominate. 
Significant relationships were observed between self-compassion and the DASS-21 
variables, with higher self-compassion associated with lower levels of depression, anxiety 
and stress. This fits with previous findings about such relationships in the wider population 
(MacBeth & Gumley, 2012). Also as expected in keeping with previous research (Ma et al., 
2016; Simpson et al., 2014; Schrag et al., 2001), significant correlations were found between 
felt stigma and depression, anxiety and stress, with higher levels of felt stigma associated 
with higher levels of distress. Similarly, moderate relationships in the same direction were 
found between enacted stigma and depression, anxiety and stress. Providing support for 
Wong et al.’s (2019) framework, self-compassion was observed to significantly correlate 
with both stigma variables, with higher self-compassion associated with less reported stigma.  
Moreover, the two stigma variables were found to mediate the relationships between 
self-compassion and the three outcome variables - depression, anxiety and stress. All six of 
the mediation analyses indicated significant indirect effects via the mediators of felt and 
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enacted stigma. The extent to which participants were self-compassionate was predictive of 
the degree of stigma they reported, which in turn was predictive of their levels of 
psychological distress. This provides support for Wong et al.’s (2019) framework for the 
effects of self-compassion on how stigma is experienced and internalised, and demonstrates 
the applicability of this framework to people with Parkinson’s.  
Part of the relationship between self-compassion and psychological distress among 
people with Parkinson’s appears to occur via the internalisation of stigma; people who are 
higher in self-compassion experience less felt stigma, and therefore experience lower levels 
of distress. If individuals who are higher in self-compassion are less prone to feelings of 
shame (Gilbert, 2009) then it follows that they may be less likely to attribute negative 
Parkinson’s-related stereotypes to themselves, or internalise potentially shaming identities. 
Lesser experiences of felt stigma are then associated with lower levels of psychological 
distress, as supported by previous research with people with Parkinson’s (Ma et al., 2016).  
The mediating effect of enacted stigma appears less straightforward, since self-
compassion is unlikely to predict actual enacted stigma. Rather, it may predict how a person 
is able to process experiences of enacted stigma (Wong et al., 2019). As such, people with 
Parkinson’s who are higher in self-compassion may experience less enacted stigma (even 
when they are exposed to it) because they cognitively appraise experiences of enacted stigma 
less negatively (Wong et al., 2019). Meanwhile, those who are less self-compassionate may 
be more hypervigilant to potential threats (Gilbert, 2010; Wong, 2019), with enacted stigma 
being a social threat associated with having Parkinson’s. These individuals may therefore be 
more likely to attend to and ruminate on enacted stigma. Further, less self-compassionate 
individuals may be less able to self-soothe (Gilbert, 2009; 2010; 2014) when confronted with 
enacted stigma, which may have contributed to the higher levels of distress for the less self-
compassionate participants in this study.  
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Notably, effect sizes were higher for felt stigma as a mediator than for enacted stigma, 
indicating that, for people with Parkinson’s, the internalisation of stigma is more important in 
the relationship between self-compassion and distress than the experience of enacted stigma. 
This expands upon the findings of previous research that felt stigma is more strongly 
associated with psychological distress than experiences of enacted stigma (Ma et al., 2016). 
Limitations and Considerations 
 A key limitation of this study was the heterogeneity of the sample. A large majority of 
participants described their ethnic background as white British, with only one participant 
reporting that they did not identify as white. Although Parkinson’s may be slightly more 
prevalent among people who are white than people from black or Asian backgrounds (Van 
Den Eeden et al., 2003), the sample in this study was disproportionately white, therefore may 
not represent the totality of experiences of people with Parkinson’s. Additionally, although 
Parkinson’s is more common among men, at an incidence ratio of three men to every two 
women (Wooten, Currie, Bovbjerg, Lee & Patrie, 2004), in this study the majority of 
participants (57%) identified as female. However, the sample was also relatively young, with 
a mean age of 64 years, at which sex ratios for incidence are more equal (Moisan et al., 
2016). The relatively young average age of the sample may also account for the level of 
functional ability among the sample and the fact that no participants reported living in 
sheltered housing, residential homes or care homes, despite this being fairly common for 
people with Parkinson’s in the UK (Porter, Henry, Gray & Walker, 2010). The younger age 
of the sample may be attributable to the online advertising of the survey. Although the option 
was given to receive a paper copy of the survey in the post, younger people are more likely 
than older people to participate in research advertised on the internet and social media 
(Topolovec-Vranic & Natarajan, 2016), therefore the recruitment strategy was likely to be 
biased. Additionally, it is assumed that participants had some level of engagement with 
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Parkinson’s-related websites or newsletters. It might be argued that individuals with higher 
levels of internalised stigma and/or psychological distress would be less likely to access such 
forums or participate in Parkinson’s-related research, due to shame, avoidance or low 
motivation. Therefore, this research may demonstrate a bias towards the experiences of 
people with Parkinson’s who have relatively high levels of psychological wellbeing and 
relatively low levels of internalised stigma, and who identify with and participate in 
Parkinson’s related forums, which may have affected the findings of the study. Overall, the 
sample in this study was not diverse, and therefore the findings may not be generalisable to 
all people with Parkinson’s.  
 A further possible limitation of this study was the use of the DASS-21 as an outcome 
measure for anxiety. Johnson et al. (2016) examined the factor structure of the DASS-21for 
people with Parkinson’s and found that, while the depression and stress subscales fit the 
factor structures well, the anxiety subscale loaded poorly onto the factor structure and had 
problems with internal consistency. Similarly, in the current study, it was required that an 
item was removed in order to bring internal consistency to an acceptable level, and even with 
the new six-item subscale Cronbach’s alpha was notably lower than the other two subscales. 
Johnson et al. (2016) suggest that this problem may be related to the emphasis within the 
subscale upon physiological symptoms of anxiety, which may have a great deal of overlap 
with other difficulties experienced by people with Parkinson’s. In the current study, the 
removed item asked about shaking of the hands, which people with Parkinson’s might be 
more likely than other populations to report, and which may not be associated with anxiety at 
all. Consequently, the findings of this study relating to anxiety should be interpreted 
cautiously. 
 Hayes (2018) highlights that the use of mediation analysis with correlational or 
observational data has limitations in how the findings can be interpreted, since cause and 
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effect cannot be inferred. Therefore, despite the significant findings of this study, it cannot be 
assumed that having more self-compassion causes people with Parkinson’s to experience less 
stigma, which causes them to experience less distress. Rather, it appears that there are 
interactions between each of the variables such that the relationships between self-
compassion and depression, anxiety and stress operate via their relationships with 
experiences of felt and enacted stigma. It may be that some of the relationships identified in 
this study are bi-directional (for example, that people who are exposed to more enacted 
stigma become less self-compassionate), or that there are additional factors which mediate or 
moderate the relationships found. There may also be underlying factors contributing to the 
relationships which were not controlled for. For example, people with lower levels of 
education have been found to demonstrate less self-compassion (López, Sanderman, Ranchor 
& Schroevers, 2018).  
Clinical Implications 
 The findings of this study may have implications for direct psychological 
interventions with people with Parkinson’s who are experiencing distress. The finding that 
self-compassion predicted the amount of felt and enacted stigma participants experienced, 
and that this in turn predicted the degree of psychological distress, suggests that interventions 
aimed at increasing self-compassion may be helpful for people with Parkinson’s. That there 
were significant (direct and indirect) effects of self-compassion on all three outcome 
variables – depression, anxiety and stress – suggests that the impact of such interventions 
could be beneficial across a range of presenting psychological difficulties. There is a growing 
evidence base for the use of Compassion-Focussed Therapy, which has a strong focus on 
reducing experiences of shame and developing feelings of compassion towards the self and 
others (Gilbert, 2010), for reducing distress among people with neurological illness and 
injury (Ashworth, Gracey & Gilbert, 2011; Collins, Gilligan & Poz, 2018; Nery-Hurwit, Yun 
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& Ebbeck, 2018). It may be hypothesised, based on the findings of this study, that this 
approach might also be helpful for people with Parkinson’s - allowing them to process 
enacted stigma differently and internalise it less, or respond to felt stigma in a more resilient 
way through more effective self-soothing, leading to increased wellbeing.  
 Although approaches aimed at increasing self-compassion at the individual level may 
be helpful for reducing distress, it is important to also consider how the wider social and 
relational context contributes to distress for people with Parkinson’s (Simpson et al., 2013). 
Enacted stigma is clearly a societal problem, being defined as the attitudes and behaviour of 
others in society on the basis of some socially discredited attribute (Scambler, 1989). The 
findings of this study suggest that experiences of enacted stigma and experiences of 
psychological distress are interrelated for people with Parkinson’s. Thus, there is clear scope 
for interventions at the societal level aimed at reducing stigma against people with 
Parkinson’s, which may in turn have a positive effect on psychological wellbeing. Heijnders 
and Van Der Meij (2006) reviewed a number of interventions for reducing health-related 
stigma. They suggest that interventions should take place at multiple levels – interpersonally 
(in the person with the stigmatised attribute’s immediate relational environment), 
organisationally, in the community, and at government and structural levels. Based on 
Heijnders and Van Der Meij’s (2006) findings, types of stigma-reduction interventions for 
people with Parkinson’s might include providing education and training, increasing the 
visibility of people with Parkinson’s in communities, advocacy programmes, and lobbying 
for the rights of people with Parkinson’s. 
 Therefore, the findings of this study may be relevant to the development of 
individualised and wider societal interventions with the aim of improving the psychological 
wellbeing of people with Parkinson’s. Clinical psychologists are well-placed to design and 




It may be useful to replicate this study with more diverse samples to increase the 
generalisability of the findings. Broadening the recruitment approach to community locations 
in addition to the online survey may ensure that more older people are able to take part 
(Topolovec-Vranic & Natarajan, 2016), while the cultural/ethnic sensitivity of the 
recruitment strategy might be improved with the assistance of cultural consultants 
(Gallagher-Thompson et al., 2004). Further research might build upon the current study by 
considering the interaction of the mediating variables of felt and enacted stigma, since this 
would provide further information about how enacted stigma becomes internalised.  
There does not appear to be any published research which considers the role of self-
compassion for people with Parkinson’s. Given the expanding evidence-base for compassion-
focussed psychological interventions and importance of self-compassion for wellbeing more 
generally, this may be an important area for further exploration in future research. For 
example, studies might explore the effectiveness of compassion-focused interventions for 
people diagnosed with Parkinson´s. Questions might include how group-based interventions 
(where there may be chance to develop a sense of shared humanity with others: a key 
component of compassion) might compare to individualised interventions; and how 
compassion-focussed approaches might be adapted to the cognitive needs of people with 
Parkinson’s.  
As noted previously, there are likely to be other factors apart from stigma which 
mediate or moderate the relationship between self-compassion and psychological distress for 
people with Parkinson’s. A better understanding of this relationship might be useful for 






  Mediation analyses indicated that part of the relationship between self-compassion 
and psychological distress occurs via the internalisation of stigma: people with Parkinson’s 
who are higher in self-compassion experience less felt stigma, and therefore experience lower 
levels of distress. Self-compassion is unlikely to predict actual enacted stigma, but may 
predict how likely a person is to notice or report it. Therefore, people with Parkinson’s who 
are higher in self-compassion may experience less enacted stigma (even when they are 
exposed to it), and therefore experience lower levels of distress. These findings may be 
relevant to the development of individualised and societal interventions with the aim of 
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Demographic and Clinical Characteristics of Sample: Continuous Variables 
Variable Mean (SD) Range 
Age (in years) 64.35 (9.43) 36-89 
Time since diagnosis (in years) 5.11 (4.76) 0-30 
FSQ subscale scores: 
         Basic activities of daily living 
















Demographic and Clinical Characteristics of Sample: Categorical Variables 
Variable Frequency Percentage 
Gender: 
         Female 







Ethnic group or background: 
         White British 
         White Irish 
         White European  
         White American  
         White Traveller 
         Sri-Lankan  


















         England  
         Scotland 
         Wales 
         USA  
         Northern Ireland 
         Spain 
         European country outside of UK (not specified) 
         Sri-Lanka 






















         With spouse/partner/family/others              
         Alone 
         With a live-in carer 












         Spouse or partner, co-habiting 
         Single  











         Widowed 1 .72 
Employment status: 
         Retired 
         Currently unable to work or on sick leave 
         Employed (full-time) 
         Self-employed 
         Employed (part-time) 
         In full-time education 

















Current treatment for Parkinson’s symptoms*: 
         Prescribed oral medication 
         No treatment  
         DBS 
         Apomorphine/Duodopa Pump 
         Prescribed exercise programmes 















Note. Percentages rounded to two decimal places; *Some participants were using more than 






Descriptive Statistics and Internal Consistency for Standardised Measures 
Measure Mean (SD) Range Cronbach’s alpha 
FSQ scaled scores: 
         Basic ADLs 










SSCI total scores: 
         Felt stigma 
         Enacted stigma 













SCS scaled score 3.07 (.76) 1.25-4.78 .92 
DASS-21 total scores: 
         Depression 
         Anxiety 
         Anxiety (item 7 removed) 
















Note. All values rounded to two decimal places; SD = Standard deviation; FSQ = Functional 
Status Questionnaire; ADLs = activities of daily living; SSCI = Stigma Scale for Chronic 





Spearman’s Rho Correlations Between Variables 

































































































































1 - .869* -.088 -.134 -.305** -.383** -.354** .212* -.137 -.172* -.232** 
2 - - -.330** -.280** .079 .174* .133 -.002 .049 .131 .065 
3 - - - .701** -.409** -.388** -.455** .179* -.218* -.363** -.263** 
4 - - - - -.379** -.346** -.403** .105 -.207* -.386** -.257** 
5 - - - - - .716** .960** -.555** .648** .591** .610** 
6 - - - - - - .865** -.392** .414** .489** .486** 
7 - - - - - - - -.520** .593** .597** .600** 
8 - - - - - - - - -.722** -.477** -.634** 
9 - - - - - - - - - .666** .711** 
10 - - - - - - - - - - .680** 
Note. All correlation coefficients rounded to three decimal places; SD = Standard deviation; 
FSQ = Functional Status Questionnaire; ADLs = activities of daily living; SSCI = Stigma 
Scale for Chronic Illness; SCS = Self-Compassion Scale; DASS-21 = Depression, Anxiety 
and Stress Scale; DASS-21 Anxiety total used 6-item subscale to increase internal 
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SPSS Outputs for Mediation Analyses 
Key: 
X = predictor variable 
Y = outcome variable 
M = mediator variable 
SELFCOMP = self-compassion 
INTSTIGM = felt stigma 
ENACSTIG = enacted stigma 
D_TOTAL = DASS-21 depression score 
A_NO_7 = DASS-21 anxiety score (without item 7) 







Analysis 1: self-compassion, felt stigma and depression 
 
 
*************** PROCESS Procedure for SPSS Version 3.3 ******************* 
 
          Written by Andrew F. Hayes, Ph.D.       www.afhayes.com 
    Documentation available in Hayes (2018). www.guilford.com/p/hayes3 
 
************************************************************************** 
Model  : 4 
    Y  : D_TOTAL 
    X  : SELFCOMP 
    M  : INTSTIGM 
 
Sample 







          R          R-sq        MSE          F               df1         df2              p 
      .5627      .3167    88.9451    63.0254     1.0000   136.0000      .0000 
 
Model 
                            coeff          se             t               p         LLCI         ULCI 
constant          57.1211     3.3469    17.0667      .0000    50.5024    63.7399 
SELFCOMP    -8.4141     1.0599    -7.9389      .0000   -10.5100    -6.3181 
 
Standardized coefficients 
                           coeff 







          R          R-sq        MSE          F              df1          df2               p 
      .7870      .6194    12.9023   109.8471     2.0000   135.0000      .0000 
 
Model 
                           coeff           se              t              p         LLCI       ULCI 
constant           13.1340     2.2595     5.8129      .0000     8.6655    17.6025 
SELFCOMP    -4.0243      .4883    -8.2411      .0000    -4.9901    -3.0586 
INTSTIGM         .1811      .0327     5.5464      .0000      .1166      .2457 
 
Standardized coefficients 
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                          coeff 
SELFCOMP   -.5294 
INTSTIGM      .3563 
 





          R         R-sq        MSE          F                df1          df2              p 
      .7298      .5327    15.7260   155.0083     1.0000   136.0000      .0000 
 
Model 
                           coeff             se            t                p         LLCI       ULCI 
constant           23.4810     1.4073    16.6848      .0000    20.6979    26.2641 
SELFCOMP    -5.5485       .4457   -12.4502      .0000     -6.4298    -4.6672 
 
Standardized coefficients 
                           coeff 
SELFCOMP     -.7298 
 
************** TOTAL, DIRECT, AND INDIRECT EFFECTS OF X ON Y ********** 
 
Total effect of X on Y 
     Effect           se             t                p          LLCI       ULCI        c_ps        c_cs 
    -5.5485      .4457    -12.4502      .0000    -6.4298    -4.6672     -.9600     -.7298 
 
Direct effect of X on Y 
     Effect         se               t               p         LLCI       ULCI        c'_ps       c'_cs 
    -4.0243      .4883    -8.2411      .0000    -4.9901    -3.0586     -.6963     -.5294 
 
Indirect effect(s) of X on Y: 
                        Effect     BootSE   BootLLCI   BootULCI 
INTSTIGM    -1.5241      .3726    -2.3225     -.8470 
 
Partially standardized indirect effect(s) of X on Y: 
                         Effect     BootSE   BootLLCI   BootULCI 
INTSTIGM     -.2637      .0635        -.3989         -.1511 
 
Completely standardized indirect effect(s) of X on Y: 
                         Effect     BootSE   BootLLCI   BootULCI 
INTSTIGM     -.2005      .0476       -.3006           -.1140 
 





                         Coeff   BootMean     BootSE   BootLLCI   BootULCI 
constant          57.1211    57.1333        3.6753    49.8322        64.3046 
2-58	
	







                           Coeff   BootMean    BootSE   BootLLCI   BootULCI 
constant            13.1340    13.0842     2.6989     7.9323       18.3038 
SELFCOMP     -4.0243     -4.0142       .5899    -5.1615       -2.8772 
INTSTIGM          .1811        .1813       .0338        .1155          .2469 
 
*********************** ANALYSIS NOTES AND ERRORS ********************* 
 
Level of confidence for all confidence intervals in output: 
  95.0000 
 
Number of bootstrap samples for percentile bootstrap confidence intervals: 
  5000 
 
NOTE: Variables names longer than eight characters can produce incorrect output. 
      Shorter variable names are recommended. 
 
------ END MATRIX ----- 





Analysis 2: self-compassion, felt stigma and anxiety 
 
 
Run MATRIX procedure:  
  
*************** PROCESS Procedure for SPSS Version 3.3 *******************  
  
          Written by Andrew F. Hayes, Ph.D.       www.afhayes.com  
    Documentation available in Hayes (2018). www.guilford.com/p/hayes3  
  
**************************************************************************  
Model  : 4  
    Y  : A_NO_7  
    X  : SELFCOMP  
    M  : INTSTIGM  
  
Sample  
Size:  138  
  
**************************************************************************  
OUTCOME VARIABLE:  
 INTSTIGM  
  
Model Summary  
          R          R-sq        MSE          F              df1          df2               p  
      .5627      .3167    88.9451    63.0254     1.0000   136.0000      .0000  
  
Model  
                          coeff            se             t                p         LLCI         ULCI  
constant           57.1211     3.3469    17.0667      .0000    50.5024    63.7399  
SELFCOMP    -8.4141     1.0599     -7.9389      .0000   -10.5100     -6.3181  
  
Standardized coefficients  
                           coeff  
SELFCOMP     -.5627  
  
**************************************************************************  
OUTCOME VARIABLE:  
 A_NO_7  
  
Model Summary  
          R         R-sq        MSE          F              df1          df2              p  
      .6295      .3963     8.8120    44.3163     2.0000   135.0000      .0000  
  
Model  
                            coeff           se             t               p         LLCI       ULCI  
constant             2.2898     1.8673     1.2263      .2222    -1.4031     5.9826  
SELFCOMP    -1.0019       .4036    -2.4827      .0143    -1.8000     -.2038  




Standardized coefficients  
                           coeff  
SELFCOMP     -.2008  
INTSTIGM        .4942  
  
************************** TOTAL EFFECT MODEL ************************* 
OUTCOME VARIABLE:  
 A_NO_7  
  
Model Summary  
          R         R-sq        MSE          F              df1          df2               p  
      .4790      .2294    11.1659    40.4872     1.0000   136.0000      .0000  
  
Model  
                           coeff           se             t               p         LLCI        ULCI  
constant           11.7093     1.1859     9.8741      .0000     9.3642    14.0544  
SELFCOMP    -2.3894       .3755    -6.3630      .0000    -3.1320    -1.6468  
  
Standardized coefficients  
                           coeff  
SELFCOMP     -.4790  
  
********* TOTAL, DIRECT, AND INDIRECT EFFECTS OF X ON Y **************  
  
Total effect of X on Y  
     Effect           se            t               p          LLCI       ULCI       c_ps         c_cs  
    -2.3894      .3755    -6.3630      .0000    -3.1320    -1.6468     -.6300     -.4790  
  
Direct effect of X on Y  
     Effect          se            t               p           LLCI       ULCI      c'_ps        c'_cs  
    -1.0019      .4036    -2.4827      .0143    -1.8000     -.2038     -.2642     -.2008  
  
Indirect effect(s) of X on Y:  
                         Effect     BootSE   BootLLCI   BootULCI  
INTSTIGM    -1.3875      .3030       -2.0301        -.8341  
  
Partially standardized indirect effect(s) of X on Y:  
                        Effect     BootSE   BootLLCI   BootULCI  
INTSTIGM     -.3658      .0675        -.5076         -.2419  
  
Completely standardized indirect effect(s) of X on Y:  
                        Effect     BootSE   BootLLCI   BootULCI  
INTSTIGM     -.2781      .0498        -.3762          -.1843  
  
****** BOOTSTRAP RESULTS FOR REGRESSION MODEL PARAMETERS ***** 
  
OUTCOME VARIABLE:  
 




                          Coeff   BootMean     BootSE   BootLLCI   BootULCI  
constant           57.1211    57.1417     3.7162       49.6263        64.3700  




OUTCOME VARIABLE:  
 A_NO_7  
  
                           Coeff   BootMean     BootSE   BootLLCI   BootULCI  
constant             2.2898     2.2983        1.7573      -1.2399       5.7060  
SELFCOMP    -1.0019    -1.0007          .4270      -1.8305       -.1557  
INTSTIGM         .1649       .1643          .0277         .1099         .2198  
  
****************** ANALYSIS NOTES AND ERRORS ******************** 
  
Level of confidence for all confidence intervals in output:  
  95.0000  
  
Number of bootstrap samples for percentile bootstrap confidence intervals:  
  5000  
  
NOTE: Variables names longer than eight characters can produce incorrect output.  
      Shorter variable names are recommended.  
  






Analysis 3: self-compassion, felt stigma and stress 
 
Run MATRIX procedure:  
  
*************** PROCESS Procedure for SPSS Version 3.3 *******************  
  
          Written by Andrew F. Hayes, Ph.D.       www.afhayes.com  
    Documentation available in Hayes (2018). www.guilford.com/p/hayes3  
  
**************************************************************************  
Model  : 4  
    Y  : S_TOTAL  
    X  : SELFCOMP  
    M  : INTSTIGM  
  
Sample  
Size:  138  
  
**************************************************************************  
OUTCOME VARIABLE:  
 INTSTIGM  
  
Model Summary  
          R         R-sq        MSE           F              df1          df2              p  
      .5627      .3167    88.9451    63.0254     1.0000   136.0000      .0000  
  
Model  
                          coeff            se              t               p         LLCI        ULCI  
constant           57.1211     3.3469    17.0667      .0000    50.5024    63.7399  
SELFCOMP    -8.4141     1.0599     -7.9389      .0000   -10.5100     -6.3181  
  
Standardized coefficients  
                           coeff  
SELFCOMP     -.5627  
  
**************************************************************************  
OUTCOME VARIABLE:  
 S_TOTAL  
  
Model Summary  
          R         R-sq        MSE           F              df1          df2              p  
      .6912      .4778    16.6040    61.7577     2.0000   135.0000      .0000  
  
Model  
                            coeff           se               t              p         LLCI       ULCI  
constant            12.9465     2.5632     5.0510      .0000     7.8774    18.0156  
SELFCOMP     -3.3767       .5540    -6.0956      .0000    -4.4723    -2.2812  
INTSTIGM          .1575       .0370     4.2517      .0000      .0842      .2308  
  
Standardized coefficients  
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                           coeff  
SELFCOMP     -.4586  
INTSTIGM        .3199  
  
************************ TOTAL EFFECT MODEL ****************************  
OUTCOME VARIABLE:  
 S_TOTAL  
  
Model Summary  
          R         R-sq        MSE          F               df1          df2              p  
      .6386      .4079    18.6889    93.6761     1.0000   136.0000      .0000  
  
Model  
                           coeff            se             t                p         LLCI       ULCI  
constant           21.9443     1.5342    14.3036      .0000    18.9103    24.9782  
SELFCOMP     -4.7021      .4858     -9.6786      .0000    -5.6629     -3.7414  
  
Standardized coefficients  
                           coeff  
SELFCOMP     -.6386  
  
************ TOTAL, DIRECT, AND INDIRECT EFFECTS OF X ON Y ************ 
  
Total effect of X on Y  
     Effect           se             t              p          LLCI       ULCI       c_ps         c_cs  
    -4.7021      .4858    -9.6786      .0000    -5.6629    -3.7414     -.8400     -.6386  
  
Direct effect of X on Y  
     Effect         se               t              p          LLCI       ULCI      c'_ps         c'_cs  
    -3.3767      .5540    -6.0956      .0000    -4.4723    -2.2812     -.6033     -.4586  
  
Indirect effect(s) of X on Y:  
                        Effect     BootSE   BootLLCI   BootULCI  
INTSTIGM    -1.3254      .4037     -2.1774        -.6074  
  
Partially standardized indirect effect(s) of X on Y:  
                         Effect     BootSE   BootLLCI   BootULCI  
INTSTIGM     -.2368      .0714        -.3876          -.1091  
  
Completely standardized indirect effect(s) of X on Y:  
                         Effect     BootSE   BootLLCI   BootULCI  
INTSTIGM     -.1800      .0536        -.2918         -.0835  
  
****** BOOTSTRAP RESULTS FOR REGRESSION MODEL PARAMETERS ********  
  
OUTCOME VARIABLE:  






                          Coeff    BootMean       BootSE   BootLLCI   BootULCI  
constant           57.1211    57.0640         3.6644      49.8280       64.1158  




OUTCOME VARIABLE:  
 S_TOTAL  
  
                           Coeff    BootMean     BootSE   BootLLCI   BootULCI  
constant           12.9465    12.9511        3.1138     6.5930         18.7329  
SELFCOMP    -3.3767    -3.3780           .6412    -4.5788         -2.0597  
INTSTIGM         .1575      .1571            .0415        .0781            .2401  
  
******************** ANALYSIS NOTES AND ERRORS ************************  
  
Level of confidence for all confidence intervals in output:  
  95.0000  
  
Number of bootstrap samples for percentile bootstrap confidence intervals:  
  5000  
  
NOTE: Variables names longer than eight characters can produce incorrect output.  
      Shorter variable names are recommended.  
  






Analysis 4: self-compassion, enacted stigma and depression 
 
Run MATRIX procedure:  
  
*************** PROCESS Procedure for SPSS Version 3.3 *******************  
  
          Written by Andrew F. Hayes, Ph.D.       www.afhayes.com  
    Documentation available in Hayes (2018). www.guilford.com/p/hayes3  
  
**************************************************************************  
Model  : 4  
    Y  : D_TOTAL  
    X  : SELFCOMP  
    M  : ENACSTIG  
  
Sample  
Size:  138  
  
**************************************************************************  
OUTCOME VARIABLE:  
 ENACSTIG  
  
Model Summary  
          R          R-sq        MSE          F              df1          df2               p  
      .3346      .1119    51.3276    17.1403     1.0000   136.0000      .0001  
  
Model  
                            coeff           se               t               p         LLCI        ULCI  
constant            27.8928     2.5425    10.9706      .0000    22.8648    32.9207  
SELFCOMP     -3.3333       .8051     -4.1401      .0001     -4.9255    -1.7411  
  
Standardized coefficients  
                           coeff  
SELFCOMP     -.3346  
  
**************************************************************************  
OUTCOME VARIABLE:  
 D_TOTAL  
  
Model Summary  
          R         R-sq        MSE           F              df1         df2               p  
      .7403      .5481    15.3199    81.8611     2.0000   135.0000      .0000  
  
Model  
                           coeff            se              t                p          LLCI       ULCI  
constant           20.6769     1.9071     10.8423      .0000    16.9053    24.4485  
SELFCOMP    -5.2134       .4668    -11.1694      .0000     -6.1365    -4.2903  
ENACSTIG        .1005       .0468       2.1459      .0337        .0079        .1932  
  
Standardized coefficients  
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                           coeff  
SELFCOMP     -.6858  
ENACSTIG       .1318  
  
*********************** TOTAL EFFECT MODEL ****************************  
OUTCOME VARIABLE:  
 D_TOTAL  
  
Model Summary  
          R         R-sq        MSE           F               df1          df2               p  
      .7298      .5327    15.7260   155.0083     1.0000   136.0000      .0000  
  
Model  
                           coeff            se               t              p          LLCI       ULCI  
constant           23.4810     1.4073     16.6848      .0000    20.6979    26.2641  
SELFCOMP    -5.5485       .4457    -12.4502      .0000     -6.4298    -4.6672  
  
Standardized coefficients  
                            coeff  
SELFCOMP     -.7298  
  
************* TOTAL, DIRECT, AND INDIRECT EFFECTS OF X ON Y ************ 
  
Total effect of X on Y  
     Effect           se            t                 p         LLCI       ULCI       c_ps         c_cs  
    -5.5485      .4457   -12.4502      .0000    -6.4298    -4.6672     -.9600     -.7298  
  
Direct effect of X on Y  
     Effect            se           t                 p        LLCI       ULCI        c'_ps        c'_cs  
    -5.2134      .4668   -11.1694      .0000    -6.1365    -4.2903     -.9020     -.6858  
  
Indirect effect(s) of X on Y:  
                          Effect     BootSE   BootLLCI   BootULCI  
ENACSTIG      -.3351      .1936        -.7672         -.0033  
  
Partially standardized indirect effect(s) of X on Y:  
                         Effect     BootSE   BootLLCI   BootULCI  
ENACSTIG     -.0580      .0337        -.1326         -.0006  
  
Completely standardized indirect effect(s) of X on Y:  
                         Effect     BootSE   BootLLCI   BootULCI  
ENACSTIG     -.0441      .0259        -.1025         -.0004  
  
******* BOOTSTRAP RESULTS FOR REGRESSION MODEL PARAMETERS ****** 
  
OUTCOME VARIABLE:  






                           Coeff   BootMean     BootSE   BootLLCI   BootULCI  
constant           27.8928    27.8555        2.9250    22.2582        33.7413  




OUTCOME VARIABLE:  
 D_TOTAL  
  
                           Coeff   BootMean   BootSE   BootLLCI   BootULCI  
constant           20.6769    20.7104     2.5212      15.7651      25.5813  
SELFCOMP    -5.2134     -5.2292       .5729      -6.3297       -4.1234  
ENACSTIG        .1005        .1008        .0543         .0009          .2117  
  
*********************** ANALYSIS NOTES AND ERRORS *********************  
  
Level of confidence for all confidence intervals in output:  
  95.0000  
  
Number of bootstrap samples for percentile bootstrap confidence intervals:  
  5000  
  
NOTE: Variables names longer than eight characters can produce incorrect output.  
      Shorter variable names are recommended.  
  






Analysis 5: self-compassion, enacted stigma and anxiety 
 
Run MATRIX procedure:  
  
*************** PROCESS Procedure for SPSS Version 3.3 *******************  
  
          Written by Andrew F. Hayes, Ph.D.       www.afhayes.com  
    Documentation available in Hayes (2018). www.guilford.com/p/hayes3  
  
**************************************************************************  
Model  : 4  
    Y  : A_NO_7  
    X  : SELFCOMP  
    M  : ENACSTIG  
  
Sample  
Size:  138  
  
**************************************************************************  
OUTCOME VARIABLE:  
 ENACSTIG  
  
Model Summary  
          R         R-sq        MSE            F             df1          df2              p  
      .3346      .1119    51.3276    17.1403     1.0000   136.0000      .0001  
  
Model  
                           coeff           se              t               p          LLCI       ULCI  
constant           27.8928     2.5425    10.9706      .0000    22.8648    32.9207  
SELFCOMP    -3.3333       .8051     -4.1401      .0001    -4.9255    -1.7411  
  
Standardized coefficients  
                           coeff  
SELFCOMP     -.3346  
  
**************************************************************************  
OUTCOME VARIABLE:  
 A_NO_7  
  
Model Summary  
          R         R-sq        MSE          F              df1           df2              p  
      .5976      .3572     9.3839    37.5014     2.0000   135.0000      .0000  
  
Model  
                            coeff           se             t               p         LLCI       ULCI  
constant             6.4124     1.4925     4.2963      .0000     3.4606      9.3642  
SELFCOMP    -1.7564       .3653    -4.8081      .0000    -2.4789    -1.0340  
ENACSTIG        .1899       .0367     5.1795      .0000       .1174        .2624  
  
Standardized coefficients  
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                           coeff  
SELFCOMP     -.3521  
ENACSTIG       .3793  
  
************************** TOTAL EFFECT MODEL **************************  
OUTCOME VARIABLE:  
 A_NO_7  
  
Model Summary  
          R         R-sq        MSE           F              df1          df2               p  
      .4790      .2294    11.1659    40.4872     1.0000   136.0000      .0000  
  
Model  
                           coeff            se             t               p         LLCI       ULCI  
constant           11.7093     1.1859     9.8741      .0000     9.3642    14.0544  
SELFCOMP    -2.3894       .3755    -6.3630      .0000    -3.1320    -1.6468  
  
Standardized coefficients  
                           coeff  
SELFCOMP     -.4790  
  
*********** TOTAL, DIRECT, AND INDIRECT EFFECTS OF X ON Y **************  
  
Total effect of X on Y  
     Effect           se            t                p         LLCI       ULCI       c_ps         c_cs  
    -2.3894      .3755    -6.3630      .0000    -3.1320    -1.6468     -.6300     -.4790  
  
Direct effect of X on Y  
     Effect           se            t               p          LLCI       ULCI      c'_ps        c'_cs  
    -1.7564      .3653    -4.8081      .0000    -2.4789    -1.0340     -.4631     -.3521  
  
Indirect effect(s) of X on Y:  
                         Effect     BootSE   BootLLCI   BootULCI  
ENACSTIG     -.6330      .2125       -1.0854        -.2609  
  
Partially standardized indirect effect(s) of X on Y:  
                          Effect     BootSE   BootLLCI   BootULCI  
ENACSTIG     -.1669      .0510        -.2718         -.0761  
  
Completely standardized indirect effect(s) of X on Y:  
                          Effect     BootSE   BootLLCI   BootULCI  
ENACSTIG     -.1269      .0393        -.2055         -.0562  
  
******* BOOTSTRAP RESULTS FOR REGRESSION MODEL PARAMETERS ******* 
  
OUTCOME VARIABLE:  






                          Coeff    BootMean     BootSE   BootLLCI   BootULCI  
constant           27.8928    27.8177       2.9575      21.8183       33.3914  




OUTCOME VARIABLE:  
 A_NO_7  
  
                            Coeff   BootMean     BootSE   BootLLCI   BootULCI  
constant             6.4124     6.4275         1.6194      3.3670         9.6092  
SELFCOMP    -1.7564    -1.7650           .4199    -2.5837          -.9677  
ENACSTIG        .1899       .1903           .0414        .1110           .2726  
  
*********************** ANALYSIS NOTES AND ERRORS *********************  
  
Level of confidence for all confidence intervals in output:  
  95.0000  
  
Number of bootstrap samples for percentile bootstrap confidence intervals:  
  5000  
  
NOTE: Variables names longer than eight characters can produce incorrect output.  
      Shorter variable names are recommended.  
  






Analysis 6: self-compassion, enacted stigma and stress 
 
Run MATRIX procedure:  
  
*************** PROCESS Procedure for SPSS Version 3.3 *******************  
  
          Written by Andrew F. Hayes, Ph.D.       www.afhayes.com  
    Documentation available in Hayes (2018). www.guilford.com/p/hayes3  
  
**************************************************************************  
Model  : 4  
    Y  : S_TOTAL  
    X  : SELFCOMP  
    M  : ENACSTIG  
  
Sample  
Size:  138  
  
**************************************************************************  
OUTCOME VARIABLE:  
 ENACSTIG  
  
Model Summary  
          R         R-sq        MSE           F              df1          df2              p  
      .3346      .1119    51.3276    17.1403     1.0000   136.0000      .0001  
  
Model  
                           coeff            se             t               p          LLCI       ULCI  
constant           27.8928     2.5425    10.9706      .0000    22.8648    32.9207  
SELFCOMP    -3.3333       .8051     -4.1401      .0001     -4.9255    -1.7411  
  
Standardized coefficients  
                           coeff  
SELFCOMP     -.3346  
  
**************************************************************************  
OUTCOME VARIABLE:  
 S_TOTAL  
  
Model Summary  
          R         R-sq        MSE           F              df1          df2               p  
      .6797      .4619    17.1084    57.9470     2.0000   135.0000      .0000  
  
Model  
                           coeff            se             t               p         LLCI       ULCI  
constant           16.8586     2.0153     8.3653      .0000    12.8730    20.8443  
SELFCOMP    -4.0944       .4933    -8.3008      .0000     -5.0699    -3.1189  
ENACSTIG        .1823       .0495     3.6829      .0003        .0844        .2802  
  
Standardized coefficients  
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                            coeff  
SELFCOMP      -.5561  
ENACSTIG        .2467  
  
************************ TOTAL EFFECT MODEL **************************  
OUTCOME VARIABLE:  
 S_TOTAL  
  
Model Summary  
          R         R-sq        MSE           F              df1          df2              p  
      .6386      .4079    18.6889    93.6761     1.0000   136.0000      .0000  
  
Model  
                           coeff            se             t               p          LLCI       ULCI  
constant           21.9443     1.5342    14.3036      .0000    18.9103    24.9782  
SELFCOMP    -4.7021       .4858     -9.6786      .0000    -5.6629     -3.7414  
  
Standardized coefficients  
                           coeff  
SELFCOMP     -.6386  
  
************ TOTAL, DIRECT, AND INDIRECT EFFECTS OF X ON Y ************  
  
Total effect of X on Y  
     Effect           se            t                p        LLCI       ULCI        c_ps         c_cs  
    -4.7021      .4858    -9.6786      .0000    -5.6629    -3.7414     -.8400     -.6386  
  
Direct effect of X on Y  
     Effect           se            t                p        LLCI       ULCI       c'_ps        c'_cs  
    -4.0944      .4933    -8.3008      .0000    -5.0699    -3.1189     -.7315     -.5561  
  
Indirect effect(s) of X on Y:  
                         Effect     BootSE   BootLLCI   BootULCI  
ENACSTIG     -.6078      .2418       -1.1211        -.1833  
  
Partially standardized indirect effect(s) of X on Y:  
                         Effect     BootSE   BootLLCI   BootULCI  
ENACSTIG     -.1086      .0430        -.2002        -.0336  
  
Completely standardized indirect effect(s) of X on Y:  
                         Effect     BootSE   BootLLCI   BootULCI  
ENACSTIG     -.0825      .0327        -.1534        -.0249  
  
******* BOOTSTRAP RESULTS FOR REGRESSION MODEL PARAMETERS *******  
OUTCOME VARIABLE:  
 ENACSTIG  
  
                          Coeff     BootMean     BootSE   BootLLCI   BootULCI  
constant          27.8928      27.8260       2.9942      21.9143      33.6817  






OUTCOME VARIABLE:  
 S_TOTAL  
  
                          Coeff     BootMean     BootSE   BootLLCI   BootULCI  
constant           16.8586    16.8840        2.4997     11.8583       21.6779  
SELFCOMP    -4.0944     -4.1003          .5540     -5.1868        -3.0058  
ENACSTIG        .1823        .1817          .0558         .0720           .2943  
  
********************* ANALYSIS NOTES AND ERRORS **********************  
  
Level of confidence for all confidence intervals in output:  
  95.0000  
  
Number of bootstrap samples for percentile bootstrap confidence intervals:  
  5000  
  
NOTE: Variables names longer than eight characters can produce incorrect output.  
      Shorter variable names are recommended.  
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 This paper will firstly summarise the main findings of the literature review and 
empirical papers, followed by a discussion of some of the decision points, challenges, 
strengths and limitations of this thesis. I will consider issues relating to the use of language 
and constructs, and issues specific to the design of each paper. 
Summary of Findings 
A systematic search of the literature was conducted, which identified 39 papers that 
had analysed relationships between cognitive factors and anxiety among people with 
Parkinson’s. These papers were reviewed and their findings synthesised. Overall, there was 
evidence to suggest that higher anxiety is associated with worse global cognitive abilities and 
worse performance in specific cognitive domains (attention, working memory, executive 
functioning, memory, language, semantic verbal fluency and visuospatial skills). There was 
also evidence to suggest that anxiety predicts cognitive abilities, and vice versa, thus that 
there may be some bi-directionality to the relationship between anxiety and cognition (this 
was in keeping with reported findings in other populations). However, there were 
inconsistencies between the papers, with several studies also finding null results. This could 
not be ascribed to any particular differences in design or quality. It was noted that many of 
the studies had small sample sizes, decreasing their power to detect significant effects, but 
this was not the case for all studies finding null results. Studies also varied as to which 
potentially confounding variables were controlled for. Therefore, firm conclusions could not 
be drawn and it was hypothesised that relationships between anxiety and cognition among 
people with Parkinson’s are complex and likely to be influenced by other factors (for 
example, awareness or perception of cognitive decline, side of onset, or time since diagnosis). 
Consequently, directions for further research were suggested. The paper also highlighted the 
need for clinical psychologists and clinical neuropsychologists who work with people with 
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Parkinson’s to be aware of potentially complex relationships between anxiety and cognitive 
factors, and to ensure that assessments, formulations or interventions relating to either 
construct should include due consideration of the other. I believe that the publication of this 
paper would be a useful contribution to the literature since it provides a comprehensive 
overview of the existing research, which prior reviews on this topic have not achieved 
(perhaps due to limited search terms and selection criteria). 
The empirical paper reports the findings of a quantitative, cross-sectional study which 
examined the relationships between self-compassion, stigma and psychological distress 
among people with Parkinson’s. Both enacted stigma (disparaging attitudes and actions of 
others) and felt stigma (the anticipation of enacted stigma and application of stigmatising 
views towards the self) were measured. Psychological distress was assessed by measures of 
depression, anxiety and stress. Significant correlational relationships were identified: higher 
levels of self-compassion were associated with lesser experiences of enacted stigma, less felt 
stigma and lower levels of depression, anxiety and stress; meanwhile higher levels of 
reported stigma (both felt and enacted) were associated with higher levels of depression, 
anxiety and stress. A series of mediation analyses found the stigma variables to mediate the 
relationships between self-compassion and depression, anxiety and stress. Therefore, it was 
concluded that for people with Parkinson’s, part of the relationship between self-compassion 
and psychological distress occurs via the ways in which stigma is experienced and 
internalised. This may have important implications for clinical psychologists and clinical 
neuropsychologists working with people with Parkinson’s who are experiencing distress. It 
may be useful for psychological assessments with people with Parkinson’s to take levels of 
self-compassion and experiences of stigma into account, while direct psychological 
interventions might benefit from a focus on developing self-compassion where this is found 
to be low. Meanwhile, societal-level interventions might address stigma through education 
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and training, facilitating inclusion of people with Parkinson’s in communities and advocacy. 
This study is the only research I am aware of into the construct of self-compassion among 
people with Parkinson’s, meaning that its publication may be a valuable contribution to the 
field.  
Use of Language and Constructs 
A consideration early in the development of this thesis was the language I wanted to 
use when referring to Parkinson’s. It was apparent from an initial scoping search of the 
literature that most peer-reviewed articles used the terminology “Parkinson’s disease”. 
However, the charity Parkinson’s UK, who supported the development and advertising of my 
empirical study, opt to leave out “disease” from the label and simply refer to “Parkinson’s”. 
This is also reflected in the language used by organisations run by and for people with 
Parkinson’s, such as Parkinson’s Movement and Parkinson’s Foundation, and campaigns 
such as Unite for Parkinson’s. People with Parkinson’s are said to have reported finding the 
“disease” terminology stigmatising (Ramaswamy, Jones & Carroll, 2018; Worth, 2019) – 
though original research or reports stating this could not be located. Given my understanding 
of the impact of stigma (whether enacted or felt) upon people with Parkinson’s through my 
work on the empirical paper, I believed that it was important from an ethical perspective to 
avoid the use of potentially stigmatising language in my thesis. However, I acknowledge 
Worth’s (2019) assertions that the use of “Parkinson’s” is grammatically unusual 
(“Parkinson’s what?”; pp. 3) and risks confusion with other similarly labelled conditions. 
When preparing my papers for publishing, I may need to liaise with the target journal 
regarding my language choices. If I am required to weigh up my ethical stance regarding use 
of language with the likelihood of the research being published (which raises its own ethical 
issues around sharing knowledge and not wasting participants’ and other contributors’ time), 
I will liaise with the research team at Parkinson’s UK for advice. 
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Further terminologies which I grappled with throughout the development of this thesis 
were the diagnostic labels of anxiety and depression. I am aware that some people with 
Parkinson’s may not identify with these labels, despite how they might be categorised based 
on questionnaire scores or whether they meet diagnostic criteria. While these labels may be 
less contentious and less stigmatising than other psychiatric labels such as personality 
disorder and schizophrenia (Markham & Trower, 2003; Wood, Birtel, Alsawy, Pyle & 
Morrison, 2014), they remain somewhat reductionist and still carry a degree of stigma 
(Corrigan, 2007; Wood et al., 2014). Nonetheless, these concepts are commonly used in 
quantitative health psychology and neuropsychology research in order to pragmatically 
measure distress: this approach was also taken in this thesis. Indeed, in the literature review 
paper, the construct of anxiety was a core component of the research question. Most of the 
papers considered anxiety as a continuous variable, which is more in keeping with my 
preferred conceptualisation, but some categorised participants according to the presence or 
absence of “anxiety disorders” or clinically significant levels of anxiety. I was also required 
to include diagnostic and potentially stigmatising labels such as “anxiety disorders” in the 
search terms; this was necessary to ensure the identification of relevant studies. In the 
empirical study, the constructs of depression and anxiety were used as outcome variables. A 
key reason for selecting the Depression, Anxiety and Stress Scale – 21-item version (DASS-
21; Lovibond & Lovibond, 1995) to measure these variables was that it is expressly not a 
diagnostic tool. Rather, it was developed as a dimensional measure of distress on the basis 
that differences between “normal” and “clinical” experiences of depression, anxiety and 
stress are differences in the degree (as measured on a continuum), rather than the nature, of 
distress (Lovibond & Lovibond, 1995). 
 For the empirical paper, I also considered the conceptualisation of cognition. 
Differentiation of cognitive domains is challenging due to a large degree of overlap between 
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functions, multiplicity of terms, and contradictory findings of factor analyses - especially 
with regards to executive functioning (Baggetta & Alexander, 2016; Packwood, Hodgetts & 
Tremblay, 2011). Further, very few cognitive tests measure any cognitive domain in its pure 
form as there is often some overlap in the skills required. Taking a critical realist perspective, 
I consider that cognitive domains exist in the “actual” level of reality, but that they cannot be 
directly observed, since they occur beyond our sensory experience (Danermark, Ekström, 
Jakobsen & Karlsson, 2002). Performance on cognitive tests, therefore, may be considered an 
outcome of the “causal” level of reality (Danermark et al., 2002): cognitive tests are a 
mechanism through which we can empirically observe the actual reality of the cognitive 
domains, but this is determined by our own conceptualisations and the tools we select. As 
such, assessment of cognition cannot be entirely objective. The same might be inferred about 
the measurement of the constructs of self-compassion and stigma in the empirical paper.  
Issues Specific to the Literature Review 
 Developing the review question.  
Due to how the thesis process is set up on the Lancaster University Doctorate in 
Clinical Psychology course, I had already designed the protocol for my empirical study 
before I arrived at the task of selecting a focus for the literature review. I was interested in 
reviewing a topic close to that of the empirical paper, however my initial searches did not 
reveal any studies into self-compassion among people with Parkinson’s, and very few studies 
into self-compassion in any neurological or long-term health conditions. The correlates of 
stigma among people with Parkinson’s had already been reviewed in a previous trainee 
clinical psychologist’s thesis (Verity, 2018). At the time, there was an additional variable in 
my empirical study: self-critical rumination (the reasons for later excluding this variable are 
discussed in the next section of this paper). Therefore, I began to explore topics in this area 
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and decided upon a cognitive focus: a systematic review of the relationships between 
attentional inflexibility and psychological distress among people with Parkinson’s.  
Attentional inflexibility was taken to include the constructs of perseveration, set-
shifting and attentional control (Stahl & Pry, 2005). Based on metacognitive models of 
depression and anxiety (Wells, 2009) which emphasise the role of rumination in the 
development and maintenance of psychological distress, along with evidence that attentional 
flexibility can be affected by Parkinson’s (Dirnberger & Jahanshahi, 2013), and the overlap 
in the constructs of attentional inflexibility and rumination (Ehring et al., 2011), I anticipated 
that significant relationships would be found between attentional inflexibility and distress.  
Unfortunately, following a lengthy systematic search of the literature (the search 
strategy necessarily lacked specificity since the target cognitive domains were rarely 
mentioned in titles or abstracts), I decided not to pursue this review. Almost all the identified 
research assumed both the affective and cognitive sequelae of Parkinson’s to be a result of 
altered dopamine levels in the brain causing disruption to fronto-striatal circuitry involved in 
cognition, and did not consider the potential roles of psychological, social or cognitive 
factors. Therefore, a review from a psychological perspective at this level of specificity 
seemed premature. Consequently, I decided to expand the review to consider relationships 
between cognitive and affective factors among people with Parkinson’s. Previous reviews 
appeared to have adequately considered relationships of the constructs of depression and 
apathy with cognition (Alzahrani & Venneri, 2015; Poletti, De Rosa & Bonuccelli, 2012), 
and there was a clear gap in the research with regards to anxiety. Thus, the final review 
question was decided upon. Given the later removal of the cognitive variable from the 
empirical paper, there is less continuity between the two papers than I had hoped for.   
 Measuring cognition. 
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 Some of the issues around conceptualising and measuring aspects of cognition are 
discussed in the Use of Language and Constructs section of this paper. Additionally, the 
measures used in some of the studies included in the review (Repeatable Battery for the 
Assessment of Neuropsychological Status, Cambridge Cognitive Test, Mini-Mental State 
Examination) are not recommended for use with people with Parkinson’s due to issues with 
validity, reliability and sensitivity to change (Skorvanek et al., 2017). Therefore, it is possible 
that these studies did not accurately reflect relationships between anxiety and cognition due 
to problems in measurement. 
Depression as a potentially confounding variable. 
 One of the weaknesses identified in the body of research into relationships between 
anxiety and cognition was that many of the studies did not consider the potential for shared 
variance between the concepts of anxiety and depression (Beuke, Fischer & McDowall, 
2003). This was surprising given the evidence that symptoms of anxiety and depression 
frequently co-occur among people with Parkinson’s (Sagna, Gallo & Pontone, 2014), and that 
the relationship between depression and cognition is well evidenced (Alzahrani & Venneri, 
2015; Poletti et al., 2012). Thus, it could not always be concluded that the studies truly 
measured relationships between ‘pure’ anxiety and cognition. The use of the State-Trait 
Anxiety Inventory (Spielberger, Gorsuch, Lushene, Vagg & Jacobs, 1983) as a measure of 
anxiety in several of the studies was potentially problematic, since research has found that 
neither subscale (state nor trait) adequately differentiates between symptoms of anxiety and 
depression (Bieling, Antony & Swinson, 1998; Kennedy, Schwab, Morris & Beldia, 2001).  
Synthesising the results. 
 Since previous reviews had identified so few relevant studies, I had not expected to 
find such a large number of results to synthesise. Given the time constraints of the thesis 
process, this was a challenging endeavour. In addition to the quantity of results, the 
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inconsistencies between findings of different studies (with some finding significant 
relationships and others not) made it difficult to draw conclusions.  
 A weakness of the literature review is that I did not extract (or calculate, where 
necessary) effect sizes for each of the analyses (due to time constraints, given the number of 
papers and the number of analyses within each). This might have added some clarity to the 
findings if, for example, effect sizes tended to be small even when they were significant, 
which might have indicated that some studies had failed to find effects because they were 
fairly weak (especially where sample sizes were small). It was identified that most of the 
significant correlations found between anxiety and cognitive factors were weak (correlation 
coefficient <.3; Cohen, 1988), indicating small effects in these studies, however it could not 
be confirmed whether this was the case for all significant findings. I will consider meta-
analysing subsets of the data prior to submitting the literature review paper for publication in 
order to strengthen the results, increase objectivity, and overcome the problems presented by 
small sample sizes (Walker, Hernandez & Kattan, 2008). This may not be advisable for the 
separate cognitive domains, given the wide variety of measures and methods used across 
studies, but might be useful for the global cognition data, where the studies were less 
heterogeneous in design. A forest plot to assess for relative homogeneity of results (using 
confidence intervals of the estimated effects) may be used to determine whether a meta-
analysis is appropriate and justified (Walker et al., 2008).  
Issues Specific to the Empirical Study 
Self-critical rumination. 
I had initially planned to include self-critical rumination as a variable in the empirical 
study. This is defined as a ruminative focus specifically upon on self-critical thoughts (Smart, 
Peters and Baer, 2016). Self-critical rumination has been found to be positively associated 
with symptoms of depression, anxiety, and stress, and negatively associated with self-
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compassion in a non-neurological population (Smart et al., 2016). As such, one of the original 
aims of the study was to investigate whether these relationships also existed for people with 
Parkinson’s. Given that one of the cognitive problems that people with Parkinson’s can 
experience is a tendency to perseverate (as discussed above), I hypothesised that becoming 
stuck upon negative thoughts about the self may be a pertinent issue, and one which could 
affect psychological wellbeing. I also considered that self-criticism, as the antithesis of self-
compassion (Gilbert, 2010), might be positively associated with felt stigma, through the 
internalisation of negative stereotypes which are inherently critical. The Self-Critical 
Rumination Scale Scale (SCRS; Smart, et al., 2016) was therefore included in the survey. The 
SCRS has been used in a limited number of research studies, and does not appear to have yet 
been used with people with neurological conditions. 
As I researched the topic area further, it became clear that there were theoretical 
distinctions in the potential relationships between self-compassion, stigma and distress versus 
self-critical rumination, stigma and distress. The theoretical framework proposed by Wong, 
Knee, Neighbors and Zvolensky (2019), whereby self-compassion allows people to 
internalise stigma less and leads to more positive outcomes, supported a mediation model 
with self-compassion as the predictor, stigma as the potential mediator and the psychological 
distress variables at the outcomes. This framework was published after the research protocol 
had been developed, at which time I had proposed that self-compassion would be the 
mediator. However, this model would not make sense with self-critical rumination in the 
place of self-compassion, since the idea that self-critical rumination would predict stigma is 
not theoretically supported. Self-critical rumination would have been required to be the 
mediator variable, with stigma as the predictor. This would therefore comprise an entirely 
different research question, introducing an additional layer of complexity to the paper that I 
would struggle to adequately describe in the prescribed word count. I therefore agreed with 
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my supervisors that it might be preferable to write two theoretically distinct papers: one about 
the relationships between self-compassion, stigma and psychological distress (as submitted as 
part of this thesis) and another about the relationships between stigma, self-critical 
rumination and psychological distress. Therefore, the SCRS data may be analysed and written 
up in a separate paper at a later date.  
Recruitment strategy. 
Participants were recruited via online advertisement on the Parkinson’s UK website, 
in the Parkinson’s UK online newsletter and on the social media platform Twitter. The survey 
was in a computerised format but participants were given the option to request a paper copy 
by post. This recruitment strategy was selected due to Parkinson’s UK having an extremely 
active Research Support Network, and the success of a previous trainee clinical psychologist 
in using a similar recruitment strategy for a similar research project (Verity, 2018). It was 
also cost-effective and allowed for recruitment across geographical barriers. However, there 
were limitations to this strategy in that it favoured individuals who were computer-literate 
and had access to a computer, and may have excluded people who did not meet these criteria. 
I did receive emails from family members of people with Parkinson’s who had seen the 
research advertised online and requested a paper-copy for their (non-computer-literate) 
relative, but only one of these was returned. To aid with computerised completion, the survey 
was designed such that individuals could save and return to their responses at any time. The 
Patient and Public Involvement volunteers from Parkinson’s UK, who participated in the 
design of the materials, were positive about the online format and did not foresee any 
problems with the recruitment strategy, given the option to request a paper copy if preferred.  
A recent report by the charity Age UK states that 36% of people over the age of 65 do 
not currently use the internet, and that the likelihood of internet use is reduced among people 
with mobility problems (Age UK, 2018). Additionally, younger people are more likely than 
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older people to participate in research advertised on the internet and social media 
(Topolovec-Vranic & Natarajan, 2016). As such, my chosen recruitment strategy may have 
been a factor in the sample being relatively young and functionally able. Future studies may 
benefit from broader recruitment strategies (such as visiting clinics and care homes), to be 
more inclusive of older and less functionally able people with Parkinson’s and to increase 
generalisability.  
People experiencing higher levels of psychological distress and/or stigma might have 
been less likely to participate in the study due to, for example, shame, avoidance or low 
motivation. Although it is important to understand the experiences of this group in order to 
improve care, recruitment strategies aimed at including these individuals require the 
consideration of ethical issues, since participation could be distressing. Future research might 
address this issue by providing additional support, both at the time of participation and 
afterwards, perhaps by building links with services for people with Parkinson’s who could 
facilitate recruitment and provide this support.  
Limitations of the study design. 
As discussed in the empirical paper, since the study was observational and cross-
sectional, cause and effect cannot be established. Hayes (2018) recommends that mediation 
anayses with correlational and cross-sectional data need not be avoided, despite causality 
being assumed in the mediation model, so long as the results are interpreted cautiously. As 
such, it cannot be assumed that having more self-compassion causes people with Parkinson’s 
to experience less stigma, which causes them to experience less distress. Rather, it appears 
that there are interactions between each of the variables such that the relationships between 
self-compassion and depression, anxiety and stress operate via their relationships with 
experiences of felt and enacted stigma. Therefore, there may be additional underlying 
variables contributing to the relationships, such as social, demographic or economic factors.  
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Mediation is only one of many possible ways of investigating the relationships 
between the variables in this study. A moderation model, where self-compassion might be 
predicted to moderate the relationships between experiences of stigma and distress, would be 
an alternative analysis. This would test a different aspect of Wong et al.’s (2019) model to 
that which was tested by the mediation analysis. If significant (and in the expected direction), 
this would suggest that as self-compassion increases, the relationship between stigma and 
psychological distress becomes less strong. This moderation analysis was considered for 
analysing the data in the empirical study but the sample size was considered inadequate 
(consideration of this model was prompted by the Wong et al. (2019) paper, which was not 
identified until after data collection was complete). This may be an area for future research. 
Additionally, it was considered that self-compassion may mediate the relationship between 
stigma and distress. However, this was less theoretically supported, self-compassion being 
conceptualised as something which develops in response to early caregiving relationships 
(Gilbert, 2010) and therefore unlikely to be predicted by Parkinson’s-related stigma. 
In addition to the above, the survey-based nature of the study meant a reliance on self-
report measures. This was particularly problematic for the enacted stigma variable, in which 
participants were required to make judgements as to whether others’ attitudes and actions 
towards them were as a result of their Parkinson’s. Self-reports of enacted stigma may 
therefore reflect an individual’s subjective experiences of stigma (potentially influenced by 
their beliefs and interpretations) rather than actual enactments of stigma. Arguably, the 
subjective experience of stigma is more important from a psychological perspective, however 
I was required to exercise caution in my interpretations of the meaning of the enacted stigma 
variable. 
Directions for Future Research 
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Some areas for future research might include further exploration of the correlates of self-
compassion among people with Parkinson’s, and the efficacy of compassion-focussed 
approaches to working with this population (potential outcomes for efficacy might be 
psychological distress and internalisation of stigma, based on the findings of the empirical 
paper). The mediation model identified in the empirical paper might be built upon by 
considering the interaction of the mediating variables of felt and enacted stigma, or by 
considering other potential mediators in the relationship between self-compassion and 
distress. Studies investigating the impact of interventions for reducing the stigma around 
Parkinson’s would also be valuable.   
Future research might also investigate the complexities of the relationships between 
anxiety and cognitive factors from a psycho-social perspective, for example by considering 
experiences of stigma, subjective cognitive performance or depression. Qualitative research 
into the social and psychological impact of cognitive decline for people with Parkinson’s 
might highlight further areas for exploration.  
Conclusions 
Two pieces of research were conducted, a systematic review and an empirical study, 
in which relationships between cognitive, psychological and social factors for people with 
Parkinson’s were explored. There were strengths in the originality of the research, and both 
papers will hopefully provide a useful contribution to knowledge for clinical psychologists 
and clinical neuropsychologists working with people with Parkinson’s. However, there were 
also limitations to both studies. Some of these might be addressed in preparing the papers for 
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(Jane has agreed to provide advice on specific aspects of the project (analysis and 
interpretation of results) but will not be involved in the day to day running of the project.) 
 
Introduction 
Parkinson’s1 is the second most common neuro-degenerative condition (after 
Alzheimer’s disease) and affects 0.1-0.2% of the population, with increasing prevalence after 
the age of 60 (Tysnes & Storstein, 2017). The symptoms of Parkinson’s are often categorised 
within the literature into motor and non-motor characteristics. Typical motor symptoms, as 
reviewed by Moustafa et al. (2016), include difficulty initiating movement (akinesia), slowed 
movement (bradykinesia), tremor, rigidity, gait disturbance and speech difficulties. Non-
motor symptoms can include cognitive impairments, difficulties with impulse control, and 
visual disturbances, as delineated by Stacy (2011). 
Several qualitative studies have described the stigma that people with Parkinson’s can 
experience in relation to the more visible symptoms of the condition (Caap-Ahlgren & 
Lannerheim, 2002; Bramley & Eatough, 2005; Hermanns, 2013). Further research has 
demonstrated stigmatizing views held by both professionals and members of the public 
towards people with Parkinson’s (Tickle-Degnen, Zebrowitz & Ma, 2011; Hemmesch, 2014). 
It has also been suggested that experiences of stigma can lead to an increase in psychological 
distress (as measured by symptoms of depression scales), both amongst people with 
Parkinson’s (Schrag, Jahanshahi & Quinn, 2001) and other neurological conditions such as 
epilepsy (Whatley, Dilorio & Yeager, 2010). For clinical psychologists working with people 
																																																						
1	“Parkinson’s” as opposed to “Parkinson’s Disease” is the label used by the charitable 
organisation Parkinson’s UK. Therefore this language has been adopted throughout this 
document, and on all participant materials.	
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with Parkinson’s with experiences of stigma and psychological distress, it appears important 
to gain a greater understanding of the relationship between these constructs.  
A factor which may be considered as a potential component in the relationship 
between stigma and psychological distress is self-compassion. Self-compassion is defined by 
Neff and Dahm (2015) as an acknowledgement of one’s own suffering (in line with principles 
of mindfulness), and a self-directed response based upon “kindness, concern and support”. 
No research could be found looking at self-compassion amongst people with Parkinson’s, 
however it has been demonstrated that interventions aimed at increasing self-compassion can 
alleviate psychological distress in people with other neurological problems – for example, 
traumatic brain injuries (Ashworth, Gracey & Gilbert, 2011) and dementia (Collins, Gilligan 
& Poz, 2017). 
It may therefore be reasonable to hypothesise that self-compassion could have a role 
in the relationship between stigma and psychological distress amongst people with 
Parkinson’s – where stigma and psychological distress might be conceptualized as suffering. 
Indeed, self-compassion has been shown to protect against the effects of stigma on 
psychological distress in parents of children with autism (Wong, Mak & Liao, 2016). 
However, no literature could be found exploring similar relationships in people with 
neurological conditions. 
An additional construct which will be considered is self-critical rumination. This is 
defined as a ruminative focus specifically upon on self-critical thoughts (Smart, Peters and 
Baer, 2016). Self-critical rumination has been found to be positively associated with 
symptoms of depression, anxiety, and stress, and negatively associated with self-compassion 
in a non-neurological population (Smart, Peters and Baer, 2016). As such, it may be useful to 
investigate whether these relationships also exist for people with Parkinson’s and whether 
4-14	
	
self-critical rumination might play a role in the relationship between stigma and 
psychological distress. 
The overall aim of this study is to explore the relationships between the constructs of 
self-compassion, self-critical rumination, stigma and psychological distress amongst people 
with Parkinson’s. It is hoped that the findings of this research will be useful to clinical 
psychologists working with individuals with Parkinson’s: it may deepen understanding of the 
relationships between internal and external experiences for people with Parkinson’s; it could 
highlight a possible future role for compassion-focussed, cognitive and metacognitive 
therapeutic approaches; and more broadly, it may highlight a role for clinical psychologists in 




Participants will be accessed via the charitable organisation Parkinson’s UK, through 
online advertising (the charity have a dedicated page for this on their website - 
https://www.parkinsons.org.uk/research/take-part-research). The study will also be advertised 
on the social media platform Twitter, via Natalie Sowter’s Twitter account. We may also 
approach other organisations who support people with Parkinson’s (including, but not limited 
to, Parkinson’s Association of Ireland, Parkinson’s Australia, and Parkinson’s New Zealand), 
to ask them to advertise the study through their websites.   
Participants will be adults (i.e. 18 years and older) with Parkinson’s who have had 
their diagnosis for a minimum of 6 months. No upper age limit will be set. 
A-priori power calculations indicate that a sample of at least 84 participants will be 
required in order to achieve sufficient statistical power for the intended statistical analyses 
(mediation analysis and correlation). Fritz and MacKinnon (2007) provide empirical 
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estimates of the sample sizes required in mediation analyses to achieve statistical power at 
80%. They suggest that a bias-corrected bootstrapped mediation analysis with medium effect 
sizes between the independent and mediator variables (a) and the mediator and dependent 
variables (b) (a, b = 0.39) requires 71 participants, in order to be adequately powered. For a 
moderate correlation (r = 0.3) and for p=0.05 at 80% power, a two-tailed Pearson’s 
correlation requires 84 participants. Therefore, a minimum of 84 participants will be 
recruited. A maximum of 300 participants will be recruited.  
Design 
This study will employ a cross-sectional, correlational design: it will aim to measure 
the strength and direction of relationships between several variables, using only one group of 
participants, at one time-point. The null hypotheses are as follows: 
 There is no relationship between participants’ self-critical rumination scores and self-
compassion scores. 
 There is no relationship between participants’ stigma scores and psychological distress 
(as measured by anxiety, depression and stress scores) 
 Stigma, self-compassion and self-critical rumination scores do not predict psychological 
distress (as measured by anxiety, depression and stress scores). 
 Neither self-compassion nor self-critical rumination mediate any relationship found 
between stigma and psychological distress .  
Materials 
The participant materials for this study will be available both online (via Qualtrics) 
and in hard copy. The participant materials have been kindly reviewed by Patient and Public 
Involvement Volunteers from Parkinson’s UK, and amended in line with the feedback 
provided. The participant materials will consist of: 
1. Information for Participants – briefly outlining the purpose of the research, how 
the data will be stored and used, how to contact the research team with any 
questions or complaints, etc. If this is accessed via Qualtrics, the option will be 
provided to download a printable copy of this document. 
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2. Eligibility and consent questions – 4 questions to check that participants are 
eligible to participate, have read the Information for Participants and give consent 
for their data to be included in the study. 
3. Demographics questionnaire – 10 questions to gather demographic and clinical 
information about participants. 
4. Functional Status Questionnaire (FSQ; Jette et al., 1986) physical function 
subscale – 9 items designed to assess functioning in basic and intermediate 
activities of daily living. This has been included for the purpose of situating the 
sample in terms of severity of physical symptoms. In a systematic review of 
disability rating scales for people with Parkinson’s by Shulman et al. (2016), this 
measure was recommended for both clinical and research use. Jette et al. (1986) 
report that it has good internal consistency (Cronbach's alpha = 0.92). 
5. Stigma Scale for Chronic Illness (SSCI; Rao et al., 2009) – a 24 item multiple-
choice questionnaire, validated for use with people with Parkinson’s. Measures 
both felt (internalised) stigma and enacted (experienced behaviourally from 
others) stigma. This distinction may be helpful in reducing bias due to the 
possibility that people who are more self-compassionate may experience less felt 
stigma. Cronbach’s alpha was reported by the authors of the scale at 0.97, 
although this analysis was conducted on a draft version of the questionnaire with 
26 items. 
6. Self-Compassion Scale (SCS; Neff, 2003) – a 26 item validated measure of self-
compassion. Neff (2003) reports that the scale’s internal consistency is high 
(Cronbach’s alpha = 0.92).  
7. Self-Critical Rumination Scale Scale (SCRS; Smart, Peters & Baer, 2016) – a 10 
item questionnaire; the only self-report measure of self-criticism found to have 
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good content and structural validity in a systematic review of available measures 
(Rose & Rimes, 2018). Smart et al. (2016) report a Cronbach’s alpha of 0.92, 
suggesting good internal consistency. Test-retest reliability is also reported for this 
measure at 0.86 (Smart et al., 2016).  
8. Depression, Anxiety and Stress Scale - 21 (DASS-21; Lovibond & Lovibond, 
1995) – a 21 item questionnaire which is validated for clinical and non-clinical 
populations. Cronbach’s alphas have been found to be 0.94 for depression, 0.87 
for anxiety, and 0.91 for stress (Antony, Bieling, Cox, Enns, & Swinson, 1998). 
9. Debrief – additional information about the purpose of the research, contact details 
for queries or concerns, and resources in the case that the research leads to any 
distress. 
Additional materials which will be required are: 
1. Research phone (to enable participant contact) 
2. Prepaid envelopes and stamps (for postage of hard copies) 
3. Qualtrics software 
4. SPSS software including Hayes PROCESS tool 
Procedure 
Participants will be recruited via Parkinson’s UK 
(https://www.parkinsons.org.uk/research/take-part-research). This has been agreed with the 
Parkinson’s UK research team. Participants will see the title of the research and a brief 
description, and when clicking on this will be taken to the landing page of the Qualtrics 
survey (the first page being the Information for Participants sheet). The study will also be 
advertised on the social media platform Twitter, via Natalie Sowter’s Twitter account. 
Twitter posts will provide a brief description of the study, and a link to the landing page of 
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the Qualtrics survey (the first page being the Information for Participants sheet). 
Organisations who support people with Parkinson’s may be “tagged” in the posts and asked 
to “retweet”. Additionally, we may approach other organisations who support people with 
Parkinson’s (including, but not limited to, Parkinson’s Association of Ireland, Parkinson’s 
Australia, and Parkinson’s New Zealand), to ask them to advertise the study through their 
websites.   
Participants will be able to choose to complete the online survey via Qualtrics, or to 
contact the lead researcher via phone, text or email to request a hard copy be posted to them, 
along with a stamped addressed envelope in which to return it. 
Data will be collated on the principal investigator’s password-protected Qualtrics 
account, and will at this stage be accessible only to the principal investigator and supervisors. 
Responses submitted in hard copy format will be entered into Qualtrics by the principal 
investigator and then destroyed. 
 
Data Analysis 
The relevant data for each analysis will be transferred from Qualtrics to SPSS data 
files. A correlation analysis will firstly be performed between self-compassion and self-
critical rumination scores, then between all other variables (Pearson or Spearman depending 
on the distribution of scores). A series of hierarchical regression analyses will then be 
conducted with the DASS variable scores as the dependent variable for each analysis (i.e. 
depression, anxiety, and stress), stigma and self-compassion and/or self-critical rumination 
scores as independent variables, and controlling for demographic and clinical variables if 
appropriate. 
If the assumptions are met to carry out mediation analyses (e.g. Hayes & Rockwood, 
2017), then this will also be completed (with bias-correction and bootstrapping as required). 
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The first proposed mediation analysis will take stigma as the independent variable, DASS 
scores as the dependent variable, and self-compassion as the potential mediator. The second 
proposed mediation analysis will take stigma as the independent variable, DASS scores as the 
dependent variable, and self-critical rumination as the potential mediator. 
 
Dissemination 
It is anticipated that the findings of this study will be disseminated as follows: 
1. Submitted as part of the principal investigator’s thesis for her Doctorate in Clinical 
Psychology (DClinPsy). 
2. Submitted for publication in a peer-reviewed journal  
3. Presented to trainee clinical psychologists, service users and course staff at the 
DClinPsy thesis presentation day at Lancaster University. 
4. Summarised for presentation on the Parkinson’s UK website. 
5. Presented at a meeting of the North West Neuropsychology Special Interest Group, 
and/or at other conferences and seminars. 
 
Practical issues 
It is hoped that the option to complete the questionnaires either online or in hard-copy 
(paper) format will enable people to participate who may wish to contribute but be otherwise 
unable. Participants will also be allowed to have help to fill in the questionnaires by a 
relative, friend or caregiver. 
Data will be submitted anonymously and stored securely on password protected 
software (Qualtrics). Data will be accessible only to Natalie Sowter and the supervisors 
named above (and the research coordinator and Research and/or Programme Director in the 
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DClinPsy team once the assignment is submitted). Once the project is complete, data will be 
sent to the research coordinator of the DClinPsy team for storage for 10 years on the 
Lancaster University secure Network or Box. Fiona Eccles will be the data custodian and will 
be responsible for overseeing the data being destroyed after 10 years. 
The licences for the necessary statistical analysis software are available through 
Lancaster University.  
 
Ethical concerns 
Since participant recruitment will be carried out through Parkinson’s UK, NHS ethical 
approval is not required and ethical approval is being sought via the FHMREC only. The 
research team at Parkinson’s UK have confirmed that this is sufficient. 
There is a slight possibility that participants may feel distressed as a result of 
completing the questionnaires. The details of organisations participants can contact for 
support in the event of distress will be provided as part of the debrief information. No risks to 
researchers have been identified. 
As above, data will be submitted anonymously and stored securely on password 
protected software (Qualtrics). Data will be accessible only to Natalie Sowter and the 
supervisors named above (and the research coordinator and Research and/or Programme 
Director in the DClinPsy team once the assignment is submitted). Once the project is 
complete, data will be sent to the research coordinator of the DClinPsy team for storage for 
10 years on the Lancaster University secure Network or Box. Fiona Eccles will be the data 
custodian and will be responsible for overseeing the data being destroyed after 10 years. 
 
Timescale 
September 2018: Submission of ethics application. 
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October-December 2018: Data collection. 
January 2019: Data analysis. 
December 2018-April 2019: Write-up. 
May 2019: Submission of report as part of thesis. 
Autumn/Winter 2019: Submission for publication; dissemination of findings by 
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Note to Ethics Committee Regarding Online Survey 
 
The online version contains the same materials and questionnaires as the paper version 
enclosed below. Any changes in wording are purely to facilitate online use. 
 
Link to qualtrics survey:  
https://lancasteruni.eu.qualtrics.com/jfe/form/SV_eKUy6NVbspAjRMV 
 
Note: the eligibility and consent questions in the online version must be answered in order to 






Paper Version of Participant Materials 




How are people with Parkinson’s treated by others, how do they view themselves, and 
how is their psychological wellbeing affected? 
 
Information for Participants      
 
My name is Natalie Sowter and I am conducting this research as a student on the Doctorate in 
Clinical Psychology programme at Lancaster University, Lancaster, United Kingdom.      
 
What is the study about?   
This study aims to find out about the relationships between four types of experiences for 
people with Parkinson’s. The types of experiences we want to find out about are:    
• signs of psychological distress (e.g. symptoms of anxiety, depression and stress), 
• signs of disapproval from oneself and others (stigma),    
• persistent critical thoughts about the self (self-critical rumination) and    
• the ability to recognise one’s own suffering and take steps to relieve it, using a kind 
and caring approach (self-compassion).    
 
Previous research has suggested that people affected by Parkinson’s may experience stigma, 
which can lead to an increase in psychological distress. The aim of this study is to investigate 
the relationship between stigma and psychological distress, by looking at other factors which 
might influence it. The other factors which we are considering are 'self-compassion' and 'self-
critical rumination'. We hope to find out about the relationship between these two concepts 
for people with Parkinson’s. We also hope to find out whether either (or both) of these 
concepts are important in explaining the relationship between stigma and psychological 
distress for people with Parkinson’s. We hope that an understanding of how these 




Who can take part in this study?   
To participate in this study, you need to be aged 18 years or over. You also need to have a 
diagnosis of Parkinson’s, and to have received this diagnosis at least 6 months ago.       
 
Do I have to take part?   
No. It’s completely up to you to decide whether or not to take part.      
 
What will I be asked to do if I take part?   
If you decide that you would like to take part, you will be asked to complete a survey. The 
survey should take around 30 minutes to complete and need not be completed in one sitting. 
You can ask somebody to help you to complete the survey if you would like.      
 
How do I take part?  
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You can take part by filling in the questionnaires in this pack and returning them in the 
stamped addressed envelope provided. Alternatively, you can complete the survey online by 
going to https://www.parkinsons.org.uk/research/take-part-research. 
 
Are there any risks?   
There are no risks anticipated with participating in this study. However, if you experience 
any distress following participation you are encouraged to inform the researcher and contact 
the resources provided below.      
 
Will my data be identifiable?   
The information you provide in the survey will remain anonymous, i.e. we will not be able to 
tell which information belongs to you. If you provide your name and address to receive a 
paper copy of the survey, this information will be destroyed once the survey has been posted 
to you.   Your responses to the survey will be combined with other participants' data and 
stored in an electronic file space on the secure server provided by Lancaster University. Paper 
copies of the survey will be stored in a locked cabinet until they have been added to the 
electronic file space, after which time they will be destroyed. The electronic file space will be 
password protected such that it will only be accessible to the researchers for this study. Since 
this research will be submitted for assessment as part of the Doctorate in Clinical Psychology, 
the anonymised data may also need to be accessed by the course's admin staff and the 
Programme and/or Research Directors. The data will be held securely in its anonymised 
electronic form by Lancaster University for 10 years, after which time it will be destroyed. 
For further information about how Lancaster University processes personal data for research 
purposes, and your data rights, please visit our webpage: www.lancaster.ac.uk/research/data-
protection.     
 
What will happen to the results?   
The results will be summarised and reported in a thesis and may also be submitted for 
publication in an academic journal and presented at seminars and conferences. The 
summarised results will also be made available on the Parkinson’s UK website.      
 
Who has reviewed the project?   
This study has been reviewed and approved by the Faculty of Health and Medicine Research 
Ethics Committee at Lancaster University.      
 
Where can I obtain further information about the study if I need it?   
If you have any questions about the study, please contact the main researcher Natalie Sowter 
(Trainee Clinical Psychologist) by email at n.sowter@lancaster.ac.uk or by telephone on 
(07508 375 665).  You can also contact my research supervisor, Fiona Eccles (Lecturer in 
Health Research) by email at f.eccles@lancaster.ac.uk or by telephone on 01524 592 807. 
 
Complaints   
If you wish to make a complaint or raise concerns about any aspect of this study and do not 
want to speak to the researcher, you can contact:   
Professor Bill Sellwood, Research Director for Doctorate in Clinical Psychology Programme  
Tel: 01524 593998   
Email: b.sellwood@lancaster.ac.uk   
Division of Health Research, Faculty of Health and Medicine  Lancaster University, 
Lancaster, LA1 4YG 
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If you wish to speak to someone outside of the Doctorate in Clinical Psychology Programme, 
you may also contact:  
Professor Roger Pickup, Associate Dean for Research   
Tel: 01524 593746   
Email: r.pickup@lancaster.ac.uk   
Division of Biomedical and Life Sciences, Faculty of Health and Medicine  Lancaster 
University, Lancaster, LA1 4YG 
  
  
Resources in the event of distress   
Should you feel distressed either as a result of taking part, or in the future, the following 
resources may be of assistance: 
 
Parkinson’s UK   
Website: www.parkinsons.org.uk   
Helpline: 0808 800 0303         
 
Samaritans   
Website: https://www.samaritans.org/   





If you would like to take part in this study, please continue by answering the questions 
below. 
 
Please note that if you answer "Yes" to the questions below, and you return these 
questionnaires, then you will not be able to withdraw your data. This is because your 




Are you aged 18 years or over? 
o Yes  
o No  
 
Have you been given a diagnosis of Parkinson's? 
o Yes, over 6 months ago  
o Yes, less than 6 months ago  
o No  
 
Have you read and understood the Information for Participants? 
o Yes  
o No  
 
Do you give consent for your responses to this survey to be used for the trainee clinical 
psychologist's research study, as described in the Information for Participants?  
o Yes  





The following questions are to help us to understand more about the people who take 
this survey, and to see whether the data we get is representative of people with 
Parkinson's across the UK. We will not be able to identify you from this information.  
 
How many years ago were you diagnosed with Parkinson's? 
(If unsure, please make your best guess) 
o I was diagnosed ______ years ago 
o I'd prefer not to say  
 
 
How are your Parkinson's symptoms currently being treated? 
Please select all that apply: 
  Medication prescribed by GP / neurologist / other healthcare professional 
  Deep Brain Stimulation surgery  
  Apomorphine pump  
  Other (please describe) __________________________________________ 
  No current treatment  
  I'd prefer not to say  
 
 
What is your age? 
o I'd prefer not to say  





Where do you currently live? 
o England  
o Northern Ireland  
o Scotland  
o Wales  
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o European country outside of the UK (please specify) 
________________________________________________ 
o Country outside of Europe (please specify) 
________________________________________________ 
o I'd prefer not to say  
 
 
Please select the option which best describes your ethnic group or background. 
o Arab 
 
Asian / Asian British: 
o Bangladeshi  
o Chinese  
o Indian  
o Pakistani  
o Any other Asian background, please describe _______________________ 
 
Black / Black British 
o African 
 (continues overleaf) 
 
o Caribbean  
o Any other Black background, please describe ________________________ 
 
 
Mixed / Multiple ethnic background 
o White and Asian  
o White and Black African  
o White and Black Caribbean  
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o British (English / Northern Irish / Scottish / Welsh)  
o Irish  
o Traveller  




o Any other ethnic background, please describe _________________________ 







Which option best describes your current living situation? 
o In my own home, by myself  
o In my own home, with my spouse/ partner/ family/ friends/ others  
o In my own home, with a live-in carer  
o In supported accomodation  
o In a nursing home  
o Long-term hospital stay  
o Other (please describe) _________________________________________ 
o I'd prefer not to say  
 
 
What is your gender identity? Please select all that apply: 
  Female  
  Male  
  Non-binary  
  Gender non-conforming  
  I'd prefer to self describe ______________________________________ 







Which option best describes your current partnership status? 
o I have a spouse or partner, whom I live with  
o I have a spouse or partner, whom I do not live with  
o I do not have a spouse or partner  
o I am widowed 
o Other (please describe) _______________________________________ 
o I'd prefer not to say 
 
 
Which option best describes your current employment status? 
o In full-time education  
o In part-time education  
o Employed (full-time)  
o Employed (part-time)  
o Self-employed  
o Unemployed  
o Retired  
o Unable to work  
o Other (please describe) _______________________________________ 





The following questions ask about how Parkinson's affects you physically. This will help 
us to understand more about the people who take this survey.  
 










not do because 
of health 
Usually did 
not do for 
other reasons 
Taking care of yourself, 
that is, eating, dressing or 
bathing?  o  o  o  o  o  
Moving in and out of a bed 
or chair?  o  o  o  o  o  
Walking indoors, such as 
around your home?  o  o  o  o  o  
Walking several blocks?  o  o  o  o  o  
Walking one block or 
climbing one flight of 
stairs?  o  o  o  o  o  
Doing work around the 
house such as cleaning, 
light yard work, home 
maintenance?  
o  o  o  o  o  
Doing errands, such as 
grocery shopping?  o  o  o  o  o  
Driving a car or using 
public transportation?  o  o  o  o  o  
Doing vigorous activities 
such as running, lifting 
heavy objects or 
participating in strenuous 
sports?  




A number of experiences are described on the following pages. Please indicate how 




 Never Rarely Sometimes Often Always 
Because of my 
illness, I felt 
emotionally 
distant from other 
people  
o  o  o  o  o  
Because of my 
illness, I felt left 
out of things  o  o  o  o  o  
Because of my 
illness, I felt 
embarrassed in 
social situations  
o  o  o  o  o  
Because of my 
illness, I worried 
about other 
people's attitudes 
towards me  
o  o  o  o  o  
I was unhappy 
about how my 
illness affected my 
appearance  
o  o  o  o  o  
Because of my 
illness, it was hard 
for me to stay neat 
and clean  
o  o  o  o  o  
Because of my 
illness, I worried 
that I was a 
burden to others  
o  o  o  o  o  
I felt embarrassed 
about my illness  o  o  o  o  o  
I felt embarrassed 
because of my 
physical 
limitations  
o  o  o  o  o  
I felt embarrassed 
about my speech  o  o  o  o  o  
Because of my 
illness, I felt 
different from 
others  
o  o  o  o  o  
I tended to blame 
myself for my 
problems  o  o  o  o  o  
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 Never Rarely Sometimes Often Always 
I avoided making 
new friends to 
avoid telling 
others about my 
illness  
o  o  o  o  o  




with me  
o  o  o  o  o  
Because of my 
illness, some 
people avoided me  o  o  o  o  o  
Because of my 
illness, people 
were unkind to me 
 
  
o  o  o  o  o  
Because of my 
illness, people 
made fun of me  o  o  o  o  o  
Because of my 
illness, people 
avoided looking at 
me  
o  o  o  o  o  
Because of my 
illness, strangers 
tended to stare at 
me  
o  o  o  o  o  
Because of my 
illness, I was 
treated unfairly by 
others  
o  o  o  o  o  
Because of my 
illness, people 
tended to ignore 
my good points  
o  o  o  o  o  
Some people acted 
as though it was 
my fault I have 
this illness  
o  o  o  o  o  
People with my 
illness lost their 
jobs when their 
employers found 
out about it  
o  o  o  o  o  
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 Never Rarely Sometimes Often Always 
I lost friends by 
telling them that I 






HOW I TYPICALLY ACT TOWARDS MYSELF IN DIFFICULT TIMES 
 
Please read each statement on the following pages carefully before answering. For each 
item, indicate how often you behave in the stated manner, using the following scale: 
 








 1 (almost never) 2 3 4 
5 (almost 
always) 
1. I’m disapproving and 
judgmental about my own 
flaws and inadequacies.  o  o  o  o  o  
2. When I’m feeling down I 
tend to obsess and fixate on 
everything that’s wrong.  o  o  o  o  o  
3. When things are going 
badly for me, I see the 
difficulties as part of life that 
everyone goes through 
o  o  o  o  o  
4. When I think about my 
inadequacies, it tends to 
make me feel more separate 
and cut off from the rest of 
the world.  
o  o  o  o  o  
5. I try to be loving towards 
myself when I’m feeling 
emotional pain.  o  o  o  o  o  
6. When I fail at something 
important to me I become 
consumed by feelings of 
inadequacy.  
o  o  o  o  o  
7. When I'm down and out, I 
remind myself that there are 
lots of other people in the 
world feeling like I am.  
o  o  o  o  o  
8. When times are really 
difficult, I tend to be tough 
on myself.  
 
o  o  o  o  o  
9. When something upsets 
me I try to keep my 
emotions in balance.  o  o  o  o  o  
10. When I feel inadequate 
in some way, I try to remind 
myself that feelings of 
inadequacy are shared by 
most people.  
o  o  o  o  o  
11. I’m intolerant and 
impatient towards those 
aspects of my personality I 
don't like.  
o  o  o  o  o  
12. When I’m going through 
a very hard time, I give 
myself the caring and 
tenderness I need.  
o  o  o  o  o  
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 1 (almost never) 2 3 4 
5 (almost 
always) 
13. When I’m feeling down, 
I tend to feel like most other 
people are probably happier 
than I am.  
o  o  o  o  o  
14. When something painful 
happens I try to take a 
balanced view of the 
situation.  
o  o  o  o  o  
15. I try to see my failings as 
part of the human condition.  o  o  o  o  o  
16. When I see aspects of 
myself that I don’t like, I get 
down on myself.  o  o  o  o  o  
17. When I fail at something 
important to me I try to keep 
things in perspective.  o  o  o  o  o  
18. When I’m really 
struggling, I tend to feel like 
other people must be having 
an easier time of it.  
o  o  o  o  o  
19. I’m kind to myself when 
I’m experiencing suffering.  o  o  o  o  o  
20. When something upsets 
me I get carried away with 
my feelings.  o  o  o  o  o  
21. I can be a bit cold-
hearted towards myself when 
I'm experiencing suffering.  o  o  o  o  o  
22. When I'm feeling down I 
try to approach my feelings 
with curiosity and openness.  o  o  o  o  o  
23. I’m tolerant of my own 
flaws and inadequacies.  o  o  o  o  o  
24. When something painful 
happens I tend to blow the 
incident out of proportion.  o  o  o  o  o  
25. When I fail at something 
that's important to me, I tend 
to feel alone in my failure.  o  o  o  o  o  
26. I try to be understanding 
and patient towards those 
aspects of my personality I 
don't like.  
o  o  o  o  o  




 Not at all A little Moderately Very well 
1. My attention is often 
focused on aspects of myself 
that I’m ashamed of.  o  o  o  o  
2. I always seem to be 
rehashing in my mind stupid 
things that I’ve said or done.  o  o  o  o  
3. Sometimes it is hard for 
me to shut off critical 
thoughts about myself.  o  o  o  o  
4. I can’t stop thinking about 
how I should have acted 
differently in certain 
situations.  
o  o  o  o  
5. I spend a lot of time 
thinking about how ashamed 
I am of some of my personal 
habits.  
o  o  o  o  
6. I criticise myself a lot for 
how I act around other 
people.  o  o  o  o  
7. I wish I spent less time 
criticising myself. o  o  o  o  
8. I often worry about all of 
the mistakes I have made.  o  o  o  o  
9. I spend a lot of time 
wishing I were different.  o  o  o  o  
10. I often berate myself for 
not being as productive as I 




Please read each statement on the following pages and select a number 0, 1, 2 or 3 which 
indicates how much the statement applied to you over the past week.  There are no right 
or wrong answers.  Do not spend too much time on any statement. 
 
The rating scale is as follows: 
 
0  Did not apply to me at all  
1 Applied to me to some degree, or some of the time 
2 Applied to me to a considerable degree, or a good part of time 





 0 (did not apply to me at all) 
1 (applied to me to 
some degree, or 
some of the time) 
2 (applied to me a 
considerable 
degree, or a good 
part of the time) 
3 (applied to me 
very much, or 
most of the time) 
I found it hard to wind 
down  o  o  o  o  
I was aware of dryness of 
my mouth  o  o  o  o  
I couldn't seem to 
experience any positive 
feeling at all   o  o  o  o  
 I experienced breathing 
difficulty (e.g. excessively 
rapid breathing, 
breathlessness in the 
absence of physical 
exertion)   
o  o  o  o  
I found it difficult to work 
up the initiative to do 
things  o  o  o  o  
  I tended to over-react to 
situations   o  o  o  o  
I experienced trembling 
(e.g. in the hands)  o  o  o  o  
 I felt that I was using a lot 
of nervous energy  o  o  o  o  
I was worried about 
situations in which I might 
panic and make a fool of 
myself  
o  o  o  o  
I felt that I had nothing to 
look forward to  o  o  o  o  
I found myself getting 
agitated  o  o  o  o  
I found it difficult to relax  o  o  o  o  
I felt down-hearted and 
blue  o  o  o  o  
I was intolerant of anything 
that kept me from getting 
on withwhat I was doing  o  o  o  o  
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 0 (did not apply to me at all) 
1 (applied to me to 
some degree, or 
some of the time) 
2 (applied to me a 
considerable 
degree, or a good 
part of the time) 
3 (applied to me 
very much, or 
most of the time) 
I felt I was close to panic  o  o  o  o  
I was unable to become 
enthusiastic about anything  o  o  o  o  
I felt I wasn't worth much 
as a person  o  o  o  o  
I felt that I was rather 
touchy o  o  o  o  
I was aware of the action 
of my heart in the absence 
of physical exertion (e.g., 
sense of heart rate increase, 
heart missing a beat)  
o  o  o  o  
I felt scared without any 
good reason  o  o  o  o  
I felt that life was 









Thank you for taking the time to complete this survey.    
    
This paragraph provides some background information to explain why we are doing this 
study. Previous research suggests that people affected by Parkinson’s experience stigma 
(signs of disapproval) from others, which can lead to an increase in psychological distress 
(symptoms of anxiety, depression and stress). The aim of this study is to investigate this 
relationship between stigma and psychological distress, by looking at other factors which 
might influence it. The other factors which we are considering are self-compassion (the 
ability to recognise one’s own suffering and take steps to relieve it, using a kind and caring 
approach) and self-critical rumination (persistent critical thoughts about the self). These two 
concepts have been found to be related to one another: people who demonstrate more self-
compassion tend to engage less in self-critical rumination. We hope to find out whether this 
same relationship exists for people with Parkinson’s. We also hope to find out whether either 
(or both) of these concepts are important in explaining the relationship between stigma and 
psychological distress (as found in previous studies), for people with Parkinson’s. We hope 
that an understanding of how these experiences are connected may help professionals to 
support people with Parkinson's who are experiencing distress. Once this research study is 
complete, the findings will be made available via the Parkinson's UK website. The results 
will also be summarised and reported in a thesis and may be submitted for publication in an 
academic journal and presented at seminars and conferences.   
 
Your responses to this survey will be combined with other participants' data and stored in an 
electronic file space on the secure server provided by Lancaster University. The file space 
will be password protected such that it will only be accessible to the researchers for this 
study. Since this research will be submitted for assessment as part of the Doctorate in Clinical 
Psychology, the anonymised data may also need to be accessed by the course's admin staff 
and the Programme and/or Research Directors. The data will be held securely in its 
anonymised electronic form by Lancaster University for 10 years, after which time it will be 
destroyed. For further information about how Lancaster University processes personal data 
for research purposes, and your data rights, please visit our 
webpage: www.lancaster.ac.uk/research/data-protection.     
 
Should you feel distressed either as a result of taking part in this study, or in the future, you 
may find the following resources helpful:  
 
 • Parkinson’s UK    
Website: www.parkinsons.org.uk   
Helpline: 0808 800 0303  
 
 • Samaritans   
Website: https://www.samaritans.org/   
Helpline: 116 123      
 
 
If you have any questions about your participation in this study, please contact me (Natalie 
Sowter) by email at n.sowter@lancaster.ac.uk or by telephone on 07508 375 665.   You can 
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also contact my research supervisor, Fiona Eccles (Lecturer in Health Research) by email at 
f.eccles@lancaster.ac.uk or by telephone on 01524 592807.       
 






Ethics Amendment Request Form 
 
 
 Faculty of Health and Medicine Research Ethics Committee 
(FHMREC) Lancaster University Application for 










 Note that where the amendment relates to a change of researcher, and 






















a) Resubmit your research ethics documents (the entire version which received final 
approval, including all participant materials, your application form and 
research protocol), with all additions highlighted in yellow, and any deletions simply 
‘struck through’, so that it is possible to see what was there previously. 
b) This should be submitted as a single PDF to Becky Case There is no need to 




 Applicant electronic signature:   Date 
 
Student applicants: please tick to confirm that you have discussed this 
amendment application with your supervisor, and that they are happy for the 


















Letter of Ethical Approval 
	
	
	
Applicant:	Natalie	Sowter		
Supervisor:	Fiona	Eccles		
Department:	Health	Research		
FHMREC	Reference:	FHMREC18052		
	
28	January	2019	
		
Dear	Natalie		
	
Re:	Stigma,	self-compassion,	self-critical	rumination	and	psychological	distress	amongst	
people	with	Parkinson’s		
	
Thank	you	for	submitting	your	research	ethics	amendment	application	for	the	above	project	
for	review	by	the	Faculty	of	Health	and	Medicine	Research	Ethics	Committee	(FHMREC).	
The	application	was	recommended	for	approval	by	FHMREC,	and	on	behalf	of	the	Chair	of	
the	Committee,	I	can	confirm	that	approval	has	been	granted	for	the	amendment	to	this	
research	project.		
	
As	principal	investigator	your	responsibilities	include:		
-	ensuring	that	(where	applicable)	all	the	necessary	legal	and	regulatory	requirements	in	
order	to	conduct	the	research	are	met,	and	the	necessary	licenses	and	approvals	have	been	
obtained;		
-	reporting	any	ethics-related	issues	that	occur	during	the	course	of	the	research	or	arising	
from	the	research	to	the	Research	Ethics	Officer	at	the	email	address	below	(e.g.	unforeseen	
ethical	issues,	complaints	about	the	conduct	of	the	research,	adverse	reactions	such	as	
extreme	distress);		
-	submitting	details	of	proposed	substantive	amendments	to	the	protocol	to	the	Research	
Ethics	Officer	for	approval.		
	
Please	contact	me	if	you	have	any	queries	or	require	further	information.		
Tel:-	01542	593987		
Email:-	fhmresearchsupport@lancaster.ac.uk		
	
Yours	sincerely,		
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Becky	Case		
Research	Ethics	Officer,	Secretary	to	FHMREC.		
